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Summary 
Caveolin-1 (CAV1) is the main structural component of cholesterol-rich microdomains 
in the plasma membrane, called caveolae. Caveolae occur in most mammalian cells 
and are involved in the regulation of cell signaling, lipid homeostasis, and response 
to mechanical stress. For turnover, CAV1 is ubiquitinated and sequestered in the 
lumen of multivesicular endosomes that eventually fuse with lysosomes. In addition 
to components of the ESCRT machinery, lysosomal sorting of ubiquitinated CAV1 
requires the AAA-ATPase p97 together with the cofactor UBXD1. However, it is 
unknown at which site CAV1 is ubiquitinated and how ubiquitination is linked to 
endosomal sorting of CAV1. Moreover, it is unknown how the p97-UBXD1 complex 
interacts with ubiquitinated CAV1 and if p97 is a general regulator of endosomal 
sorting. 
In this study, we show through systematic mutagenesis of lysine residues in CAV1 
that ubiquitination of CAV1 occurs at any of the six lysines 5, 26, 30, 39, 47, and 57; 
and only the combined mutation of all six lysines together abolishes ubiquitination. 
The ubiquitination site is located in the flexible N-terminal region of CAV1 that is not 
involved in CAV1 oligomerization or membrane localization of CAV1. Importantly, 
mutation of the lysines 5 to 57 to arginine interfered with trafficking of CAV1 to early 
endosomes. As a consequence, the K5-57R variant accumulated at an early 
transport stage that was marked by the caveolar coat protein PTRF/cavin-1. 
Previous studies established that overexpression of dominant negative p97 prevents 
sorting of CAV1 into the lumen of late endosomes. Consistently, we showed here 
that the ubiquitination site in the N-terminal region of CAV1 was necessary for the 
interaction between CAV1 and p97-UBXD1 as well as recruitment of p97-UBXD1 to 
endosomes. Moreover, cellular depletion or pharmacological inhibition of p97 
accumulated ubiquitinated CAV1. These results indicate that p97-UBXD1 acts 
downstream of CAV1 ubiquitination and is required for the turnover of ubiquitinated 
CAV1 on late endosomes. In this context, we demonstrated that p97 also mediated 
lysosomal degradation of ligand-activated EGF receptor and, thus, acts as a general 
regulator of endosomal sorting. 
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Zusammenfassung 
Caveolin-1 (CAV1) ist ein wichtiger struktureller Bestandteil cholesterinreicher 
Mikrodomänen in der Plasmamembran, die Caveolae genannt werden. Caveolae 
finden sich in den meisten Säugerzellen und sind and der Regulation zellulärer 
Signalübertragung, des Fettstoffwechsels und der Reaktion auf mechanische Reize 
beteiligt. CAV1 wird für seinen eigenen Abbau ubiquitiniert und im Lumen 
multivesikulärer Endosomen, die letztendlich mit Lysosomen fusionieren, 
sequestriert. Der Transport von CAV1 zum Lysosom erfordert, neben Komponenten 
der ESCRT-Maschinerie, auch die AAA-ATPase p97 zusammmen mit dem Kofaktor 
UBXD1. Es ist allerdings unbekannt, an welcher Stelle CAV1 ubiquitiniert wird und 
wie Ubiquitinierung von CAV1 und endosomaler Transport miteinander verknüpft 
sind. Weiterhin ist unbekannt, wie genau der p97-UBXD1 Komplex mit CAV1 
interagiert und ob p97 als allgemeiner Regulator für den endosomalen Transport 
fungiert. 
Wir zeigen hier mittels systematischer Mutagenese, dass die Ubiquitinierung von 
CAV1 an einem beliebigen der sechs Lysine 5, 26, 30, 39, 47 und 57 in der N-
terminalen Region stattfinden kann und dass die Mutation aller sechs Lysine 
zusammen notwendig ist, um die Ubiquitinierung zu verhindern. Die 
Ubiquitinierungsregion befindet sich in der flexiblen N-terminalen Region von CAV1, 
die nicht an der Oligomerisierung oder der Membranlokalisierung von CAV1 beteiligt 
ist. Bemerkenswerterweise behinderte die Mutation der Lysine 5 bis 57 den 
Transport von CAV1 zu frühen Endosomen. In der Folge akkumulierte CAV1 in 
einem frühen Transportschritt, der durch das caveoläre Hüllprotein PTRF/cavin-1 
gekennzeichnet war. 
Frühere Untersuchungen haben gezeigt, dass Expression einer dominant negativen 
Variante von p97 den Transport von CAV1 in das Lumen später Endosomen 
verhindert. In der Folge zeigten wir hier, dass die Ubiquitinierungsregion in CAV1 
sowohl für die Interaktion zwischen CAV1 und dem p97-UBXD1 Komplex als auch 
die Rekrutierung von p97-UBXD1 zu Endosomen notwendig war. Weiterhin 
akkumulierte ubiquitiniertes CAV1 nach zellulärer Depletion oder pharmakologischer 
Inhibition von p97. Diese experimentellen Daten weisen darauf hin, dass p97-UBXD1 
zeitlich nach der Ubiquitinierung von CAV1 agiert und notwendig für die 
Prozessierung von ubiquitiniertem CAV1 an späten Endosomen ist. In diesem 
  Zusammenfassung 
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Zusammenhang zeigten wir weiterhin, dass p97 den lysosomalen Abbau von 
aktiviertem EGF Rezeptor vermittelte und deshalb als ein allgemeiner Regulator des 
endosomalen Transports agiert. 
 
  Introduction 
 15 
1 Introduction 
1.1 Ubiquitination regulates protein turnover and activity 
The term ubiquitination describes the posttranslational modification of lysine residues 
within a substrate protein with the small globular protein ubiquitin. This covalent 
modification is carried out by a three-step enzymatic cascade (Figure 1.1 A and B). 
Initially, ubiquitin is activated by an E1 ubiquitin-activating enzyme and subsequently 
transferred to an E2 ubiquitin-conjugating enzyme. Finally, an E3 ubiquitin ligase 
mediates the transfer of ubiquitin onto a specific substrate protein (Chen and Sun, 
2009; Pickart, 2004). The E3 ubiquitin ligases constitute a large group of proteins 
with more than 600 members that can be divided into two families based on their 
catalytic domains. E3 ligases of the first family harbor a RING (Really Interesting 
New Gene) domain whereas members of the second family contain a HECT 
(Homology to E6AP C-terminus) domain (Deshaies and Joazeiro, 2009; Rotin and 
Kumar, 2009). Importantly, ubiquitin itself harbors seven lysines that can be 
ubiquitinated yielding poly-ubiquitin chains with specific linkages and specific cellular 
function. Ubiquitin binding proteins can discriminate between the different poly-
ubiquitin chains and direct the ubiquitinated substrate protein into certain pathways 
(Ikeda and Dikic, 2008; Komander and Rape, 2012; Ye and Rape, 2009). The 
different topologies of ubiquitination are depicted in Figure 1.1 C. 
Generally, poly-ubiquitin chains linked through lysine-48 induce proteasomal 
degradation of the substrate protein (Xu et al., 2009). In contrast, short poly-ubiquitin 
chains linked through lysine-63 mediate endocytosis of plasma membrane proteins 
(Duncan et al., 2006). However, other poly-ubiquitin chains, for example lysine-11 
linked chains, can be a signal for proteasomal degradation as well as endocytosis 
(Boname et al., 2010; Xu et al., 2009). Chains that contain a mixture of different 
linkages further increase the complexity of the signals that are encoded by poly-
ubiquitin chains (Ikeda and Dikic, 2008; Kim et al., 2007). Additionally, modification of 
proteins with a single ubiquitin is a signal for endocytosis and endosomal sorting of 
plasma membrane proteins. The substrate protein can be modified with a single 
ubiquitin (mono-ubiquitination), or several individual ubiquitin moieties (multiple 
mono-ubiquitination) (Haglund et al., 2003; Mosesson and Yarden, 2006; Sigismund 
et al., 2005; Stringer and Piper, 2011). Interestingly, poly-ubiquitin chains formed 
through lysine-63 linkages have an elongated conformation that makes them more 
  Introduction 
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similar to mono-ubiquitin compared to the closed conformation of lysine-48 linked 
chains (Komander and Rape, 2012). In addition to mediating the turnover of cytosolic 
and membrane proteins, ubiquitination can regulate diverse cellular functions like 
DNA damage repair or cell signaling (Chen and Sun, 2009; Haglund and Dikic, 
2005). 
 
Figure 1.1 Mechanism of ubiquitination and topologies of ubiquitination. 
A, schematic overview of the ubiquitination cycle. Substrates are ubiquitinated on 
surface lysines (K) by a cascade of E1 activating, E2 conjugating, and E3 ligase 
enzymes. Prior to substrate degradation for example in the 26S proteasome, 
ubiquitin is recovered and can be reused for ubiquitination. B, E1 ubiquitin-activating 
enzymes use the energy of ATP hydrolysis to form an ubiquitin thiol ester. 
Subsequently, ubiquitin is handed over to a cysteine residue in an E2 conjugating 
enzyme. Finally, an E3 ubiquitin ligase catalyzes the transfer of ubiquitin from the E2 
conjugating enzyme to the substrate lysine. C, substrate proteins can be modified 
with a single lysine (mono-ubiquitination) or several individual ubiquitin moieties 
(multi/multiple-mono-ubiquitination). Poly-ubiquitin chains can contain homogenous 
ubiquitin linkages or a mixture of different ubiquitin linkages. (panel A and B are 
adopted from Pickart, 2004; panel C is adopted from Komander and Rape, 2012) 
Ubiquitin-conjugated proteins can be deubiquitinated to recover ubiquitin prior to 
proteolysis of the substrate protein or to modify the ubiquitin signal (Komander and 
Rape, 2012). Deubiquitinating enzymes (DUBs) are vital to maintain sufficient 
cytosolic levels of free ubiquitin for proteasomal degradation as well as lysosomal 
degradation (Clague and Urbe, 2006; Finley, 2009). Additionally, deubiquitination is 
an important step prior to the extraction of ubiquitinated proteins from the 
endoplasmic reticulum (ER) (Claessen et al., 2012). Other cellular processes that are 
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regulated by deubiquitination are membrane fusion of Golgi fragments after mitosis 
or endosomal sorting of membrane proteins (Wang et al., 2004; Wright et al., 2011).  
Finally, mammalian cells express several UBL (ubiquitin-like) proteins that can 
modify substrate proteins analogous to ubiquitin. The conjugation of UBL often 
modulates the activity and binding surfaces of proteins (Kerscher et al., 2006). For 
example, the lipid raft component caveolin-3 (CAV3) can be modified with the small 
ubiquitin like modifier SUMO and this modification affects the interaction with plasma 
membrane ion channels (Fuhs and Insel, 2011). Another example is autophagy that 
uses two highly specific ubiquitin conjugation systems to regulate the formation of 
autophagosomes (Ohsumi, 2001). 
1.2 Endosomal sorting of plasma membrane proteins 
Endosomal sorting of plasma membrane proteins is a process that has been 
extensively studied in yeast and mammalian cells. Many principles of endosomal 
sorting in mammalian cells have been elucidated using the epidermal growth factor 
receptor (EGFR) as a model substrate (Goh and Sorkin, 2013; Madshus and Stang, 
2009). In general, small areas of the plasma membrane are internalized as vesicles 
in a process called endocytosis. Following endocytosis, these vesicles fuse with each 
other and early endosomes that act as an important sorting platform within the cell 
(Huotari and Helenius, 2011; Jovic et al., 2010). From early endosomes, proteins can 
recycle back to the plasma membrane (Maxfield and McGraw, 2004), engage in 
retrograde transport to the Golgi apparatus (Johannes and Popoff, 2008), or be 
targeted for lysosomal degradation (Huotari and Helenius, 2011). Furthermore, 
endosomes can regulate the timing and localization of intracellular signaling events 
(Scita and Di Fiore, 2010). Membrane proteins targeted for lysosomal degradation 
are sequestered on intralumenal vesicles (ILV) that bud inwards from the membrane 
of multivesicular endosomes (MVE) (Piper and Katzmann, 2007). Subsequently, 
these MVE mature into late endosomes and fuse with lysosomes to form 
endolysosomes. Endolysosomes are acidified organelles that contain a high 
concentration of proteases and digestive enzymes to degrade lumenal cargo (Huotari 
and Helenius, 2011; Luzio et al., 2007). Along this sorting pathway, endosomes can 
fuse to incorporate cargo proteins from different sources and also recycle membrane 
proteins back to the plasma membrane (Grant and Donaldson, 2009). 
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1.2.1 Clathrin dependent and independent endocytosis 
The most prominent and fastest pathway for endocytosis of plasma membrane 
proteins and extracellular molecules is through clathrin-coated pits (McMahon and 
Boucrot, 2011; Ungewickell and Hinrichsen, 2007) (Figure 1.2 A, B, and C). The 
defining structural component of clathrin-mediated endocytosis is the clathrin hetero-
hexamer, called triskelion (Greene et al., 2000; Liu et al., 1995). Plasma membrane 
proteins are clustered in clathrin-coated pits by adapter-proteins that mediate 
interaction between clathrin and endocytic cargo proteins. Most adapter-proteins, for 
example the abundant AP2 complex, additionally contain binding domains for 
phosphatidylinositol (PI)-4,5-bisphosphate (PI3,5P2) lipids that mediate interaction 
with the plasma membrane (Mousavi et al., 2004). Cells express a wide variety of 
substrate adapters to mediate endocytosis of diverse cargo proteins (Ungewickell 
and Hinrichsen, 2007). For example, the Epsin, Eps15, and Eps15R adapters harbor 
ubiquitin-interacting motifs (UIM) and recognize ubiquitinated proteins (Tanno and 
Komada, 2013). These adapters can themselves be ubiquitinated in a process called 
coupled mono-ubiquitination to form a network of UIM-ubiquitin interactions that 
stabilizes the low affinity binding of the UIM to mono-ubiquitin (Barriere et al., 2006; 
Polo et al., 2002; Woelk et al., 2006). Interaction between adapter proteins, the 
plasma membrane, and cargo proteins induces nucleation of a clathrin coated-pit.  
Subsequently, clathrin is recruited to this seminal structure and induces further 
invagination of the plasma membrane. Finally, the GTPase dynamin mediates 
abscission of the clathrin-coated vesicle from the plasma membrane (McMahon and 
Boucrot, 2011; Ungewickell and Hinrichsen, 2007). Following endocytosis, the 
clathrin-coated vesicle fuses with the early endosome, where the clathrin coat is 
disassembled. However, clathrin can stay bound to early endosomes as part of 
special microdomains that contain ubiquitinated cargo proteins. These microdomains 
are important for recruitment of the downstream endosomal sorting machinery 
(Raiborg et al., 2002; Raiborg et al., 2006; Sachse et al., 2002). 
In addition to the clathrin-dependent pathway, several pathways exist for clathrin-
independent endocytosis (CIE) (Figure 1.2 A, and D). Generally, CIE requires lipid 
rafts and can be classified according to the requirement of dynamin for membrane 
abscission as well as the scaffold and regulatory proteins involved (Howes et al., 
2010; Mayor and Pagano, 2007). The best-studied CIE pathway is the dynamin 
dependent endocytosis of plasma membrane caveolae that will be discussed in detail 
below. The second clathrin independent but dynamin dependent CIE mechanism 
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requires the small GTPase RHOA and no coat protein (Lamaze et al., 2001). In 
contrast, two small GTPases ARF1 and ARF6 were described to mediate plasma 
membrane endocytosis that is both independent of clathrin and dynamin (Howes et 
al., 2010; Mayor and Pagano, 2007). The ARF1 and ARF6 pathways possibly involve 
flotillin proteins that can induce membrane invaginations similar to caveolins (Glebov 
et al., 2006; Hansen and Nichols, 2009; Mayor and Pagano, 2007). Other 
mechanisms for endocytosis are phagocytosis and macropinocytosis. They are 
associated with actin-dependent membrane ruffles and generate large endocytic 
vesicles (Hansen and Nichols, 2009).  
 
Figure 1.2 Pathways of endocytosis 
A, Phagocytosis and macropinocytosis are actin-dependent pathways for the 
endocytosis of large particles or fluids respectively. Clathrin-mediated endocytosis is 
facilitated by the coat-protein clathrin and requires the GTPase dynamin for 
abscission of vesicles from the plasma membrane. Caveolae are specialized lipid raft 
domains that constitute a clathrin-independent but dynamin-dependent pathway for 
endocytosis. Other lipid raft-dependent endocytic pathways are independent of 
clathrin and caveolin but may require the activity of dynamin. Most internalized cargo 
molecules are delivered to the early endosome via clathrin- or caveolin-coated 
vesicles. B, thin section views of reticulocytes show clustering of gold-conjugated 
transferrin in clathrin-coated pits and endocytosis. C, Rapid-freeze, deep-etch view of 
clathrin lattices on the inner surface of a normal chick fibroblast. D, thin-section (left 
panel) and rapid-freeze, deep-etch (right panel) images of caveolae in endothelial 
cells. (modified from Mayor and Pagano, 2007) 
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1.2.2 The early endosome as a platform for protein sorting 
Endocytic vesicles are short lived and either fuse homotypically to generate early 
endosomes de novo or fuse directly with the early endosomal compartment 
(Gruenberg and Maxfield, 1995; Ungewickell and Hinrichsen, 2007). Some endocytic 
vesicles might fuse with early endosomes only after several maturation steps as 
described for macropinocytosis of activated H-RAS (Porat-Shliom et al., 2008). 
Moreover, several studies found evidence for sorting of endocytic vesicles prior to the 
early endosome. These endocytic vesicles often carry unique membrane markers 
that distinguish them from early endosomes (Hayakawa et al., 2006; Lakadamyali et 
al., 2006; Zoncu et al., 2009). The early endosome is a pleomorphic organelle with a 
high rate of homotypic fusion and fission. It consists of vacuolar and tubular domains 
that accumulate cargo destined for degradation or recycling respectively (Gruenberg 
and Maxfield, 1995; Mellman, 1996) (Figure 1.3). Additionally, the early endosome 
can act as a coordination center for retrograde transport and quality control of plasma 
membrane proteins (Johannes and Popoff, 2008; Okiyoneda et al., 2010).  
Due to the wide variety and vast number of endosomes, fusion between endocytic 
vesicles and endosomes has to be tightly regulated. This is achieved through small 
GTPases of the RAB family that are specific for the various endosomal 
compartments (Grosshans et al., 2006; Zerial and McBride, 2001). The RAB proteins 
recruit specific tethering factors that bridge between two vesicles to bring them in 
close proximity prior to fusion. Additionally, RAB proteins regulate the molecular 
machinery that facilitates membrane fusion together with a large number of effector 
proteins (Balderhaar and Ungermann, 2013; Zerial and McBride, 2001). In case of 
the early endosome, the small GTPase RAB5 governs the size and fusion rate of 
vesicles (Zeigerer et al., 2012). As an important effector protein, RAB5 recruits the 
PI3-kinase VPS34 that maintains the high levels of PI3P lipids that are specific for 
early endosomal membranes (Raiborg et al., 2013). The specific accumulation of 
PI3P lipids on early endosomes is necessary because tethering factors like EEA1 
(Early Endosomal Antigen 1) require interaction with RAB5 and PI3P for their 
localization to early endosomes (Christoforidis et al., 1999). Consequently, removing 
PI3P from early endosomes inhibits endosomal trafficking through the early 
endosome (Raiborg et al., 2013).  
Lysosomal degradation of membrane proteins involves the budding of intralumenal 
vesicles from the endosomal membrane into the lumen in a process called 
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multivesicular endosome (MVE) sorting (Figure 1.3). MVE sorting is mediated by the 
endosomal-sorting complex required for transport (ESCRT) that will be described in 
the next section. This process begins on early endosomes and continues during 
maturation into late endosomes. Late endosomes contain large numbers of 
intralumenal vesicles and are called multivesicular endosomes (Huotari and 
Helenius, 2011). The generation of intralumenal vesicles requires the induction of 
membrane curvature away from the cytoplasm (Raiborg and Stenmark, 2009). This 
topological change sequesters the cytoplasmic domains of transmembrane proteins 
from the cytoplasm and terminates signaling from activated transmembrane 
receptors (Goh and Sorkin, 2013; Huotari and Helenius, 2011).  
 
Figure 1.3 The endosome/lysosome system. 
Endocytic vesicles from a variety of endocytic pathways deliver their contents and 
membranes to the early endosome. From the early endosome, cargo molecules can 
recycle back to the plasma membrane either directly or via the recycling endosome. 
Vacuolar domains of the early endosomes mature into late endosomes and 
eventually fuse with lysosomes. During maturation, endosomes grow in size through 
homotypic fusion and acquire intralumenal vesicles. The abscission of intralumenal 
vesicles that is mediated by the ESCRT machinery begins on early endosomes and 
continues throughout maturation. Additionally, endosomes can exchange 
membranes and content with the secretory pathway (retrograde transport). Late 
endosomes fuse with lysosomes and form endolysosomes where active degradation 
of the lumenal cargo takes place. (adopted from Huotari and Helenius, 2010) 
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Furthermore, during maturation into late endosomes the RAB5 GTPase is exchanged 
for the RAB7 GTPase, endosomes become increasingly acidified, and PI3P is 
converted into PI3,5P2 (Huotari and Helenius, 2011; Rink et al., 2005). 
1.2.3 The ESCRT machinery mediates MVE sorting of ubiquitinated substrates 
The sorting of ubiquitinated membrane proteins into intralumenal vesicles by the 
ESCRT machinery has been extensively studied in the last years and is the subject 
of many comprehensive reviews (Henne et al., 2011; Piper and Katzmann, 2007; 
Raiborg and Stenmark, 2009; Roxrud et al., 2010). The signal for recognition of 
membrane proteins by the ESCRT machinery and subsequent MVE sorting are short 
lysine-63 linked poly-ubiquitin chains or mono-ubiquitin (Erpapazoglou et al., 2012; 
MacDonald et al., 2012; Sigismund et al., 2005; Stringer and Piper, 2011). The 
different architecture of this modification, in contrast to lysine-48 linked poly-ubiquitin 
chains, avoids targeting of membrane proteins to the proteasome (Komander and 
Rape, 2012). However, the affinity of the ESCRT ubiquitin-adapter proteins for single 
ubiquitin moieties is low and efficient sorting of mono-ubiquitinated proteins probably 
requires the clustering of mono-ubiquitin (Raiborg et al., 2002; Ren and Hurley, 
2010). This is comparable to recognition of mono-ubiquitinated proteins in clathrin-
mediated endocytosis (Barriere et al., 2006; Polo et al., 2002). 
Many ubiquitinated membrane proteins engage ubiquitin adapters at the plasma 
membrane to initiate clathrin-mediated endocytosis. Following endocytosis, 
ubiquitinated substrates are recognized by the ESCRT-0 factors HRS (Hepatocyte 
growth factor-Regulated tyrosine kinase Substrate) and STAM (Signal Transducing 
Adapter Molecule) (Acconcia et al., 2009; Polo et al., 2002). Depletion of ESCRT-0 
prevents the lysosomal degradation of ubiquitinated membrane proteins and induces 
recycling (Raiborg et al., 2008). The interaction between ubiquitinated membrane 
proteins and ESCRT-0 is localized on the early endosome and involves the clathrin 
coat protein (Raiborg et al., 2002; Raiborg et al., 2006; Sachse et al., 2002). HRS 
recruits another ubiquitin-receptor TSG101 (Tumor Susceptibility Gene 101) that 
constitutes the ESCRT-I complex together with additional protein factors (Henne et 
al., 2011; Roxrud et al., 2010). The ubiquitinated cargo is then handed over to VPS36 
(vacuolar proteins sorting associated protein 36) that is a part of the ESCRT-II 
complex (Im and Hurley, 2008). Interestingly, several ESCRT components 
themselves are ubiquitinated and this directly regulates MVE-sorting (Amit et al., 
2004; McCullough et al., 2004). In general, ubiquitinated proteins are captured by 
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ESCRT-0 and subsequently handed over to ESCRT-I and ESCRT-II. These protein 
complexes, in turn, mediate clustering on the endosomal membrane and possibly 
initiate membrane deformation (Henne et al., 2011; Roxrud et al., 2010). Finally, 
ESCRT-II recruits the multi-subunit ESCRT-III machinery that contains no ubiquitin 
binding motifs but is required for further deformation of the membrane and ILV 
abscission. After abscission of the ILV, the ESCRT proteins that have assembled on 
the endosomal membrane are recycled for subsequent rounds of ILV biogenesis. 
ESCRT-III proteins recruit the AAA-ATPase VPS4 that uses the energy of ATP 
hydrolysis to disassemble the ESCRT complexes (Henne et al., 2011; Roxrud et al., 
2010) (Figure 1.4). 
 
Figure 1.4 Schematic overview of the ESCRT machinery involved in 
intralumenal vesicle formation. 
Endosomal sorting of membrane protein into intralumenal vesicles requires the 
coordinated action of four multi-subunit complexes that constitute the ESCRT 
machinery. ESCRT-0 interacts with PI3P lipids, and clathrin complexes and captures 
ubiquitinated cargo proteins on the surface of endosomes. ESCRT-0 subsequently 
recruits ESCRT-I and ESCRT-II. These large protein complexes can interact with 
ubiquitinated cargo and, in the case of ESCRT-II with PI3P lipids. The action of 
ESCRT-I and ESCRT-II clusters ubiquitinated proteins on the surface of late 
endosomes. The ESCRT-III complex, in turn, is required to induce membrane 
deformation and vesicle abscission. This may require the help of membrane 
curvature inducing lipids, for example lysobisphosphatidic acid. Following vesicle 
abscission, the ESCRT complexes are recycled by the activity of the AAA-ATPase 
VPS4. The components of ESCRT complexes in yeast as well as mammalian cells 
are listed. (adopted from Williams and Urbe, 2007) 
In light of the multiple protein interactions that are mediated through ubiquitin and 
ubiquitin binding domains it comes as no surprise that deubiquitination is an 
important step in MVE sorting (Clague and Urbe, 2006; Wright et al., 2011). In yeast, 
  Introduction 
 24 
Doa4 (Degradation of alpha 4) mediates deubiquitination of endosomal cargo. Even 
though deubiquitination is not required for MVE sorting, Doa4-deletion strains have 
reduced levels of free ubiquitin due to ubiquitin being degraded in the vacuole 
(Amerik et al., 2000; Luhtala and Odorizzi, 2004). In mammalian cells, the 
deubiquitinating enzymes UBPY (Ubiquitin-specific Protease Y) and AMSH 
(Associated Molecule with the SH3 domain of STAM) interact with the ESCRT-0 
proteins HRS and STAM. Both DUBs can deubiquitinate cargo proteins, like the EGF 
receptor, as well as the ESCRT-0 ubiquitin-adapters. Depletion of AMSH promotes 
EGFR ubiquitination and subsequent degradation. (Bowers et al., 2006; McCullough 
et al., 2006). Likewise, knockdown of UBPY prevents deubiquitination of the EGF 
receptor; however, there is debate about the effect on MVE sorting (Berlin et al., 
2010; Niendorf et al., 2007; Row et al., 2006). Deubiquitination of ESCRT-0 by 
AMSH and UBPY might prevent proteasomal degradation of these proteins and 
promote MVE sorting (Niendorf et al., 2007; Row et al., 2006). Importantly, both 
AMSH and UBPY cannot substitute for each other and likely perform other non-
redundant functions. In general, deubiquitination of cargo after interaction with the 
ESCRT machinery favors degradation, while deubiquitination prior to ESCRT 
engagement favors recycling (Goh and Sorkin, 2013). 
1.2.4 Endosomal sorting of ligand activated EGFR as an example for 
endocytosis and MVE sorting 
Endocytosis and lysosomal degradation of the EGF receptor after ligand binding is a 
well-studied example for MVE sorting. Following binding of EGF, the EGF receptor 
dimerizes and auto-phosphorylates. This enables recruitment of phosphotyrosine-
binding proteins like GRB2 (Growth factor Receptor-Bound protein 2) and activation 
of downstream signaling cascades (Goh and Sorkin, 2013; Madshus and Stang, 
2009; Tomas et al., 2013). Simultaneously, the EGFR is ubiquitinated by ubiquitin 
ligases of the CBL (Casitas B-lineage Lymphoma) family and localizes together with 
GRB2 to clathrin-coated pits (Johannessen et al., 2006; Pennock and Wang, 2008). 
Following stimulation and ubiquitination, the receptor is endocytosed and transported 
to early endosomes (Figure 1.5). This might involve ubiquitination of not yet identified 
proteins, because also a non-ubiquitinatable EGFR variant is taken up efficiently 
(Huang et al., 2007; Huang et al., 2006). However, non-ubiquitinated EGFR is 
constitutively recycled back to the plasma membrane. Interestingly, even in the 
absence of stimulation, the EGFR undergoes constant rounds of endocytosis and 
recycling (Rush and Ceresa, 2013). The strength of EGF stimulation affects which 
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pathway is used for endocytosis and decides the subsequent fate of the receptor. 
Low levels of EGF favor clathrin-mediated endocytosis and recycling, while high 
levels of EGF induce clathrin-independent endocytosis and degradation (Sigismund 
et al., 2013; Sigismund et al., 2008). The EGF receptor has been shown to locate to 
caveolae in response to EGF stimulation. However, depletion of caveolin does not 
affect EGFR endocytosis (Kazazic et al., 2006; Sigismund et al., 2008). 
 
Figure 1.5 Endocytic trafficking of transmembrane receptors. 
Receptor tyrosine kinases (RTKs) enter the cell through clathrin-mediated 
endocytosis but also can use lipid raft-dependent endocytosis under certain 
conditions. Clathrin-mediated endocytosis requires substrate-adapter proteins that 
recognize cargo proteins, like the AP-2 complex, and the GTPase dynamin for 
vesicle abscission. Other membrane proteins, for example MHC class I molecules, 
preferentially enter the cell via lipid raft-dependent endocytosis. Both pathways 
combine at the early endosome. From the early endosome, receptors can recycle 
back to the plasma membrane or engage in ESCRT-mediated sequestration in 
intralumenal vesicles and transport to the lysosome. Lysosomal degradation requires 
ubiquitination of the receptor and terminates signaling. Endosomal sorting is 
governed by small GTPases of the RAB family that specify separate endosomal 
compartments and pathways. (adopted from Scita and Di Fiore, 2010) 
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On early endosomes, the ubiquitinated EGFR engages the ESCRT-0 and this is 
necessary for sorting into ILVs and lysosomal degradation (Goh and Sorkin, 2013; 
Madshus and Stang, 2009) (Figure 1.5). Alternatively, the EGF receptor can be 
deubiquitinated on early endosomes to prevent lysosomal degradation. Along this 
line, a non-ubiquitinatable receptor constitutively recycles from late endosomes to the 
plasma membrane (Eden et al., 2012). Endocytosis of the EGFR can be a 
mechanism to control the duration of EGF-induced signaling. The decreased pH in 
the lumen of early endosomes in comparison to the extracellular space causes 
dissociation of EGF from the receptor and thus can terminate the signaling cascade 
(Roepstorff et al., 2009; Tomas et al., 2013). Furthermore, endocytosis of the 
activated EGFR offers a possibility to modify the interaction with signaling partners 
and modulate the EGF induced signaling (Scita and Di Fiore, 2010). However, once 
the EGFR is sequestered within MVE all signaling is terminated and the receptor is 
degraded.  
This sequence of events is similar for most receptor tyrosine kinases (RTKs) but 
often involves specific adapters and effectors for each receptor (Goh and Sorkin, 
2013; Madshus and Stang, 2009). For example, many RTK are ubiquitinated by 
members of the NEDD4 (Neural precursor cell expressed Developmentally Down-
regulated protein 4) family of ubiquitin ligases (Rotin and Kumar, 2009). Other 
receptors like the transferrin receptor are not subject to lysosomal degradation after 
ligand binding but recycle to the plasma membrane after endocytosis (Grant and 
Donaldson, 2009). 
1.2.5 Diseases associated with defects in MVE sorting 
Defects in the ESCRT machinery in yeast and mammalian cells manifest in a 
distinctive abnormal subcellular structure that is called class E compartment. This 
compartment appears as stacked, flat cisternae that are not interconnected and 
represents aberrant MVE (Doyotte et al., 2005; Razi and Futter, 2006; Wollert et al., 
2009). Depletion of ESCRT components in cell culture causes defects in MVE sorting 
and degradation of endosomal cargo proteins. For example, depletion of HRS 
(ESCRT-0) or TSG101 (ESCRT-I) causes a partial delay in EGFR degradation 
kinetics and induces recycling to the plasma membrane (Doyotte et al., 2005; 
Raiborg et al., 2008; Razi and Futter, 2006). Likewise, depletion of ESCRT-II or 
ESCRT-III components results in impaired EGF receptor degradation (Williams and 
Urbe, 2007). Importantly, this also affects signaling from the EGFR and can modulate 
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cell survival and apoptosis (Bache et al., 2004; Rush et al., 2012). Along this line, 
TSG101 and another mammalian ESCRT-I component, VPS37A, were originally 
identified as tumor-suppressor genes and map to chromosomal regions that are often 
deleted or mutated in cancers (Bache et al., 2004; Saksena and Emr, 2009). The 
control of cell signaling through endosomal sorting is an important regulator of 
growth-factor signaling and, therefore, associated with the origin of malignant growth 
(Goh and Sorkin, 2013; Tomas et al., 2013).  
Furthermore, mutations in ESCRT proteins can affect cell cycle control, transcription 
regulation, and have been associated with neurodegenerative diseases (Saksena 
and Emr, 2009). Mutation in the ESCRT-III protein VPS2/CHMP2B causes a 
hereditary form of frontotemporal dementia (FTD) that is associated with 
ubiquitinated inclusions positive for the autophagy marker p62 (Urwin et al., 2010). 
Mutations in another ESCRT-III protein VPS24/CHMP3 inhibit the degradation of 
expanded poly-glutamine aggregates in Huntington’s disease (Filimonenko et al., 
2007). These mutations demonstrate that there is a connection between aggregate 
handling through autophagy and MVE sorting (Rusten and Simonsen, 2008). 
Interestingly, recent studies revealed that another hereditary neurological disorder, 
Charcot-Marie-Tooth disease type 1C, might be associated with MVE sorting. The 
SIMPLE (Small Integral Membrane Protein of Lysosome/late Endosome) protein 
interacts and colocalizes with ESCRT components and mutation of SIMPLE affects 
endosomal sorting of the RTK ErbB2 (Lee et al., 2012). In addition, the ability of the 
ESCRT machinery to induce membrane deformation can be hijacked by viruses to 
mediate budding of viral particles from the plasma membrane. For example, efficient 
release of the human immunodeficiency virus (HIV) requires interaction between 
TSG101 and viral surface proteins (Saksena and Emr, 2009). 
1.3 Autophagy 
Autophagy is used as a collective term for three related pathways that are highly 
conserved from yeast to mammals and facilitate degradation of cytosolic cargo in the 
lysosome (Weidberg et al., 2011). Macroautophagy is characterized by formation of a 
crescent shaped phagophore that expands to form a double-membrane 
autophagosome (Figure 1.6). Autophagosomes then fuse with endosomal 
compartments and eventually lysosomes to degrade the lumenal cargo. In 
microautophagy or chaperone mediated autophagy cytosolic proteins are directly 
delivered to the lumen of lysosomes by invagination of the lysosomal membrane or 
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translocation across the lysosomal membrane respectively (Kirkin et al., 2009b). 
Macroautophagy, here referred to simply as autophagy, can sequester and degrade 
large fractions of cytosolic material, for example as a reaction to starvation (Yang and 
Klionsky, 2010). In addition, cells can induce selective autophagy to degrade various 
cellular structures including protein aggregates, mitochondria, and microbes. 
Importantly, selective autophagy depends on the ubiquitination of substrates (Kirkin 
et al., 2009b). 
 
Figure 1.6 Schematic overview of general end selective autophagy. 
A, Mammalian autophagy initiates at the phagophore assembly site (PAS) that 
incorporates signaling from upstream regulators. The ULK1/2 complex, for example, 
activates autophagy under starvation conditions. The phagophore is elongated by 
action of the two ubiquitin-like proteins ATG12 and ATG8 (LC3 in mammalian cells). 
This sequesters a fraction of the cytoplasm that is surrounded by a double 
membrane after phagophore closure. Autophagosomes dock at or fuse with 
lysosomes and form autolysosomes that degrade the sequestered cytoplasmic 
molecules. The resulting macromolecules are transported back into the cytoplasm 
through membrane permeases. B, the ubiquitin adapter p62 interacts with poly-
ubiquitinated proteins and induces aggregation. Sequestration of these aggregates in 
autophagosomes is mediated by the direct interaction between p62 and the 
phagophore-membrane protein LC3. (panel A is modified from Yang and Klionsky, 
2010; panel B is adopted from Komatsu and Ichimura, 2010) 
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Genetic studies in yeast revealed more than 30 autophagy-related (ATG) proteins 
that govern biogenesis, maturation, and degradation of the autophagosome (Suzuki 
and Ohsumi, 2007). Two pivotal elements of autophagosome formation are the 
ATG12 and ATG8 ubiquitin-like proteins. ATG12 is covalently attached to another 
autophagy protein ATG5, while ATG8 is conjugated to phosphatidylethanolamine 
(PE) lipids in the autophagosome membrane. In mammalian cells, several 
homologues of Atg8 are known of which LC3 (microtubule-associated proteins 1A/1B 
(MAP1) Light Chain 3) is the best characterized. ATG8-PE probably is the driving 
force that facilitates elongation of the phagophore and stays attached to the 
membrane through fusion of the autophagosome with the lysosome (Ohsumi, 2001). 
Therefore, Atg8 or LC3 are extensively used as markers for autophagosomes 
(Klionsky et al., 2008). However, the process of autophagosome formation is not 
completely understood and, for example, the source of autophagic membranes is still 
under debate (Hamasaki and Yoshimori, 2010). 
1.3.1 Selective autophagy of ubiquitinated proteins 
One important type of cargo for selective autophagy is aggregates of misfolded 
proteins that occur under stress condition or due to expression of aberrant peptides. 
Cells actively accumulate misfolded proteins in large aggregates called aggresomes. 
This requires microtubules together with motor proteins and the intermediate-filament 
protein vimentin (Kopito, 2000). In contrast, cells can form stress-induced 
aggregates, called aggresome-like induced structures (ALIS) that contain defective 
ribosomal products as well as long lived proteins and do not require active transport 
(Szeto et al., 2006). These intracellular aggregates are substrates for the proteasome 
and autophagy. Importantly, ALIS and other protein-aggregates are recognized by 
the ubiquitin-adapter p62 and directed towards autophagic degradation (Pankiv et al., 
2007). The adapter protein p62 interacts with ubiquitin through an ubiquitin-
associated domain (UBA) and dimerizes to aggregate ubiquitinated proteins. 
Additionally, p62 binds to the autophagosomal membrane protein LC3 trough an 
LC3-interacting region (LIR). Therefore, p62 can crosslink ubiquitinated substrates 
and target them to autophagy (Komatsu et al., 2007; Pankiv et al., 2007) (Figure 1.6). 
During autophagosome maturation, p62 stays bound to LC3 and is eventually 
degraded in lysosomes. As a consequence, abolishing autophagy causes 
accumulation of p62 and unspecific aggregation of ubiquitinated proteins in the cell 
that can lead to cell death (Komatsu et al., 2007; Korolchuk et al., 2009). In contrast, 
depletion of p62 does not result in visible accumulation of ubiquitinated aggregates 
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due to the presence of further ubiquitin-adapter proteins (Clausen et al., 2010; Kirkin 
et al., 2009a). In addition to protein aggregates, selective autophagy can facilitate the 
degradation of large protein complexes like ribosomes or whole organelles (Kirkin et 
al., 2009b). For example, damaged mitochondria are ubiquitinated by the E3 ubiquitin 
ligase Parkin and targeted for autophagic clearance. Interestingly, this too might 
involve p62 as an ubiquitin-adapter protein (Geisler et al., 2010). Taken together, the 
action of ubiquitin adapter proteins makes it possible to selectively target cytosolic 
components for autophagy (Kirkin et al., 2009b; Weidberg et al., 2011). 
1.3.2 Autophagy and human disease. 
Defects in selective autophagy are associated with a number of diseases that mainly 
arise from accumulation of protein aggregates in cells (Komatsu and Ichimura, 2010). 
Mutations in the ubiquitin-binding domain of p62 cause Paget disease of the bone 
(PDB). The disease mechanism of PDB has been originally attributed to defective 
NFκB signaling in osteoclasts. However, it is possible that mutations in p62 cause 
defects in autophagy that contribute to the disease phenotype (Goode and Layfield, 
2010). Another congenital disorder with a similar bone phenotype is inclusion body 
myopathy, Paget disease of the bone and frontotemporal dementia (IBMPFD). 
Importantly, recent studies showed that IBMPFD is associated with inefficient 
clearance of autophagosomes (Ju et al., 2009; Tresse et al., 2010). Moreover, 
several neurological disorders are linked to defects in autophagy and inefficient 
degradation of protein aggregates. Mutations in ESCRT proteins that interfere with 
the fusion of autophagosomes and lysosomes and subsequent clearance of 
autophagosomes might be a cause for neurological disease (Rusten and Simonsen, 
2008). In addition to cytosolic aggregates, autophagy was recently discovered to 
degrade misfolded proteins that accumulate in the ER in response to ER-stress 
(Yorimitsu and Klionsky, 2007). Moreover, autophagy can directly defend the cell 
against invading cytosolic pathogens. Recognition of Salmonella species by the 
ubiquitin-adapter optineurin induces enclosure of the bacterium in autophagosomes 
and autophagic degradation (Wild et al., 2011). 
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1.4 Caveolins and cavins. 
The plasma membrane of all cells is composed of a phospholipids bilayer that 
separates the cytosol from the surrounding extracellular space. However, the plasma 
membrane is not homogenous but contains regions of higher and lower mobility. The 
liquid ordered regions of lower mobility, called lipid rafts, are enriched in sphingolipids 
and cholesterol and are stabilized by membrane proteins (Hancock, 2006). One 
special kind of cholesterol-rich lipid raft microdomains in the plasma membrane is 
defined by the 21 kD protein caveolin-1 (CAV1) and called caveolae for the 
distinctive flask-like shape (Figure 1.7 A). Caveolae have been implicated in a wide 
variety of cellular processes including endocytosis, cell signaling, membrane 
homeostasis, and mechanosensing (Parton and del Pozo, 2013).  
1.4.1 Structure of caveolins and formation of caveolae. 
The family of caveolin proteins is highly conserved between metazoan organisms 
and expression of most caveolins results in the spontaneous formation of caveolae in 
the plasma membrane (Kirkham et al., 2008). In humans, three caveolin isoforms are 
identified with CAV3 being expressed exclusively in muscle tissue and CAV1 and 
CAV2 in almost all other tissues. CAV1 and CAV2 show overlapping expression 
profiles and overexpressed CAV2 does not form caveolae on its own (Parton and del 
Pozo, 2013). Therefore, CAV2 possibly has a regulatory role in caveola formation 
and dynamics as observed in CAV2 deficient mice (Razani et al., 2002). All caveolins 
share a hairpin-like structure and insert into the cytoplasmic leaflet of the plasma 
membrane bilayer with a 33-residue intra membrane domain (Figure 1.7 B). As a 
consequence, both N- and C-terminus are facing the cytoplasm. During biogenesis, 
the C-terminal domain is palmitoylated; however, this modification is not required for 
targeting of CAV1 to caveolae (Parton et al., 2006). CAV1 and CAV3 can form high-
molecular weight complexes through homo-oligomerization (Monier et al., 1995; 
Tang et al., 1996). In CAV1, the amino acids 61-101 are sufficient to form oligomers. 
In detail, the amino acids 79-96 form an alpha helix that mediates the oligomerization 
(Fernandez et al., 2002; Sargiacomo et al., 1995). The minimal CAV1 protein that 
can form caveolae spans the amino acids 49-147 and contains the oligomerization 
and intramembrane domains as well as two of three palmitoylation sites (Kirkham et 
al., 2008). Furthermore, CAV1 contains a scaffolding domain (CSD) that is made up 
by the amino acids 81-101 in CAV1 and has been described to take part in a wide 
variety of intermolecular interactions. For example, heterotrimeric G proteins, SRC 
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family tyrosine kinases, integrins, EGFR, and endothelial ion channels interact with 
CAV1 through a caveolin-binding motif (CBM). However, prediction of binding 
partners by bioinformatics based on the CBM proved to be difficult (Byrne et al., 
2012; Collins et al., 2012). Additionally, studies using antibodies targeting the CSD 
suggest that this region is probably buried within CAV1 oligomers and not readily 
accessible for interaction (Parton and Simons, 2007; Pol et al., 2005). 
 
Figure 1.7 Caveolae and membrane topology of CAV1. 
A, thin section image (upper left panel) of plasma membrane caveolae in adipocytes 
and schematic depiction of multiple caveolae forming continuous invaginations (lower 
left panel). The right panel illustrates a section through a single caveola and shows 
the flask-like shape. Cav1 is inserted into the cytoplasmic leaflet of the plasma 
membrane with N- and C-termini facing the cytoplasm (blowup). The scaffolding 
domain of CAV1 may directly interact with cholesterol. B, Topological model of CAV1 
in the plasma membrane. The intra-membrane domain is buried in the plasma 
membrane with the N- and C-termini facing the cytoplasm. The scaffolding domain at 
least partially enters the hydrocarbon core of the membrane, while the C-terminal 
domain is anchored in the plasma membrane through palmitoylation. Parts of the N- 
and C-terminal regions form amphipathic helices at the plasma membrane interface. 
The very N-terminal region is more flexible and protrudes into the cytoplasm. (panel 
A is adopted from Parton and Simons, 2007; panel B is adopted from Parton et al., 
2006) 
  Introduction 
 33 
CAV1 can be expressed from two distinct mRNAs as a full-length α-isoform or a β-
isoform that is lacking the first 31 amino acids (Kogo and Fujimoto, 2000). However, 
the functional difference between the two isoforms is not clear (Parat, 2009). CAV1 is 
cotranslationally inserted into the endoplasmic reticulum (ER) in a signal recognition 
particle (SRP)-dependent manner (Monier et al., 1995). In the ER, CAV1 monomers 
assemble into 8S oligomers, named for their sedimentation coefficient, and are 
transported to the Golgi apparatus (Fernandez et al., 2002; Hayer et al., 2010a; 
Sargiacomo et al., 1995). If transport of CAV1 to the Golgi apparatus is inhibited, 
CAV1 re-localizes from the ER to lipid droplets (Ostermeyer et al., 2001). In the Golgi 
apparatus, 8S oligomers further assemble into larger 70S caveolar scaffolds and this 
causes the masking of certain epitopes that become buried within the oligomers (Pol 
et al., 2005). Importantly, this is accompanied by recruitment of cholesterol to the 70s 
complexes and resistance to extraction with the detergent Triton X-100. The 70S 
caveolar assemblies are subsequently transported to the plasma membrane in 
vesicular carriers that incorporate secretory cargo proteins (Hayer et al., 2010a). 
Each complex contains as many as 160 CAV1 proteins that arrive at the plasma 
membrane simultaneously (Hayer et al., 2010a; Pelkmans and Zerial, 2005). 
Crucially, several mutant variants of CAV1 that affect oligomerization cause 
accumulation of CAV1 in the Golgi apparatus (Ren et al., 2004). The best-studied 
mutation is the exchange of proline-132 to leucine that affects the intramembrane 
helix and favors dimerization over oligomerization (Rieth et al., 2012). 
1.4.2 Cavins as regulators of caveolar stability 
Recent studies identified several proteins that interact with caveolae and regulate 
their biogenesis and stability. These proteins were initially identified within diverse 
cellular processes and only later grouped together into the cavin family (Hansen and 
Nichols, 2010). PTRF (Polymerase I and Transcript Release Factor)/cavin-1 is a 
caveolar coat protein necessary for caveolae formation in cells usually lacking 
caveolae (Hill et al., 2008; Vinten et al., 2005). Depletion of PTRF/cavin-1 was shown 
to mobilize CAV1 from caveolae and induce bulk endocytosis of oligomeric CAV1 
(Hayer et al., 2010b). In the absence of PTRF/cavin-1, CAV1 forms tubule-like 
structures on the plasma membrane while PTRF/cavin-1 overexpression stabilizes 
caveolae (Liu and Pilch, 2008; Verma et al., 2010). The stabilization of caveolae 
requires the interaction between PTRF/cavin-1 and the cytoskeleton (Liu and Pilch, 
2008) (Figure 1.8). Interestingly, in the absence of CAV1 expression, PTRF/cavin-1 
by itself can assemble into large oligomers that contain other cavin-family members 
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(Hayer et al., 2010b). Three more cavin-family proteins were identified and perform 
functions similar to PTRF/cavin-1 (Hansen and Nichols, 2010). For example, SRBC 
(Sdr-Related gene product that Binds to C-kinase)/cavin-3 associates with budding 
caveolae and might regulate vesicular trafficking through caveolae (McMahon et al., 
2009). However, it is not known whether there is hierarchical binding of the cavins to 
caveolae or if cavins define special sub-populations of caveolae within the cell 
(Hansen and Nichols, 2010). Importantly, the different cavin-family proteins show 
tissue specific expression and function in the morphogenesis of caveolae (Hansen et 
al., 2013). 
     
Figure 1.8 Cavins mediate interaction between CAV1 and the cytoskeleton. 
A, under normal conditions, caveolae are tightly associated with the cortical actin 
cytoskeleton and immobilized within the plasma membrane. This involves the F-actin 
binding protein Filamin that interacts with CAV1. Cavins probably form a second coat 
on the cytoplasmic site of caveolae and mediate the interaction with actin. B, after 
stimulation, for example by entry of SV40 virus, multiple signaling events are 
activated. This might involve phosphorylation of CAV1. C, the cortical actin 
disassembles and endocytic vesicles bud from the plasma membrane in a dynamin 
dependent fashion. D, importantly, the cavin-coat stays associated with the caveolar 
vesicle after budding. The CAV1 vesicle can then fuse with the early endosome to 
deliver its cargo. (adopted from Hansen and Nichols, 2010) 
1.4.3 Endocytosis of caveolae 
It has been shown in several studies that caveolae are stable domains in the plasma 
membrane that do not move laterally or exchange subunits (Hayer et al., 2010b; 
Mundy et al., 2002). However, caveolae can be mobilized and bud off from the 
plasma membrane in reaction to certain stimuli (Kirkham et al., 2005; Tagawa et al., 
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2005) (Figure 1.8). Moreover, in addition to an immobile plasma membrane pool a 
cytoplasmic pool of caveolae can be observed to undergo repeated rounds of “kiss-
and-run” interaction with the plasma membrane (Pelkmans and Zerial, 2005). 
Caveolae can engage in dynamin-dependent endocytosis and several extracellular 
cargo proteins can enter the cell via caveolae (Hansen and Nichols, 2009; Howes et 
al., 2010; Mayor and Pagano, 2007). However, the relevance of caveolae for 
endocytosis has been under debate because few cargo proteins require the 
presence of caveolae for endocytosis (Parton and del Pozo, 2013). Overexpression 
of CAV1 is sufficient to induce endocytosis of caveolae and ubiquitination dependent 
degradation in the lysosome (Hayer et al., 2010b). Importantly, we could show that a 
complex between the AAA-ATPase p97 and the UBX-domain containing cofactor 
UBXD1 regulates endosomal trafficking of ubiquitinated CAV1 (Ritz et al., 2011). In 
contrast, CAV1 enters the endosomal system as oligomers after destabilization of 
caveolae by cholesterol depletion or knockdown of PTRF/cavin-1 (Hayer et al., 
2010b). 
Following endocytosis, caveolae can fuse with the RAB5-positive early endosome 
and form stable domains (Pelkmans et al., 2004) (Figure 1.9). Interestingly, the coat 
of PTRF/cavin-1 proteins stays associated with caveolae during endocytosis and on 
early endosomes indicating that caveolae maintain the 70S scaffold on early 
endosomes (Boucrot et al., 2011; Hayer et al., 2010b; Parton and del Pozo, 2013). 
From the early endosome caveolae may recycle to the plasma membrane and the 
rate of recycling can regulate the number of plasma membrane caveolae (Parton and 
del Pozo, 2013; Pelkmans et al., 2004). For example, disruption of integrin-mediated 
adhesion induces endocytosis of caveolae and integrins. CAV1 recycles to the 
plasma membrane in a microtubule dependent manner after restoration of integrin 
adhesion (del Pozo et al., 2005; Parton and del Pozo, 2013). Along this line, 
caveolae redistribute from the plasma membrane to endosomal organelles during 
mitosis and this requires functional microtubules (Boucrot et al., 2011). Generally, 
microtubules mediate intracellular transport of endocytosed caveolae while the 
cortical actin cytoskeleton restricts the movement of caveolae in the plasma 
membrane (Mundy et al., 2002). Recent studies identified the ATPase EHD2 (Eps-15 
Homology Domain-containing protein 2) as a linker between CAV1 and the actin 
cytoskeleton that regulates endocytosis of caveolae (Stoeber et al., 2012). 
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Figure 1.9 Endocytic and exocytic trafficking of CAV1. 
Schematic representation of membrane trafficking of CAV1 in the biosynthetic and 
endosomal pathway. CAV1 is cotranslationally inserted into the ER and assembles 
into oligomers. Subsequently, CAV1 oligomers are transported to the Golgi 
apparatus, where they bind cholesterol and associate into large 70s scaffolds that 
are exported to the plasma membrane. On the plasma membrane CAV1 associates 
with cavin proteins that regulate the stability of caveolae. The cavin-coat stays bound 
to caveolar vesicles following stimulus dependent endocytosis. Non-caveolar CAV1 
or CAV1 that is mobilized after cholesterol depletion can be taken up via other 
endocytic pathways. On early endosomes, the cavin-coat dissociates and CAV1 is 
disassembled into oligomers that are sorted into intralumenal vesicles (ILVs) and 
eventually degraded in the lysosome. This requires ubiquitination of CAV1 and the 
AAA-ATPase p97/VCP. Alternatively, after stimulation with lipids, CAV1 can be 
transported to lipid droplets in the vicinity of the nucleus. Flattening of caveolae in 
response to mechanical stress may release the cavin-coat proteins and induce 
downstream signaling events. (adopted from Parton and del Pozo, 2013) 
1.4.4 Cellular functions of caveolins and caveolae. 
Caveolae form distinct microdomains in the plasma membrane that contribute to the 
regulation of signaling, plasma membrane dynamics, and define a pathway for 
clathrin independent endocytosis (Parton and del Pozo, 2013). Plasma membrane 
receptors like the EGF receptor or the insulin-like growth factor-I receptor (IGF-IR) 
localize to caveolae upon stimulation. This has been shown to induce caveolae-
mediated endocytosis of the IGF-IR but not the EGFR (Salani et al., 2010; Sigismund 
et al., 2005). Furthermore, the compartmentation of signaling molecules in lipid rafts 
and the interaction with CAV1 might be required to coordinate signaling events 
(Schwencke et al., 2006). A well-described membrane protein whose activity is 
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modulated through interaction with CAV1 is the endothelial nitric oxide synthase 
(eNOS) (Collins et al., 2012). Interaction between CAV1 and eNOS negatively 
regulates the eNOS activity and decreases nitric oxide (NO) production after 
induction. Interestingly, this interaction appears to be further regulated in a negative 
feedback loop through NO-induced phosphorylation of CAV1 in the N-terminal region 
(Chen et al., 2012). Additionally, caveolins regulate the surface expression of ion 
channels by mediating interaction between the ion channels and E3 ubiquitin ligases 
in the plasma membrane (Guo et al., 2012; Lee et al., 2009). Even though the 
interaction between CAV1 and signaling proteins in the plasma membrane is well 
documented, the molecular consequences are not yet understood (Byrne et al., 
2012; Collins et al., 2012). 
In addition to signaling, caveolae can mediate cellular adhesion, respond to 
mechanical stresses, and control lipid homeostasis (Parton and del Pozo, 2013) 
(Figure 1.9). Due to their flask-shaped nature, caveolae contain a large amount of 
membrane that can be released by flattening in response to mechanical stress. 
Additionally, cells might sense mechanical forces through signaling events created by 
the flattening of caveolae (Sinha et al., 2011; Yu et al., 2006). Caveolae sequester 
large amounts of cholesterol during biogenesis (Hayer et al., 2010b) and can 
regulate lipid homeostasis. For example, cholesterol treatment of adipocytes induces 
localization of CAV1 to lipid droplets, while knockdown of CAV1 depletes cholesterol 
from this organelle (Le Lay et al., 2006). Along this line, accumulation of cholesterol 
in late endosomes/lysosomes recruits CAV1 from the plasma membrane to the 
membranes of late endosomes/lysosomes (Mundy et al., 2012). Furthermore, non-
caveolar as well as caveolar CAV1 can regulate integrin mediated cell adhesion. 
Phosphorylated CAV1 localizes to focal adhesions, and can induce their turnover to 
regulate cell migration (Nethe and Hordijk, 2011). As mentioned above, disruption of 
integrin adhesion triggers CAV1 dependent endocytosis of adhesion molecules (del 
Pozo et al., 2005). Importantly, the function of CAV1 and caveolae probably differs 
between cell types and depends on associated proteins, like cavins, or 
posttranslational modifications, for example phosphorylation (Parton and del Pozo, 
2013). 
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1.4.5 Caveolins in human disease. 
Even though caveolae are associated with many cellular processes the phenotypes 
of CAV1 knockout mice are rather mild. The mice are viable but show vascular 
disease, cardiomyopathy, and reduced life span. Interestingly, deletion of different 
exons of the CAV1 gene results in different phenotypes, in line with the multitude of 
functions associated with CAV1 (Parat, 2009). The vascular phenotypes are probably 
associated with altered eNOS function in the absence of caveolae (Chen et al., 2012; 
Wunderlich et al., 2008). In human patients, two homologous missense mutations in 
CAV1 and CAV3 have been described. The CAV3 P104L missense mutation is 
associated with limb girdle muscular dystrophy. This CAV3 variant fails to 
oligomerize in the Golgi apparatus and is subsequently degraded via the proteasome 
(Galbiati et al., 2000). The homologous mutation in CAV1, P132L, is associated with 
severe forms of breast cancer due to increased cell migration and invasiveness 
(Bonuccelli et al., 2009). Interestingly, CAV1 has been identified as a tumor 
suppressor gene as well as a proto-oncogene. The tumor-cell type and the 
surrounding tissue most likely determine if loss of plasma membrane CAV1 
stimulates neoplastic growth or prevents tumor development (Schwencke et al., 
2006). Moreover, CAV1 and caveolae have been implicated in insulin mediated 
signaling in diabetes, in cardiomyopathy, and in inflammatory signaling (Chidlow and 
Sessa, 2010; Schwencke et al., 2006). In the brain, CAV1 has a protective role after 
injury, regulates neurotransmitter signaling, and enhances dendritic growth (Head et 
al., 2011). 
1.5 The AAA-ATPase p97 
The hexameric protein p97 belongs to the group of AAA+ (ATPases associated with 
diverse cellular activities) ATPases. Hexameric AAA-ATPases are often involved in 
ATP-driven unfolding of proteins and reshaping of protein complexes (Bukau et al., 
2006). The p97 AAA-ATPase (also known as valosin containing protein (VCP) in 
mammals, Cell division control protein 48 (Cdc48) in yeast, and transitional 
endoplasmic reticulum ATPase 94 (TER94) in fruit flies) is a highly conserved and 
abundant protein (Baek et al., 2013; Meyer et al., 2012; Yamanaka et al., 2012). It 
was identified as a factor for ubiquitin-mediated extraction of proteins from protein 
complexes or membranes as well as membrane fusion. Recent studies expand the 
functional spectrum of p97 to include regulation of the chromatin, endosomal sorting, 
and autophagy. Generally, p97 is recruited to ubiquitinated substrates and utilizes the 
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energy of ATP hydrolysis to segregate or unfold proteins (Meyer et al., 2012). This 
often facilitates degradation of the extracted proteins in the proteasome. A large 
number of protein cofactors associates with p97 that mediates interaction with 
ubiquitinated substrates or modulates posttranslational modifications and is important 
for the activity and functional diversity of p97 (Schuberth and Buchberger, 2008; 
Yeung et al., 2008). Mutations in p97 are associated with an autosomal dominant 
multisystemic disorder described as inclusion body myopathy associated with Paget 
disease of the bone and frontotemporal dementia (IBMPFD, OMIM 167320) (Ju and 
Weihl, 2010; Nalbandian et al., 2011) as well as amyotrophic lateral sclerosis (ALS) 
(Johnson et al., 2010). 
1.5.1 Structure and segregase activity of p97 
The AAA-ATPase protein superfamily constitutes a distinct sub-class of the P-loop 
NTPases. The large class of P-loop NTPases is characterized by the presence of a 
P-loop, also referred to as the Walker A motif, and a second, more variable region, 
called the Walker B motif (Snider and Houry, 2008). The Walker A motif is involved in 
ATP binding while the Walker B motif mediates ATP hydrolysis (Yakushiji et al., 
2006). Each monomer of p97 consists of an N-terminal (N) domain, two AAA-ATPase 
domains D1 and D2, and a C-terminal region. Six p97 monomers together build an 
hourglass-like homo-hexamer with the D1 and D2 ATPase domains forming two 
concentric rings that are stacked on top of each other (DeLaBarre and Brunger, 
2003; Rouiller et al., 2002) (Figure 1.10 A). The N domains are attached peripherally 
to the D1 ring and can move along the central axis of the p97 barrel. In all crystal 
structures of wild type p97, ADP is bound to the D1 domains and the N domains are 
located in one plane with the D1 ring (“down conformation”) (DeLaBarre and Brunger, 
2003). However, cryo-electron microscopy shows that the N domains are flexible and 
move in response to the presence of different nucleotides (Rouiller et al., 2002).  
The D1 domain has low ATPase activity and is mainly responsible for hexamerization 
of p97, while the main ATPase activity that provides the energy for the p97 function is 
located in the D2 domain (Song et al., 2003). Some studies reported that the two 
AAA-ATPase domains operate independently; however, other studies showed 
evidence of inter-dependence (Tang and Xia, 2012). Importantly, the p97 E578Q 
variant that cannot hydrolyze ATP in the D2 domain is dominant negative and traps 
ubiquitinated protein substrates after binding (Ramadan et al., 2007; Ye et al., 2003). 
The globular N domain can either mediate the recruitment of p97 cofactors or directly 
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engage with mono-ubiquitinated substrates (Rape et al., 2001; Schuberth and 
Buchberger, 2008Yeung, 2008 #304; Ye et al., 2003). Furthermore, the N domain 
can stabilize unfolded proteins, may regulate ATP hydrolysis in p97, and even couple 
substrate or adapter binding to hydrolysis (DeLaBarre and Brunger, 2005; Meyer et 
al., 2012). ATP hydrolysis in the D2 domain induces conformational changes that are 
propagated via the relatively immobile D1 domain onto the N domain (DeLaBarre and 
Brunger, 2005; Pye et al., 2006). These conformational changes enable p97 to unfold 
substrate proteins, take apart protein aggregates, or detach proteins from substrates 
like membranes or DNA (Meyer et al., 2012; Stolz et al., 2011; Yamanaka et al., 
2012) (Figure 1.10 B). The interface between the N and D1 domains is of special 
importance because mutations in this region are associated with human disease 
(Nalbandian et al., 2011; Tang and Xia, 2012) that will be discussed in greater detail 
below. Several model exist how ATP hydrolysis could translate to the molecular 
segregase activity of p97. This could involve threading of the substrate protein 
through the central pore or unfolding of substrates on the surface of the p97 
hexamer. However, the precise mechanism of ATP-driven action of p97 in cellular 
processes is not known (Baek et al., 2013). 
The ability of p97 to segregate proteins was first postulated to be involved in the 
disassembly of SNARE (soluble N-ethylmaleimide-sensitive factor (NSF) attachment 
protein receptor) complexes following vesicles fusion (Rabouille et al., 1998). In the 
following, the yeast homologue of p97, Cdc48, was shown to act as a molecular 
segregase in the OLE pathway that is important for fatty acid synthesis and 
membrane fluidity (Hoppe et al., 2000). The transcription factor Spt23 localizes to the 
ER membrane as an inactive precursor called p120. Activation causes dimerization 
and mono-ubiquitination followed by proteasomal cleavage of one p120 molecule to 
yield the active p90 transcription factor. After processing, Cdc48 together with the 
UFD1-NPL4 cofactor recognizes the mono-ubiquitinated p90 and extracts it from the 
p90-p120 dimer. This allows p90 to translocate into the nucleus and activate 
transcription (Rape et al., 2001). The processing of p120 in yeast is similar to the 
activation of the NFκB transcription factor in higher eukaryotes. Interestingly, p97 
was identified to regulate proteasomal degradation of ubiquitinated IκBα (inhibitor of 
NFκB signaling α) in response to cytokine signaling (Dai et al., 1998; Li et al., 2013).  
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Figure 1.10 Structure of p97 and general model for the p97 segregase activity. 
A, crystal structure and schematic representation of the p97 hexamer. Each p97-
monomer consists of an N domain and two ATPase domains D1 and D2. Six 
monomers associate to a p97-hexamer with the D1 (cyan) and D2 (blue) forming two 
concentric rings that are stacked on top of each other. The N domains (green) are 
attached in plane with the D1 ring. The C-terminal tails (grey) are less structured. B, 
schematic model of the general segregase activity of p97. A substrate protein (S) is 
ubiquitinated by a cascade of E1, E2, and E3 enzymes. This ubiquitinated substrate 
is recognized by p97 with the help of cofactor proteins (C). ATP hydrolysis in p97 
segregates the substrate from binding partners (B) or cellular surfaces. Following 
extraction, ubiquitin chain-editing (E4) or deubiquitinating (DUB) enzymes may 
modulate the ubiquitination state of substrate proteins. This can process the 
substrate protein for degradation in the proteasome (Pr) or release it into the 
cytoplasm after deubiquitination. (panels A and B adopted from Meyer et al., 2012) 
1.5.2 Cofactors regulate specificity and functional diversity of p97 
A large number of cofactors associate with p97 to direct the p97 segregase activity 
toward specific cellular processes and regulate the activity of p97 temporally and 
spatially. While most p97 cofactors interact with the N domain, some cofactors can 
interact with the C-terminal region of p97 (Baek et al., 2013; Schuberth and 
Buchberger, 2008; Yeung et al., 2008). The largest family of cofactors binds to p97 
via a UBX (ubiquitin-regulatory X) or UBX-like domain that assumes an ubiquitin-like 
fold and interacts with two partially overlapping binding sites on the p97 N domain 
(Kloppsteck et al., 2012; Meyer et al., 2012; Schuberth and Buchberger, 2008). Other 
general binding modules are the PUB (PNGase (peptide N-glycosidase)/ubiquitin-
associated), or PUL (PLAA, Ufd3, Lub1) domains that interact with the C-terminal 
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region of p97. In addition, some cofactors bind to the p97 hexamer through shorter 
linear binding motifs like the VIM (VCP-interacting motif) or the SHP box. Importantly, 
cofactors can harbor more than one p97-binding site. For example, the cofactor 
UBXD1 (UBX domain containing cofactor 1) interacts with the N domain as well as 
the C-terminal region via a VIM motif and a PUB domain respectively (Madsen et al., 
2008; Stapf et al., 2011).  
The p97 cofactors can be divided into groups according to their p97-binding site, 
mutual exclusivity and enzymatic activity (Jentsch and Rumpf, 2007; Schuberth and 
Buchberger, 2008). Substrate-recruiting cofactors harbor an ubiquitin-binding domain 
in addition to a p97-binding site. Substrate-processing cofactors possess enzymatic 
activity and can modify p97-bound substrate proteins. However, this classification 
oversimplifies the connection between the molecular function of cofactors and their 
structural elements. For example, the UBXD1 protein is an important cofactor in p97-
regulated endosomal sorting even though it harbors no ubiquitin-binding domain and 
does not interact with p97 via its UBX domain but through other interaction sites 
(Madsen et al., 2008; Ritz et al., 2011). Another possibility to categorize p97 
cofactors is a hierarchical model (Meyer et al., 2012; Schuberth and Buchberger, 
2008). Some cofactors bind mutually exclusive to p97 and can be called major 
cofactors. These major cofactors, including the UFD1 (ubiquitin fusion degradation 
protein 1)–NPL4 (nuclear protein localization protein 4) heterodimer, p47, or UBXD1 
define core complexes of p97. Each core complex can act in several pathways by 
recruiting accessory protein factors that mediate localization to specific cellular 
compartments or catalyze additional enzymatic reactions. The main challenge of the 
p97 cofactor system is to investigate the interplay between p97 dependent pathways 
and to link cofactors to specific cellular processes (Meyer et al., 2012; Schuberth and 
Buchberger, 2008). 
The two major cofactors UFD1-NPL4 and p47 harbor ubiquitin-binding domains and 
are examples of substrate-recruiting cofactors. Substrate-recruiting cofactors contain 
p97-binding sites together with one or more ubiquitin-binding domain and often 
mediate the interaction between p97 and ubiquitinated proteins (Jentsch and Rumpf, 
2007; Meyer et al., 2002). However, p97 can also directly interact with ubiquitinated 
substrates via its N domain (Rape et al., 2001; Ye et al., 2003). The UFD1-NPL4 
cofactor directs p97 to poly-ubiquitinated substrates on the ER membrane or 
chromatin and mediates their extraction  (Ramadan et al., 2007; Rape et al., 2001; 
  Introduction 
 43 
Verma et al., 2011; Ye et al., 2003). In turn, the p47 cofactor predominantly binds to 
mono-ubiquitinated substrates and is important for p97-dependent fusion of ER or 
Golgi membranes (Totsukawa et al., 2011). Furthermore, p47 was identified as an 
important factor in the regulation of membranes in autophagy (Krick et al., 2010). In 
contrast, the third major cofactor UBXD1 does not harbor an ubiquitin-binding site 
and probably recruits additional unidentified protein factors that mediate binding to 
ubiquitinated substrates {Ritz, 2010 #164). The UBXD1 cofactor is involved in 
trafficking of membrane proteins in the exocytic and endocytic pathway (Haines et 
al., 2012; Ritz, 2010). 
Another group of p97 cofactors modulates the posttranslational modification of 
substrate proteins and can be called substrate-processing cofactors (Jentsch and 
Rumpf, 2007). Many substrate-processing cofactors are ubiquitin ligases or 
deubiquitinating enzymes. This positions p97 as a coordination center of protein 
ubiquitination and add a further layer of control to the function of p97 in the ubiquitin 
system (Meyer et al., 2012). Several E3 ubiquitin ligases, like HRD1 or AMFR directly 
interact with p97 and regulate ubiquitination of proteins in ER-associated degradation 
(ERAD) (Claessen et al., 2012). Furthermore, several ubiquitin ligases of the cullin 
RING ligase family bind to p97 via the UBX domain containing cofactor UBXD7 and 
are implicated in HIF1α (hypoxia-inducible factor 1 α) turnover (Alexandru et al., 
2008). Additionally, deubiquitinating enzymes like VCPIP1, Otu1, YOD1, or Ataxin-3 
bind to p97 and are involved in various cellular pathways (Ernst et al., 2009; Rumpf 
and Jentsch, 2006; Wang et al., 2006; Wang et al., 2004). However, ubiquitination is 
not the only posttranslational modification that is regulated by p97 substrate-
processing cofactors. For example, glycosylation of ER proteins is modulated by 
peptide N-glycanase (PNGase) that is recruited to p97 together as part of a larger 
regulatory complex (Li et al., 2006). 
In addition to recruiting and modifying substrates, p97 cofactors can directly regulate 
the p97 hexamer. For example, UBXD9/TUG (tether, containing an UBX domain, for 
GLUT4) modulates the oligomeric state of p97 in the early secretory pathway (Orme 
and Bogan, 2012). Along this line, binding of the cofactor p47 regulates the ATPase 
activity of p97 (Meyer et al., 1998). 
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1.5.3 The function of p97 in the ubiquitin-proteasome system 
As described above for the yeast OLE pathway, p97 acts as a driving force that 
segregates ubiquitinated protein complexes. This segregase function of p97 was 
shown to be involved in a wide variety of cellular processes that involve the 
extraction of ubiquitinated proteins from binding partners or cellular surfaces (Meyer 
et al., 2012). This is often connected to proteasomal degradation after extraction 
(Figure 1.11).  
An important cellular process that requires p97 to extract proteins from membranes is 
ER-associated degradation (ERAD). Misfolded or incompletely assembled ER 
proteins are selectively exported from the ER in a process termed retro-translocation 
and degraded in the cytosol by the proteasome (Stolz et al., 2011; Ye, 2006). The 
energy required to extract the ERAD substrates from the ER membrane is provided 
by p97 together with the UFD1-NPL4 cofactor (Ye et al., 2003). The p97-UFD1-NPL4 
complex is recruited to the ER membrane with the help of ER membrane localized 
cofactors, for example UBXD2, UBXD8, or VIMP (Claessen et al., 2012). 
Additionally, the UBX domain containing cofactors UBXD6 and SAKS1 were recently 
identified to localize at the ER membrane together with p97 (Glinka et al., 2013; 
Madsen et al., 2011). Furthermore, p97 associates with ubiquitin-processing factors 
that are necessary to mediate deubiquitination and re-ubiquitination of ERAD 
substrates for extraction and proteasomal degradation (Ballar et al., 2006; Ernst et 
al., 2009; Wang et al., 2006). Many of the large number of p97 cofactors that has 
been described to associate with p97 during ERAD might mediate extraction of 
special substrates or associate with p97 under certain conditions (Baek et al., 2013; 
Claessen et al., 2012). However, the complexity of p97 cofactors in ERAD is not 
understood. The ability of p97 to mobilize proteins from membranes is also utilized in 
other cellular processes. For example, p97 facilitates the extraction and degradation 
of ubiquitinated proteins from the outer mitochondrial membrane (Xu et al., 2011). 
The activity of p97 is not limited to the extraction of proteins from membranes but 
furthermore can mobilize chromatin-bound proteins. During the final stages of 
mitosis, the chromatin-bound mitotic kinase Aurora B keeps the chromatin in a 
condensed state. At the exit from mitosis, Aurora B is ubiquitinated and subsequently 
extracted from the chromatin by the p97-UFD1-NPL4 complex and this enables de-
condensation of chromosomes. (Dobrynin et al., 2011; Ramadan et al., 2007). Upon 
DNA damage, p97-UFD1-NPL4 facilitates proteasomal degradation of the CDC25A 
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phosphatase as an integral part of the G2/M checkpoint (Riemer et al., 2014). Along 
this line, p97 is involved in the regulation of DNA replication and repair of double 
strand breaks in response to radiation damage. Moreover, p97 regulates the activity 
of cyclin-dependent kinases (CDKs) and controls bipolar spindle assembly during 
metaphase. In interphase cells, p97 regulates the stability and turnover of 
transcription factors (Meyer et al., 2012; Yamanaka et al., 2012). 
 
Figure 1.11 Cellular functions of p97 in the ubiquitin-proteasome system and 
membrane trafficking. 
In interphase cells, p97 mediates a wide variety of cellular processes that involve 
degradation of substrate proteins in the proteasome (Pr). Other cellular roles of p97 
are proteasome independent. Most prominently, p97 is required for the degradation 
of misfolded proteins in ER-associated degradation. Additionally, p97 facilitates the 
proteasome dependent degradation of chromatin-associated proteins or proteins of 
the outer mitochondrial membrane. The activity of p97 in the ubiquitin-proteasome 
system prevents the aggregation of misfolded proteins and protects the cell from 
protein stress. In addition, p97 controls cellular signaling and chromatin remodeling 
during DNA replication and repair. In parallel, p97 is involved in proteasome-
independent membrane trafficking. For example, p97 regulates endosomal sorting of 
ubiquitinated membrane proteins to the lysosomes as well as clearance of 
ubiquitinated protein aggregates in autophagy. (adopted from Meyer et al., 2012) 
1.5.4 p97 in membrane trafficking. 
In addition to facilitating proteasomal degradation of ubiquitinated proteins, p97 was 
identified to regulate membrane fusion and trafficking. These functions are less 
extensively characterized compared to the proteasome-associated functions of p97 
and probably involve the remodeling of large protein complexes (Figure 1.11). 
  Introduction 
 46 
During mitosis, the ER and Golgi apparatus are fragmented into vesicles that fuse 
again after exit from mitosis. The reformation of the Golgi apparatus requires the 
action of p97 together with one of the closely related cofactors p47 or p37 
(Totsukawa et al., 2011). Furthermore, the deubiquitinating enzyme VCPIP1 is 
involved in both the p47 and p37 dependent vesicle fusion pathway. However, only 
p47-mediated fusion requires the deubiquitination activity of VCPIP1 (Totsukawa et 
al., 2011; Wang et al., 2004). It is not known which target protein is deubiquitinated 
by VCPIP1 and why deubiquitination is selectively required in the p47-mediated 
pathway. Importantly, the function of p97 in membrane fusion is independent of the 
proteasome and possibly involves cycles of deubiquitination and re-ubiquitination 
(Meyer, 2005). In this pathway, p97 is proposed to act together with a second AAA-
ATPase, NSF, in the disassembly of SNARE complexes following vesicle fusion 
(Rabouille et al., 1998). Another membrane-associated cellular process that is 
regulated by p97 together with the p47 cofactor is autophagy (discussed below). 
Several recent studies from our lab and others have linked p97 to trafficking of 
ubiquitinated membrane proteins to the lysosome (Baek et al., 2013; Bug and Meyer, 
2012). We could show that p97 together with the recently identified cofactor UBXD1 
mediates endosomal sorting of the ubiquitinated membrane protein CAV1 (Hayer et 
al., 2010b; Ritz et al., 2011). Overexpression of the dominant negative p97 variant 
E578Q prevents formation of intralumenal vesicles and this causes accumulation of 
CAV1 on late endosomes. The same phenotype is observed in cells overexpressing 
disease-associated variants of p97 as well as patient fibroblasts. Moreover, 
pharmacological inhibition of p97 prevents lysosomal degradation of ligand activated 
EGF receptor (Ritz et al., 2011). In yeast, protein sorting at multivesicular endosomes 
involves the substrate-recruiting cofactor Ufd3 and deletion of Ufd3 decreases the 
levels of free ubiquitin (Ren et al., 2008). In mammalian cells, p97 is recruited to the 
early endosome by the tethering factor EEA1. The segregase function of p97 might 
regulate the oligomeric state of the EEA1 and, as a consequence, sorting on the 
early endosome (Ramanathan and Ye, 2012). Another factor that recruits p97 to 
endosomes in dendritic cells is poly-ubiquitinated mannose receptor (Zehner et al., 
2011). In the immune system, the segregase activity of p97 is required to extract 
antigens from endosomes for efficient cross-presentation. These data together 
indicate that p97 could regulate endosomal trafficking of diverse cargo proteins (Bug 
and Meyer, 2012). 
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Another proteasome independent degradation pathway that is regulated by p97 is 
autophagy. In yeast, a complex between Cdc48 and the cofactor p47 interacts with 
the ubiquitin-like Atg8 protein during autophagosome formation (Krick et al., 2010). 
The action of p97-p47 could be required to extract Atg8 from the growing 
phagophore. Similar to Golgi vesicle fusion, this function of p97 does not require the 
activity of the proteasome and probably involves segregation of protein complexes. In 
mammalian cells, defective autophagy was shown to be one of the hallmark features 
of the p97-associated congenital disease IBMPFD (Ju and Weihl, 2010). Importantly, 
accumulation of the autophagy marker proteins p62 and LC3 is reproduced in 
mammalian cells as well as transgenic mice that overexpress disease-associated 
variants of p97 (Custer et al., 2010; Ju et al., 2009; Tresse et al., 2010). Other 
examples for p97-mediated autophagy include the ubiquitin-mediated autophagic 
degradation of ribosomes in yeast. This requires the substrate-recruiting cofactor 
Ufd3 together with the deubiquitinating enzyme Ubp3 (Ossareh-Nazari et al., 2010). 
In eukaryotic cells, disease associated cytoplasmic aggregates of ribonucleoprotein 
complexes, called stress granules, are targeted for autophagic degradation in a p97-
dependent fashion (Buchan et al., 2013). However, the mechanistic details of the 
function of p97 in autophagy remain unclear with many models being proposed (Bug 
and Meyer, 2012). Interestingly, endosomal sorting and autophagy are 
interconnected and it was shown that mutations in the membrane sorting machinery 
at multivesicular endosomes inhibit autophagy  (Rusten and Simonsen, 2008). 
Therefore, the function of p97 in endosomal sorting and autophagy might be linked 
(Bug and Meyer, 2012).  
1.5.5 Disease associated mutations in p97. 
Several missense mutations in the N domain or the D1 domain of p97 are associated 
with the multi systemic disorder inclusion body myopathy associated with Paget 
disease of the bone and frontotemporal dementia (IBMPFD, Figure 1.12 A and B). 
The most frequent mutation is the exchange of lysine-155 for histidine (R155H). 
Importantly, all mutations cluster at the interface between the N- and D1-domain, 
which is not part of the nucleotide-binding pocket and not close to any known 
cofactor-binding site (Nalbandian et al., 2011; Tang and Xia, 2012). Importantly, the 
mutations do not abolish but rather increase the ATPase activity of the p97 D2 
domain that provides the energy for p97 activity (Fernandez-Saiz and Buchberger, 
2010; Niwa et al., 2012; Weihl et al., 2006). Moreover, overexpression of the 
pathogenic p97 variants in yeast rescues a lethal Cdc48 disruption in contrast to the 
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p97 wild type (Takata et al., 2012). However, recent studies suggest that the 
mutations could increase the mobility of the N domain in response to nucleotide 
binding in D1 and may affect the interaction between p97 and cofactors (Fernandez-
Saiz and Buchberger, 2010; Ritz et al., 2011; Tang and Xia, 2012). The pathology of 
IBMPFD includes tissue degeneration with patient cells showing rimmed vacuoles, 
re-localization of the nuclear protein TDP-43 into the cytoplasm and accumulation in 
ubiquitin-positive protein aggregates (Nalbandian et al., 2011) (Figure 1.12 C). 
Because p97 is involved in a multitude of processes, it is not surprising that many 
cellular pathways are affected by mutations in p97 (Ju and Weihl, 2010; Nalbandian 
et al., 2011). This includes NFκB signaling, homeostasis of cellular ATP levels and, 
most prominently, autophagy. However, these imbalances are rather mild and take 
several decades to manifest in the IBMPFD phenotype. 
 
Figure 1.12 Disease associated mutation in p97 and cellular phenotype. 
A, schematic representation of the p97 domain structure indicating the position of 
missense mutations associated with IBMPFD (inclusion body myopathy associated 
with Paget disease of the bone and frontotemporal dementia). B, cartoon model of 
the interface between N and D1 domain from crystal structures of p97 showing the 
three-dimensional position of the disease associated mutations. Importantly, all 
mutations are located within the interface of the N and D1 domain. C, IBMPFD 
patient muscle tissue processed for (A) congo red histochemistry or (B) TDP-43 
(TAR DNA binding Protein-43) immunohistochemistry. The micrograph show large 
rimmed vacuoles (A) and re-localization of TDP-43 from the nucleus to cytoplasmic 
inclusions (B) in degenerating muscle fibers. 
Importantly, IBMPFD mutations in p97 were shown to affect the interaction between 
p97 and cofactor proteins (Fernandez-Saiz and Buchberger, 2010; Ritz et al., 2011). 
The interaction of the two major cofactors UFD1-NPL4 and p47 with the IBMPFD 
variants is increased; however, the mutually exclusive binding of UFD1-NPL4 and 
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p47 is not affected by the mutations (Fernandez-Saiz and Buchberger, 2010). In 
addition, several substrate-processing cofactors show differential binding to disease-
associated variants of p97. Importantly, we could show that the p97 R155H mutation 
prevents the interaction between p97 and the major cofactor UBXD1 and that this 
disrupts endosomal trafficking of ubiquitinated CAV1 (Ritz et al., 2011). In cells 
expressing p97 R155H, CAV1 accumulates on the limiting membrane of enlarged 
late endosomes. Crucially, in patient muscle tissue, p97 mutations cause a similar 
delocalization of the caveolin-family member CAV3. In this context, recent studies 
showed that defective autophagy is an important pathogenic feature of IBMPFD 
(Custer et al., 2010; Ju et al., 2009; Tresse et al., 2010). The defect in autophagy 
probably is responsible for the accumulation of ubiquitinated protein inclusions and 
vacuolization in patient tissue. As described above, endosomal sorting and 
autophagy are liked, probably because the sorting machinery on multivesicular 
endosomes is required for fusion of autophagosomes and lysosomes (Rusten and 
Simonsen, 2008). Therefore, the IBMPFD variants of p97 may affect the proteasome 
independent degradation of membrane proteins in endosomal sorting and clearance 
of cytoplasmic aggregates in autophagy through a common mechanism (Bug and 
Meyer, 2012; Custer et al., 2010; Ju et al., 2009; Ju and Weihl, 2010; Tresse et al., 
2010). 
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1.6 The aims of the thesis 
We recently showed that ubiquitinated CAV1 interacted with p97 in a complex with 
the cofactor UBXD1. Importantly, overexpression of dominant-negative or disease-
associated variants of p97 prevented trafficking of CAV1 on late endosomes. 
However, the functional connection between CAV1 ubiquitination and endosomal 
sorting by the p97-UBXD1 complex remained unknown. 
In this context, the goal of this study was to investigate the structural and functional 
consequences of CAV1 ubiquitination; as well as characterize the role of the p97-
UBXD1 complex in trafficking at late endosomes. Therefore, we aimed at identifying 
the ubiquitination site in CAV1 and analyzing the effect of ubiquitination on the 
transport of CAV1 from the plasma membrane to lysosomes. Additionally, we wanted 
to characterize the interaction between CAV1 and the p97-UBXD1 complex; and 
investigate how the p97-UBXD1 complex affected the turnover of ubiquitinated CAV1 
on late endosomes. Finally, we aimed at addressing the question if p97 mediated 
trafficking of further membrane proteins and could be established as a more general 
regulator of endosomal sorting.  
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2 Materials and methods 
2.1  Cell culture 
HEK293, U2OS and HeLa Kyoto cells were maintained in DMEM (Sigma) 
supplemented with 10% fetal bovine serum (FBS, PAA, Lot No: A10110-2432) and 
1% penicillin/streptomycin (PAA). U2OS cell constitutively expressing CAV1-HA 
(U2OS-pIRES-CAV1-HA) were generated by random integration after transfection of 
the linearized pIRESpuro2b-CAV1-HA plasmid. Single clones were selected for 
integration with 0.4 µg/ml puromycin (PAA). U2OS-FRT cells carrying a single 
integrated FRT (Flp recombination target) site were generated by transfection of the 
pFRT/LacZEO plasmid (Invitrogen) according to the manufacturers instructions. 
Single integration was confirmed by Southern blotting (S. Bremer). The U2OS-FRT 
cells were transfected with the pcDNA6/TR plasmid (Invitrogen) to achieve stable 
integration of the tetracycline (Tet) repressor according to the manufacturers 
instructions. Single clones were selected for integration of the Tet repressor gene 
with 50 µg/ml Zeocin (Invitrogen). Presence of the Tet repressor was confirmed in 
Western blotting (M. Bug). The U2OS-FRT cells were used to generate U2OS cells 
expressing either p97-myc-strep (U2OS-p97) or CAV1-HA (U2OS-CAV1-HA) under 
control of a tetracycline-inducible promoter. U2OS-FRT cells were transfected with 
either pcDNA5-p97-myc-strep-FRT/TO or pcDNA5-CAV1-HA-FRT/TO plasmid 
together with the pOG44 Flp-recombinase plasmid (Invitrogen) to achieve integration 
into the FRT site. Single clones were selected. The inducible cell lines were 
maintained in DMEM supplemented with 10% tetracycline free FBS (PAN, Lot No: 
P2880209) and 1 % penicillin/streptomycin with additionally 4 µg/ml blasticidin S 
(PAA) and 130 µg/ml hygromycin B (PAA) for U2OS-p97 or 4 µg/ml blasticidin S and 
120 µg/ml hygromycin B for U2OS-CAV1-HA. Expression was induced with 1 µg/ml 
doxycycline (Sigma-Aldrich). All cell lines were maintained at 37°C in 5% CO2. 
2.2 Transfections 
HEK293 cells were transfected at 60 - 80% confluence using the JetPRIME reagent 
(Polyplus) or a Ca3(PO4)2 based protocol. For JetPRIME transfection in a 3 cm 
diameter well (6 well plate) 2 µg DNA were diluted in 200 µl JetPRIME buffer 
(Polyplus) and briefly vortexed. To this dilution, 4 µl JetPRIME transfection reagent 
were added, vortexed briefly and dropped onto the cells after 10 to 15 minute 
incubation at room temperature. For transfection of HEK293 cells in a 10 cm dish 4 
  Materials and methods 
 52 
µg DNA were diluted in 1095 µl sterile Mili-Q H2O. Then, 155 µl sterile 2M CaCl2 
were added and gently mixed. 1250 µl 2xHBS buffer were added dropwise while 
gently shaking and mixed by inverting the reaction tube 10 times. The transfection 
mix was added drop wise onto the cells without further incubation. U2OS cells and 
derived cell lines were transfected at 60 - 80% confluence using the JetPEI reagent 
(Polyplus). For a 3 cm diameter well (6 well plate) 2 µg DNA were diluted in 100 µl 
150 mM NaCl and briefly vortexed. 4 µ l of the JetPEI transfection reagent were 
diluted in 100 µl 150 mM NaCl, vortexed briefly and added to the DNA dilution. The 
mixture was vortexed briefly and dropped onto the cells after 20 minutes incubation 
at room temperature. The medium was exchanged for fresh growth medium 4 h after 
transfection. For transfection in 12 well plates half the amounts used for transfection 
in 6 well plates were used. All transiently transfected cells were analyzed 24 h post 
transfection. 
2.3 Plasmid constructs 
The plasmid constructs used in this study are detailed in Table 2.2. (page 54). 
Coding sequences were cloned from origin constructs into target plasmid backbones 
either directly through restriction and ligation or after polymerase chain reaction 
(PCR) amplification of the target sequence with DNA primers including novel 
restriction sites. DNA primers carrying restriction sites were designed with 10 to 15 
nucleotides binding to the target sequence and one to three nucleotides overhang 
after the restriction site. The length of the overhang was chosen according to enzyme 
manufacturer recommendations (New England Biolabs). The DNA primers and the 
strategies used for cloning are given in Table 2.2 (page 56). DNA primers were 
purchased from Metabion. The target cDNA sequence was amplified using 2 U of 
Phusion DNA polymerase (Thermo scientific) with the 5x Phusion HF buffer (Thermo 
scientific) in 50 µl reactions. Forward and reverse primers were used at 400 nM 
together with 10 ng DNA template and 200 µM dNTPs. The PCR was carried out in a 
TPersonal thermocycler (Biometra). One PCR cycle consisted of 30 seconds 
denaturing at 98°C, annealing for 30 seconds at 50 – 54°C, and synthesis of the new 
DNA strand at 72°C. The annealing temperature was chosen depending on the 
primers used and the extension time was one minute per one kilobase of the target 
sequence. The PCR program consisted of 30 cycles with a final extension step at 
72°C for 10 minutes. The PCR product was purified using a PCR clean-up kit 
(Machery-Nagel) or used directly for the restriction reaction if the restriction 
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endonucleases had sufficient activity in the Phusion HF buffer. Restriction 
endonucleases were used from New England Biolabs (NEB) in the appropriate 
buffers. 5 to 10 U of enzyme were used to digest one PCR reaction or 2 µg of 
plasmid DNA for 1 h at 37°C. Small DNA fragments were removed with a PCR clean-
up kit (Machery-Nagel). To remove larger DNA fragments the digestion reaction was 
separated on a 0.8 to 1.5 % agarose gel, the band of the target DNA fragment was 
cut out, and purified with a gel extraction kit (Machery-Nagel). To ligate the target 
DNA fragment into a plasmid vector 100 ng of the digested vector were incubated 
with three times excess of the target fragment and 0.2 µl T4 DNA ligase (NEB) in 10 
µl reactions for 2h at 16°C. Chemically competent DH5α cells were transformed with 
2 µl of the ligation reaction with a 42°C heat shock for 45 seconds and grown on LB-
agar plates containing 50 µg/ml ampicillin or 25 µg/ml kanamycin. Insertion of the 
target fragment into the plasmid vector was confirmed in control restrictions and 
directionality and identity of the insert was confirmed through sequencing (GATC 
Biotech). 
2.4 Annealing of primer duplexes 
Short complementary DNA fragments, purchased from Metabion, were designed with 
short overhangs to allow for direct ligation into digested plasmid vectors without need 
for endonuclease digestion. Equal amounts of forward and reverse primer (40 µM) 
were incubated in 25 µl reactions with 2.5 µl T4 ligase buffer (NEB) and 1 µl 
polynucleotide kinase (NEB) for 1h at 37°C to phosphorylate the primers for efficient 
ligation. The reactions were denatured at 95°C for 10 minutes and allowed to cool to 
5°C below the calculated annealing temperature of the primer duplex and incubated 
at this temperature for another 1.5 h. The annealing reactions were allowed to cool to 
room temperature and ligated into appropriately digested plasmid vectors as detailed 
above.  
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Table 2.1 DNA constructs used in this study. 
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Table 2.1 (continued) 
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Table 2.2 DNA primers and cloning strategies. 
 
!"#$#%&' &(%)'#$#%&' *)+")',) -$#$.$*)/)'#(0
121 3&( 4567646777774!"!654765754 89:
(); 764654765#$#7444445754567 89<
=:8><?1 3&( 4564654!""444554554!""7445677 89@
(); 4456774$$#766766777$$#7657567 892
=:81 3&( 74554564654!""4445545545577 AA2
(); 4466766766777$$#76575676674 AA8
=<?1 3&( 7444554554!""7445677457 AAA
(); 4674456774$$#7667667774 AAB
=<91 3&( 757467574757!""455767654754 8A8
(); 764765454667$$#464746457464 8AA
=@A1 3&( 4747454544!""7575647544 8AB
(); 7764756464$$#7767674747 8A9
=2A1 3&( 4474754446!"!4544645547 8B?
(); 4766757767#$#5777647477 8BC
=821 3&( 4756754767764!""5667546667557 8B:
(); 4664555764556$$#7544547645647 8B<
=B81 3&( 4774566677!""74457466454 8B@
(); 76755746774$$#4455567447 8B2
=981 3&( 4546767547!"!654677666654474 8B8
(); 747765555445765#$#4764545767 8BA
=C<21 3&( 765445674566!""5746644675667 89?
(); 4556457755746$$#556745677654 89C
=C221 3&( 755746766777!"!5656645745567 8A:
(); 4566746755656#$#444554574664 8A<
=CA81 3&( 74564554667457!"!75556574774 8A@
(); 74474656664#$#46745576675674 8A2
12= 3&( 4567646777774!!!654765754 A9:
(); 764654765###7444445754567 A9<
1:8= 3&( 74554564654!!"4445545545777 A9@
(); 4446766766777$##76575676674 A92
1<?= 3&( 7444554554!!"7445677457 A98
(); 4674456774$##7667667774 A9A
1<9= 3&( 757467574757!!"455767654754 A9B
(); 764765454667$##464746457464 A99
1@A= 3&( 4747454544!!"7575647544 B??
(); 7764756464$##7767674747 B?C
12A= 3&( 4474754446!!!4544645547 B?:
(); 4766757767###5777647477 B?<
DC@E 3&( 7775456464##$544766444564 BCC
(); 756777554776"!!7575676444 BC:
FC<:G 3&( 77745766765$#!674566557574 BAA
(); 746466556745#!"65455467444 BAB
G0*/#&/5(H/I!%**!$#,J/,&-&'/%'/.&K-L
&#J)(/$!%'&/$,%-/)M,J$'H)*/I!%**!$#,J/,&-&'/%'/.&K-L
5(H/#&/G0*/I!%**!$#,J/,&-&'/%'/.&K-L
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Table 2.2 (continued) 
 
2.5 Site directed mutagenesis 
To introduce single amino acid exchanges or longer deletions into the coding 
sequence of expression constructs, a site directed mutagenesis protocol was used. 
DNA primers were designed with a single base exchange flanked by at least 10 
nucleotides. For larger mutations, at least 12 nucleotides were chosen flanking the 
DNA sequence that was to be looped out. Mutagenesis primers were purchased from 
Metabion and are listed in Table 2.2 (page 56). To introduce the mutation, the whole 
plasmid vector was amplified using 1.25 U PfuUltra II DNA polymerase (Agilent 
Technologies) in 50 µl reactions. The forward and reverse mutagenesis primers were 
used at 300 nM together with 50 – 100 ng template DNA and 400 µM dNTPs. The 
mutagenesis PCR was carried out in a TPersonal thermocycler (Biometra). One PCR 
cycle consisted of 30 seconds denaturing at 98°C, annealing for 60 seconds at 52°C 
!"#$%&'(&)&(*+ ,-. //0111/1//0/11/2111012/22// +'3
."4 22//2/01000/200212202000122 +''
!"#$%&'(&)&(5( ,-. //0111/1//0/11/002/020/02// +'6
."4 22/121/12/11200212202000122 +*5
!"#$%&'(&)&(78 ,-. //0111/1//0/11/11212/00//02 +*7
."4 /122112/0/00200212202000122 +*8
!"#$%&'(&)&(*+ ,-. //0121/1//0/11/2111012/22// +'*
."4 22//2/01000/2002122020/0122 +'+
!"#$%&'(&)&(5( ,-. //0121/1//0/11/002/020/02// +*(
."4 22/121/12/112002122020/0122 +*9
!"#$%&'(&)&(78 ,-. //0121/1//0/11/11212/00//02 +*3
."4 /122112/0/002002122020/0122 +*'
-.:";$%$:-; <"=>";?" !%$%@%<"&";$.A
,-. &22//2/101///101/21/20///121/01/2/012/012/ (55'
."4 0/212/012/012/20120/02221/20/20102220102/ (55*
,-. 210/21100/22/1/2122222// *35
."4 /2102210///012/012/20120/022 *3(
,-. 01/2112210//1/0120//1202022 +*6
."4 /11//220102/102/012/20120/02221/2 ++5
$B"&?%4"-#:;)(&<"=>";?"&C%<&?#-;"!&,.-D&/1E(FDA?&G357H&:;$-&I?JK1)L1&G3(+H&%<&!"#MNF$#%N&,.%OD";$P
0B"&?%4"-#:;)()L1&<"=>";?"&C%<&?#-;"!&:;$-&I?JK1)7QL1)<$."I&G'(8H&%<&R%DLNF1O"N&,.%OD";$&A:"#!:;O&/1E()L1)<$."I
!"#"$:-;&D>$%O";"<:<&-;&/1E(&S3)3*M
!"#"$:-;&D>$%O";"<:<&-;&/1E(&C:#!&$AI"
0B"&?%4"-#:;)()L1&<"=>";?"&C%<&?#-;"!&,.-D&/1E()L1&:;$-&I?JK1&3FTM0F0U&%<&!"#MNF&'#N&,.%OD";$
0B"&?%4"-#:;)()L1&<"=>";?"&C%<&?#-;"!&,.-D&/1E()L1&G377H&:;$-&INMVWI>.-9@&G(66H&%<&!"#MNF()*LN&,.%OD";$
1;;"%#"!&I.:D".&?-!:;O&,-.&%;&L1)$%O&C:$B&$#%NF&'# N&-4".B%;O<&C"."&?#-;"!&:;$-&I?JK1&7P(&G99+H&A:"#!:;O&I?JK1)L1&G3(+HP
X.:D".<&%;!&<$.%$"O:"<&><"!&,-.&D-#"?>#%.&?#-;:;O
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and synthesis of the new DNA strand at 72°C. The annealing temperature was fixed 
at 52°C for all primers and lowered to if the PCR yielded no product. The 
mutagenesis primers were designed to have an annealing temperature (Tm) of 70 to 
72°C when calculated as: Tm = 81.5 + 0.41(%GC) – 675/N - %mismatch. Here %GC 
stands for the GC content of the primer, N denotes the primer length and %mismatch 
is the percentage of the whole primer not pairing with the target sequence. The 
extension time was one minute per one kilobase of plasmid DNA. The PCR program 
consisted of 16 cycles with a final extension step at 72°C for 15 minutes. To digest 
the template DNA, the reactions were incubated with 5 U DpnI (NEB) for 1 h at 37°C. 
The template DNA is methylated and, therefore, specifically degraded by DpnI. The 
digested PCR reactions were purified with a PCR clean-up kit (Machery-Nagel). 
DH5α cells were transformed with the mutated plasmid DNA using a heat shock at 
42°C for 45 seconds. Transformed DH5α were grown on LB plates containing 50 
µg/ml ampicillin or 25 µg/ml kanamycin. Presence of the introduced mutation and 
absence of additional mutations were confirmed by sequencing (GATC Biotech). 
2.6 RNA interference (RNAi) 
Small interfering RNA (siRNA) duplexes were purchased from Microsynth. RNA 
duplexes were designed with a 19 nucleotide core sequence specific for the targeted 
mRNA and 5’ and 3’ dTdT overhangs to improve incorporation into the RISC 
complex. RNA sequences are given in Table 2.3 (page 59). For RNA interference 
experiments cells were either seeded one day in advance (forward transfection) or at 
the same time as RNAi transfection (reverse transfection). The cells were transfected 
at 30 – 50% confluence using the Lipofectamine RNAiMAX transfection reagent 
(Invitrogen). For a forward transfection of 10 nM siRNA in a 6 well plate format, 1.25 
µl of a 20 mM stock solution were diluted in 250 µl Opti-MEM I (Gibco) and vortexed 
briefly. 3.2 µl of the RNAiMAX transfection reagent (Invitrogen) were diluted in 250 µl 
Opti-MEM I, vortexed briefly and added to the diluted siRNA duplexes. The 
transfection reaction was vortexed briefly and drop wise added to the cells after 20 
minutes incubation at room temperature. For transfection of higher concentrations of 
siRNA, like 20 or 40 nM, the volume of RNAiMAX was increased to 4.5 or 6 µl 
respectively. The higher siRNA amounts were used for depletion of the NEDD4, 
NEDD4L, WWP1, and WWP2 E3 ubiquitin ligases because they were published to 
deplete their targets at these concentrations. For transfection in 12 well plates half 
the volumes of 6 well plates were used. For reverse transfection of 10 nM siRNA 
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duplexes in 96 well plates 0.075 µl of a 20 mM stock solution were diluted in 25 µl 
Opti-MEM I and vortexed briefly. 0.2 µl of RNAiMAX transfection reagent were diluted 
in 25 µl Opti-MEM I, vortexed briefly and added to the diluted siRNA duplexes. The 
transfection reaction was vortexed briefly and added to a well on a 96 well plate. 
After 20 minutes incubation 100 µl of a suspension of U2OS-CAV1-HA cells with 
8000 cell/ml were added to the well. RNAi transfected cells were analyzed 48 h or 72 
h post transfection. 
Table 2.3 siRNA oligonucleotides used in this study. 
 
!"#$ %&'$()$*+$!%$ )$!)$(&,$'-"!. )&+'%$ /"0"1")$($!0'2
3456()7 839883::9338:399::: /;/; <+''($0("=>?(@A77 BCD
30"EF!G()7 :88938338838838::39 /;/; H"!.($0("=>?(@A7@ BCG
9<I()7 99:9:9::99338939:83 /;/; J+"!.($0("=>?(@AAK B7D
%0'= ::9:9983398:8:9398: /;/; 6F0L($0("=>?(@A77 M7N
9:IG()7 9339:::9::9333989:3 /;/; J+&0"'F($0("=>(@A7@ M7A
5357()7 99399::93:93:9:38:9 /;/; O"'P($0("=>?(@AAM BBB
J6Q()7 98393383399939398:9 /;/; <"%-$($0("=>?(@AAG MKN
RSTTNI()7 9939339393338:93939 /;/; IF!($0("=>?(@A7A B7M
RSTTNI()@ 8:883933:::38899833 /;/; U"#"/"($0("=>?(@A7@ CNC
RSSTN()7 993:833:9:383383393 /;/; IF!($0("=>?(@A7A B7K
ROIN()7 98:88:883883:8383:: /;/; T&1'2!F!($0("=>?(@A77 MGM
VNM()7 3899389:9::993:9::3 /;/; T&1'2!F!($0("=>?(@A77 DBC
VCM()@ 33938993::9:933393833 /;/; W+F".$!?(J)XY9OXM MAC
VCM()G 338:3888:3:83:8393::8 /;/; H&Z%FP($0("=>?(@AAN MNA
OI33()@ 9938:83:83999::88::33 /;/; W+F".$!?(J)XOI33XC BGG
OI33()G 88393839:98:9:33:93 /;/; W+F".$!?(J)XOI33XK BGN
63<M()7 883:8399:9:38833833 /;/; QVF!&)"($0("=>?(@AAB BBG
Q3[Q7()7 :388838893:899:3883 /;/; W+F".$!?(J)XI\9D7AGDX@ BBC
Q3[Q7()@ 893898883898:833833 /;/; W+F".$!?(J)XI\9D7AGDXD CNB
;Q87A7 983:88938::99388833 /;/; <F)-&V($0("=>?(@AA@ MK7
:<]T7()7 99388:83833388339:: /;/; 6F0L($0("=>?(@A77 DC7
:<]T7()G :9383:399398::88:99 /9/; W+F".$!?(J)X:<]T7XD BBD
:<]TK()7 883:83983833::888:3 /;/; W+F".$!?(J)X:<]TKX@ MC7
:<]TM()7 9389::83338838:8::: /;/; W+F".$!?(J)X[^33AMCNX@ BCA
:<]TB()7 8338::3:::939:33:33 /;/; Q+L+PF($0("=>?(@A7@ BC7
:<]TC()7 999:8:833:3:83:9:83 /;/; \'#$("!/(<&."!?(@A7@ BC@
:5T7()@ 8:8899399:39:99333: /;/; T&1'2!F!($0("=>?(@A77 DCN
Y9O^O7()7 99983:83::3:39:99:8 /;/; W+F".$!?(J)XY9^O^7GDXG B@K
Y9O^O7()@ 93888393839:::38:33 /;/; W+F".$!?(J)XY9^O^7GDX@ B@M
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2.7 Pharmacological treatments 
To inhibit p97 function cells were treated with 10 µM DBeQ (Interbioscreen or Sigma-
Aldrich), or 10 µM I8, or 10 µM I5, or 10 µM I1 for 4 h. Because we received the 
unpublished inhibitors I8, I5, and I1 from for testing, unfortunately an information 
embargo prohibits us from giving up the full names and structures. To inhibit 
lysosomal degradation cells were treated with 200 ng/ml Bafilomycin A1 (Sigma-
Aldrich), 20 mM ammonium chloride (NH4Cl, Fluka), or a mixture of 10 µM leupeptin 
(Sigma-Aldrich) and pepstatin A (Sigma-Aldrich) for 18 h. Proteasomal degradation 
was blocked with 10 µM MG132 (Calbiochem) for 4 h. 
2.8 Preparation of cell extracts 
To stop biochemical processes and preserve proteins all steps during cell lysis were 
carried out on ice. For protein extraction from cells on a 6 well plate the cells were 
washed in 2 ml ice cold PBS. The cells were lysed in 60 µl extraction buffer (detailed 
below) added directly into the well. The extraction buffer was supplemented with 
1:100 protease inhibitor (Roche, Complete EDTA-free) and, if required, 1:10 
phosphatase inhibitor (Roche, PhosSTOP), or 10 mM NEM (Sigma-Aldrich) to inhibit 
deubiquitination by cysteine proteases. The cells were scraped from the well bottom 
using a cell scraper (BD Falcon) and transferred to reaction tubes. After incubation 
on ice for 20 minutes the extracts were centrifuged for 15 minutes at 14000 x g or 
17000 x g to remove nuclei and heavy membrane fragments. Protein concentration 
was measured using a BCA assay (Interchim) in 96 well plate format. For storage the 
extracts were frozen in liquid nitrogen and kept at -80°C. 
2.9 Immunoprecipitation 
To affinity isolate proteins from cell extracts using specific antibodies, the protein 
concentration of the cell lysates was adjusted to 1 – 2 µg/ml in extraction buffer. 
Extracts were supplemented with 1:100 protease inhibitor (Roche, Complete EDTA-
free) and 1 µg/ml BSA (Interchim). For one immunoprecipitation sample 250 µg to 
500 µg protein were used. The samples were pre-cleared with 5 µl Dynabeads 
protein G (Invitrogen) (washed three times in extraction buffer) for 1 h at 4°C, rolling. 
All washing steps of Dynabeads protein G were carried out with a DynaMag Spin 
magnetic tube holder (Invitrogen). After pre-clearing the supernatant was collected 
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and 5 % were taken as an input sample. After addition of 0.6 µg antibody the 
samples were incubated 2 h at 4°C, rolling. To capture the antigen-antibody 
complexes 20 µl Dynabeads protein G were washed three times in extraction buffer 
and incubated with the samples for 1h at 4°C, rolling. From the supernatant, 5 % 
were taken as flow-through samples. The beads were washed three times in 
extraction buffer or once in extraction buffer and two times in PBS and resuspended 
in 18 µl extraction buffer. To the samples 6 µ l of 6x SDS loading buffer freshly 
supplemented with 1:10 1M DTT were added. The samples were boiled at 95°C for 5 
minutes. After boiling, the Dynabeads protein G were removed and the supernatants 
analyzed in Western blotting. 
2.10 SDS-PAGE and Western blotting 
Protein samples from cell extracts or immunoprecipitations were separated by size in 
SDS polyacrylamide gels using a Tris/glycine buffer and the Mini Trans-Blot system 
(Bio-Rad). The polyacrylamide concentration, ranging from 7.5 to 13 %, was chosen 
to provide good resolution target proteins. The gels were run with constant current of 
15 to 20 mA. The gels were either directly stained using Coomassie G-250 or used 
for Western blotting. For Western blotting, the proteins were transferred from the gels 
onto nitrocellulose Hybond-C Extra (Amersham) or PVDF Hybond-P (Amersham) 
using semi-dry or wet blotting protocols. The PVDF membrane was activated in 
methanol for one minute and than soaked in blotting buffer prior to usage. For semi-
dry blots the membrane was placed on top of two filters soaked in blotting buffer. The 
gel was placed on top and the sandwich was finished with another layer of two filter 
papers soaked in blotting buffer. Air bubbles were forced out by rolling the sandwich 
with a plastic tube. Proteins were transferred in semi-dry Trans-blot SD transfer 
chambers (BioRad) at 120 mA constant current for 45 to 55 minutes. The 
membranes were stained in Ponceau-S dye to verify equal transfer and blocked in 10 
% fat free milk in PBS-T or TBS-T for 1 h. For wet blotting, either the blotting buffer 
for semi dry transfer or a special wet blot transfer buffer with reduced SDS were used 
(detailed below). The blotting sandwich was assembled as described above. Proteins 
were transferred in Mini Trans-Blot (Bio-Rad) chambers at 4°C. Voltage was held 
constant at either 70 V for 3 h (blotting of the EGF-receptor) or at 30 V for 2 h. The 
membranes were then stained in Ponceau-S dye and blocked in 10% fat free milk in 
PBS-T or TBS-T. Membranes were washed 3 times for 5 minutes in PBS-T or TBS-T 
after blocking. Primary antibodies were diluted as detailed in Table 2.4 (page 63) and 
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incubated with the membranes over night at 4°C, or 2 h at room temperature in 50 ml 
tubes. Membranes were washed 3 times in PBS-T or TBS-T for 5 minutes. HRP-
coupled Secondary antibodies were diluted 1:10000 or 1:20000 in either PBS-T or 
TBS-T and incubated with the membranes for 45 minutes at room temperature. For 
Western blots of immunoprecipitated proteins, HRP coupled secondary antibodies 
specific for the F(ab’)2 fragment were used to reduce recognition of the denatured 
light and heavy chain of the antibody that was used for capturing the target antigen in 
the immunoprecipitation. The membranes were washed 3 times in PBS-T or TBS-T 
for 15 minutes. To detect the bound secondary antibody, membranes were incubated 
with freshly prepared SuperSignal West Pico enhanced chemiluminescence (ECL) 
substrate (Pierce) for 3 minutes or ECL Plus substrate (Amersham) for 5 minutes. 
The light signals were detected on Super RX films (FUJIFILM). Films were developed 
in a Cawomat 200 IR (Cawo) developing machine. Films were digitalized with a 
ScanMaker i480 film scanner (Microtek). For quantification the signals were detected 
with a Fusion FX7 image acquisition system (Vilber Lourmat) using a cooled CCD 
camera. Digital images were quantified using Bio1D analysis software (Vilber 
Lourmat) or using ImageJ (1.45k, National Institutes of Health). 
2.11 EGFR degradation assay 
The ligand induced lysosomal degradation of the EGFR (epidermal growth factor 
receptor) is established as a model for endosomal sorting and lysosomal degradation 
of membrane proteins. This model was used to investigate the effect the p97 system 
on endosomal sorting. For RNAi experiments HeLa cells were transfected with siRNA 
for 72 h and then serum starved for 4h in DMEM without FCS. For inhibitor 
experiments HeLa or HEK293 cells were grown to confluence and serum starved for 
4 h in DMEM containing p97 inhibitor or DMSO. Starvation accumulates the EGFR 
on the plasma membrane and poses it for stimulation by EGF. Internalization and 
degradation of the EGFR was induced by addition of 50 ng/ml (HEK293) or 100 
ng/ml (HeLa) EGF. The cells were harvested in regular intervals after addition of 
EGF. Cell lysates were analyzed for the EGFR in Western blots as described above. 
The EGFR levels were calculated as percentage of the zero-minute time point. 
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Table 2.4 Primary and secondary antibodies used in this study 
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2.12 Fluorescence imaging 
For visualization of cellular structures specific primary antibodies and fluorophore 
coupled secondary antibodies were used. U2OS Cells were seeded on glass cover 
slips (#1, 0.13 – 0.17 mm thickness, VWR) in cell culture dishes. The cells were 
seeded for sub-confluence at the time of fixation. After transfection or treatment the 
cells were fixed in 4% formaldehyde (CH2O, PFA) in PBS or ice cold methanol. If it 
was desired to remove cytoplasmic proteins prior to fixation, the cells were incubated 
in pre-extraction buffer with 0.0025% saponin for 2 minutes. Cells were then washed 
in PBS and fixed in 4% PFA in PBS. For formaldehyde fixation, cells were washed 
twice in PBS and fixed in 4% PFA in PBS at room temperature for 20 minutes. The 
cells were washed twice in PBS and permeabilized in 0.1% Triton X-100 in PBS for 
10 minutes. After washing three times five minutes in PBS the cells were blocked in 
3% BSA in PBS for 30 minutes. For methanol fixation the cells were washed twice in 
PBS and fixed in ice-cold (-20°C) methanol for 10 minutes at room temperature. After 
washing three times five minutes in PBS the cells were blocked in 3% BSA in PBS 
for 30 minutes. After blocking, the cover slips were placed with the cell side down on 
drops of primary antibody solution on Parafilm (Pechiney) in a wet chamber and 
incubated for 90 minutes. The primary antibodies were diluted in 3% BSA in PBS as 
detailed in Table 2.4 (page 63). The cover slips were washed three times for five 
minutes in PBS and incubated in secondary antibody solution (1:500 in 3% BSA in 
PBS) for 30 minutes. The cover slips were washed three times for five minutes in 
PBS. After rinsing in Mili-Q H2O to remove residual salts, the cover slips were 
mounted with the cell side down onto drops of Mowiol (Calbiochem) solution, 
containing 0.5 µg/ml DAPI, on microscopy slides (Marienfeld). The microscopy slides 
were dried at room temperature and stored at 4°C. Imaging was performed on an 
inverted spinning-disc confocal microscope (Nikon Eclipse Ti equipped with a 
Yokogawa CSU X-1 spinning disk unit) using an x100, 1.49 NA or an x40, 0.94 NA 
objective. Images were acquired with an Andor iXon X3 EMCCD (electron multiplying 
charge coupled device) camera. Epifluorescence microscopy was carried out on an 
inverted fluorescence microscope (Axio Observer Z1, Zeiss) using an x 63, 1.4 NA 
objective. Images were acquired with an AxioCam MRm CCD camera. 
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2.13 Co-localization analysis 
To quantify the colocalization of CAV1-HA or PTRF/cavin-1 positive vesicles with 
staining for ubiquitin or markers of the endosomal system an ImageJ (1.45k, National 
Institutes of Health) routine was developed. The routine identifies CAV1-HA or 
PTRF/cavin-1 positive vesicles in series of images acquired with equal laser intensity 
and exposure time. The vesicles are then classified as positive for colocalization if 
the signal of the ubiquitin or endosomal marker staining is above a certain threshold. 
In detail, the image of the CAV1-HA or PTRF/cavin-1 staining is thresholded to 
remove background signaling. The CAV1-HA or PTRF-cavin-1 threshold parameters 
for the different analyses are listed in Table 2.5 (page 66). The ImageJ Watershed 
algorithm is used to discriminate vesicles in close proximity. Vesicles are identified 
using the Analyze Particles function in ImageJ (vesicle size 10 – 400 pixel, 
roundness 0.5 – 1.0). For each vesicle the colocalizing signal of ubiquitin staining or 
staining for endosomal markers is measured. A vesicle is considered positive if the 
colocalizing signal is above a defined threshold and signal variation is not greater 
than four times the signal variation over the whole image. The thresholds used for the 
different markers are given in Table 2.5 (page 66). For each cell the total number of 
vesicles and of vesicles with colocalizing signal is given as a result. The complete 
algorithm is shown below. 
Code for the ImageJ routine that was used for automated colocalization analysis: 
/* The standard macro used to identify Cav1 vesicles (red) and measure colocalizing signal in the green channel. Results are 
buffered in an array and displayed in the results window after the run. For this only picture files may be present in the folder 
chosen for analysis. The thresholds for vesicles recognition and colocalization can be used to adapt the macro for different 
signal intensities and differences in background staining. The vesicles size can be further used to improve detection of vesicles. 
The table below contains information about the setting used for the different quantifications. Version from 12_08_10. This macro 
is based on the 1.45K version of ImageJ, NIH. */ 
dir1 = getDirectory("Choose Directory "); list = getFileList(dir1); 
total = newArray(list.length);   positive = newArray(list.length); 
setBatchMode(true); 
for (i=0; i<list.length; i++) {   showProgress(i+1, list.length); 
open(dir1+list[i]); 
number_of_vesicles = 0;  positive_vesicles = 0;  
run("Stack to Images"); 
selectWindow("Green");  run("Measure"); 
mean_green = getResult('Mean',nResults-1); std_green = getResult('StdDev',nResults-1);
 green_max = getResult('Max',nResults-1); 
selectWindow("Red");  run("Measure"); 
mean_red = getResult('Mean',nResults-1); std_red = getResult('StdDev',nResults-1); 
threshold_green = mean_green+3*std_green; threshold_red = mean_red+3*std_red;   
threshold_red_std = 4*std_red;  
selectWindow("Green");  setThreshold(threshold_green,16384); 
run("Convert to Mask");  run("Watershed"); 
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run("Analyze Particles...", "size=10-400 pixel circularity=0.50-1.00 show=Nothing add"); 
selectWindow("Red"); 
count = roiManager("count"); 
for (j = 0; j < count; j++) {  roiManager("select", j); 
run("Measure"); 
if (getResult('Mean',nResults-1) > threshold_red && getResult('StdDev',nResults-1) < 
threshold_red_std) { positive_vesicles++; number_of_vesicles++;} 
else  number_of_vesicles++; 
} 
total[i] = number_of_vesicles;   positive[i] = positive_vesicles; 
roiManager("delete"); run("Clear Results"); 
while (nImages>0) {selectImage(nImages);  close();} 
} 
for (matrix=0; matrix<total.length; matrix++) 
{setResult("vesicles", matrix, total[matrix]); 
setResult("positive", matrix, positive[matrix]);} 
updateResults(); 
 
 
Table 2.5 Parameters used for the different colocalization analyses. 
 
2.14 Statistical analyses 
Statistical analyses were performed in SigmaPlot software (Systat) as Mann-Whitney 
U tests. Values of p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***) were considered 
statistically significant. Box plots show median, lower and upper quartiles (line and 
box), 10th and 90th percentile (whiskers), and outliers (). 
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2.15 Buffers and solutions 
2xHBS 
270 mM NaCl 
10 mM KCl 
1.5 mM H2PO4 
10 mM glucose 
40 mM HEPES 
pH 7.05, sterile filter, store at 4°C 
 
extraction buffer 
150 mM KCl 
5 mM MgCl2 
25 mM Tris-HCl 
1% Triton X-100 
5% Glycerol 
2 mM ß-Mercaptoethanol 
pH 7.4, store at -20°C 
 
protease inhibitor 100x 
Dissolve 1 protease inhibitor tablet 
(Roche, Complete EDTA-free) in 500 
µl Mili-Q H2O. 
Store at -20°C. 
 
phosphatase inhibitor 10x 
Dissolve 1 phosphatase inhibitor tablet 
(Roche, PosSTOP) in 1 ml extraction 
buffer. 
Store at -20°C 
6x SDS loading buffer 
0.35 M Tris, pH 6.8 
30% glycerol (87%) 
10% SDS 
600 mM DTT 
dissolve components completely 
add 0.02% bromphenol blue 
 
10x SDS running buffer 
1.9 M glycine 
250 mM Tris base 
pH 8.8 
1% SDS 
 
blotting buffer 
20% methanol 
in 1x SDS running buffer 
 
10x wet blot transfer buffer 
1.92 mM glycine 
205 mM Tris base 
pH 8.3 
0.04% SDS 
 
add 20% methanol to 1x wet blot 
transfer buffer before use 
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Western blot blocking solution 
3% BSA (Albumin fraction V, 
Applichem) 
in PBS-T or TBS-T 
 
LB medium 
10g peptone (Fluka) 
10 g NaCl 
5 g yeast extract (Applichem) 
ad 1 l Mili-Q H2O 
pH 7.0 
autoclave 
 
LB agar 
20 g agar (Applichem) 
ad 1 l LB medium 
autoclave 
 
10x PBS pH 7.4 
100 mM Na2HPO4 
21.7 NaH2PO4 
1.54 M NaCl 
pH 7.4 
 
PBS-T 
0.05 % Tween 20 
in PBS pH 7.5 
 
10x TBS pH 7.6 
1.5 M NaCl 
100 mM Tris 
pH 7.6 
TBS-T 
0.1% Tween 20 
in TBS pH 7.6 
 
stripping buffer 
200 mM gylcine 
0.1% SDS 
1% Tween 20 
pH 2.2 
 
pre-extraction buffer 
80 mM PIPES 
5 mM EGTA 
1 mM MgCl2 
add 0.0025% saponin before use 
 
PFA solution 
4% paraformaldehyde 
in PBS pH 7.4 
store at -20°C 
(store thawed aliquots at 4°C) 
 
IF blocking solution 
3% BSA (Albumin fraction V, 
Applichem) 
in PBS pH 7.4 
 
Mowiol 
5 g Mowiol in 20 ml PBS 
stir over night 
add 10 ml glycerol (87%) 
centrifuge 15 minutes at 17000 x g 
add 0.5 µg/ml DAPI 
store at -20°C 
  Results 
 69 
3 Results 
3.1 CAV1 is ubiquitinated in the N-terminal region 
Ubiquitination of the 178-amino acid membrane protein caveolin-1 (CAV1) was 
shown in previous studies. This modification is functional and governs the half-life of 
overexpressed caveolin-1 (Hayer et al., 2010b; Ritz et al., 2011). However, these 
analyses were performed using a lysine-less variant of CAV1 (K5-176R) in which all 
lysines were mutated to arginine. These extensive mutations in the CAV1 gene might 
affect the behavior of the protein in addition to preventing ubiquitination. The first goal 
of this study was, therefore, to define the ubiquitination site of CAV1 in more detail 
and possibly reduce the number of mutations necessary to abolish CAV1 
ubiquitination.  
3.1.1 Optimizing the assay to investigate ubiquitination of CAV1 variants 
Previous studies of CAV1 ubiquitination in our lab made use of co-expression of 
human CAV1-myc and HA-ubiquitin to bolster the ubiquitination signal (Ritz et al., 
2011). Therefore, we initially chose the same approach and mutated groups of 
lysines in CAV1-myc based on the CAV1 domain structure. Human caveolin-1 
contains 12 lysine residues within four structural domains (Figure 3.1 A). First, we 
mutated the lysines 39 to 96 to arginine that are located N-terminally of the intra-
membrane domain and are present in the both isoforms α -CAV1 and β -CAV1. In a 
second variant, we mutated the two lysines 155 and 176 in the C-terminal domain. 
These CAV1-myc variants were co-expressed with HA-ubiquitin in HEK293 cells and 
immunoprecipitated using myc-specific antibodies. We analyzed conjugation of HA-
ubiquitin to CAV1-myc by Western blotting using HA-specific antibodies and could 
confirm the ubiquitination of CAV1 wild type shown in our lab (Ritz et al., 2011). In 
consistence with these data, we found that the lysine-less variant of CAV1 (K5-176R) 
displayed greatly reduced ubiquitination. Interestingly, we observed that mutation of 
the lysines 39 to 96 but not of lysine 155 and 176 reduced conjugation of HA-
ubiquitin to CAV1-myc (data not shown). This prompted us to focus on the lysines in 
the N-terminal region. Therefore, we mutated the lysines 39 and 47, or 26 to 47, or all 
lysines in the N-terminal region (5 to 57) to arginine (Figure 3.1 A). We co-transfected 
these mutant CAV1 variants and HA-ubiquitin in HEK293 cells and 
immunoprecipitated CAV1-myc as described above. Again, we confirmed 
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modification of CAV1 wild type with HA-ubiquitin (Figure 3.1 B). Ubiquitinated CAV1 
appeared as a slower migrating double band and additional slower migrating bands 
in Western blotting with HA-specific antibodies (Figure 3.1 B, double lines and 
arrow). This indicated that CAV1 was predominantly modified with mono-ubiquitin in 
addition to multi-ubiquitin (Ritz et al., 2011). Importantly, mutation of lysines in the N-
terminal region greatly reduced modification of CAV1 with HA-ubiquitin comparable 
to mutation of all lysines in CAV1 to arginine (K5-176R). Furthermore, two important 
observations were made in this experiment. First, the mutation of lysines in CAV1 
affected the running behavior of the CAV1 protein in SDS-gels. The lysine-less CAV1 
K5-176R variant migrated faster in comparison to the wild type. In general, the CAV1 
protein migrated faster the more lysines in CAV1 were mutated to arginine. Second, 
the lysine-less variant of CAV1-myc was still conjugated with HA-ubiquitin even 
though all lysines were mutated to arginine. This probably resulted from a lysine that 
is present in the myc epitope-tag and made CAV1-myc an unsuitable tool to 
investigate ubiquitination of CAV1. To circumvent the problem of unspecific 
ubiquitination of the myc-tag, we decided to use HA-tagged CAV1 instead because 
the HA-epitope contains no lysine. Furthermore, we chose to generate a CAV1-HA 
construct from human CAV1 cDNA instead of using the HA-tagged CAV1 from dog 
that was described by Hayer and colleagues (Hayer et al., 2010b). Since we 
exclusively used cell lines from human origin as our experimental systems, this 
excluded unspecific effects from differences in the CAV1 amino-acid sequence 
between the two species. To verify that ubiquitination and subcellular localization of 
human CAV1-HA in immunofluorescence microscopy was comparable to dog CAV1-
HA or human CAV1-myc, we transfected these CAV1 variants into U2OS cells. The 
cells were stained with antibodies specific for either the HA- or myc-tag, and ubiquitin 
(FK2). Previous studies of overexpressed dog CAV1-HA showed that CAV1 localized 
to GFP-RAB marked early endosomes. Furthermore, CAV1 wild type but not the 
lysine-less CAV1 K5-176R colocalized with ubiquitin signal on endosomes (Hayer et 
al., 2010b; Ritz et al., 2011). Here, we confirmed the localization of dog CAV1-HA 
wild type and K5-176R to endosomes and the colocalization of dog CAV1-HA wild 
type positive endosomes with ubiquitin signal (Figure 3.1 C). Importantly, also the 
newly generated human CAV1-HA as well as the CAV1-myc constructs localized to 
endosomes. Consistently, only the wild type variants colocalized with ubiquitin signal 
comparable to dog CAV1-HA.  
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Figure 3.1 CAV1-myc is modified with HA-ubiquitin and shows subcellular 
distribution and ubiquitination similar to human, or dog CAV1-HA. 
A, domain structure of the caveolin-1 (CAV1) protein showing the position of all lysine 
residues. Brackets indicate the groups of lysine residues in CAV1-myc that were 
mutated to arginine in this experiment. B, mutation of lysines in the N-terminal region 
interferes with ubiquitination of CAV1-myc. HEK293 cells were transfected with 
pcDNA3.1 empty vector (-), CAV1-myc wild type, or indicated variants in combination 
with HA-ubiquitin and lysed after 24 h. Cell lysates were immunoprecipitated using 
myc-specific antibodies. Immunoprecipitates (IP) were analyzed together with input 
samples in Western blotting using HA- and myc-specific antibodies. CAV1-myc 
modified with one (CAV1-myc + HA-Ub) or several (CAV1-myc + HA-Ubn) HA-
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ubiquitin moieties is indicated. The cross marks the position of the antibody light 
chain. C, CAV1 variants with different tags and from different species show the same 
localization and colocalization with ubiquitin. U2OS cells were transiently transfected 
with CAV1-HA wild type or K5-176R of either human or dog origin or CAV1-myc wild 
type or K5-57R of human origin and formaldehyde fixed after 24 h. The cells were 
stained with HA- and ubiquitin (FK2)-specific antibodies. Images were acquired by 
spinning disk microscopy using an x 100 objective. Representative images are 
shown. Scale bars = 10 µm. 
Taken together, using CAV1-myc we could confirm modification of CAV1 with 
predominantly mono-ubiquitin and found indications that CAV1 might be ubiquitinated 
in the N-terminal region. Furthermore, we generated human HA-tagged CAV1 and 
could show that it localized to endosomes and colocalized with ubiquitin signal 
comparable to dog CAV1-HA. This human CAV1-HA enabled us to investigate the 
ubiquitination of a CAV1 variant that originated from the same species as our cell 
lines without introducing an additional lysine through the tag. 
3.1.2 The lysines in the N-terminal region of CAV1 are sufficient and required 
for CAV1 ubiquitination 
After establishing an appropriate experimental system to analyze the ubiquitination of 
CAV1, we investigated the effect of mutating groups of lysines in CAV1-HA to 
arginine. Based on the domain assignment of CAV1 (Figure 3.2 A) and the 
preliminary results gathered with CAV1-myc (Figure 3.1 B), we mutated the six 
lysines in the N-terminal region of CAV1-HA (K5-57R). A converse variant with the 
six lysines that are not part of the N-terminal region mutated to arginine (K65-176R) 
was generated additionally to a lysine-less CAV1-HA (K5-176R). The mutagenized 
CAV1-HA variants were transfected into U2OS cells and cell lysates were probed in 
Western blotting with caveolin-1-specific antibodies (Figure 3.2 B) CAV1-HA 
migrated slightly above endogenous CAV1 due to the additional residues of the HA-
tag. In addition to the unmodified CAV1-HA wild type protein, we observed several 
slower migrating ubiquitinated species that correspond to the mono- and multi-
ubiquitinated CAV1 described above and in previous studies (Ritz et al., 2011). This 
ubiquitination was unchanged by mutation of the six lysines that are not part of the N-
terminal region of CAV1 (K65-176R). However, we did not observe ubiquitination of 
the CAV1 variant lacking the lysines of the N-terminal region (K5-57R) or the lysine-
less CAV1 (K5-176R). 
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Figure 3.2 Mutation of lysines in the N-terminal region prevents 
ubiquitination of CAV1. 
A, domain structure of the caveolin-1 (CAV1) protein showing the position of all lysine 
residues and the position of tyrosine-14 in the N-terminal region. Brackets indicate 
the groups of lysine residues in CAV1-HA that were mutated to arginine in this 
experiment. B, ubiquitination of CAV1-HA variants in U2OS cells. U2OS cells were 
transfected with pcDNA3.1 empty vector (-), CAV1-HA wild type, or indicated variants 
and lysed after 24 h. Cell lysates were analyzed in Western blotting using caveolin-1-
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specific antibodies. Staining for α -tubulin served as a loading control. The asterisk 
indicates an unspecific band recognized by the anti-caveolin-1 antibody that was 
visible after long exposure. The position of mono-ubiquitinated (CAV1-HA + Ub) or 
multi-ubiquitinated (CAV1-HA + Ubn) CAV1-HA is indicated. C, colocalization of 
CAV1-HA positive endosomes with ubiquitin signal in U2OS cells. U2OS cells were 
transfected with CAV1-HA wild type or indicated variants and formaldehyde fixed 
after 24 h. The cells were stained with HA- and ubiquitin (FK2)-specific antibodies 
and visualized by spinning disk microscopy using an x 100 objective. Representative 
images are shown. Scale bars = 10 µm. D, quantification of C. Automated 
identification of CAV1-HA vesicles and colocalization with ubiquitin (FK2) signal was 
carried out as detailed in “material and methods”. Whiskers indicate the 10th/90th 
percentile and () indicates outliers. ***, p < 0.001, n = 20 cells/condition. E, 
ubiquitination of a phosphorylation-deficient CAV1 variant (Y14F). U2OS cells were 
transfected with CAV1-HA wild type or the Y14F variant and processed for 
immunofluorescence microscopy as in C. Scale bars = 10 µm. 
To support the finding that the lysines 5 to 57 are required for ubiquitination of CAV1, 
we investigated localization of overexpressed CAV1 and colocalization with ubiquitin 
signal in immunofluorescence microscopy. Based on colocalization with the 
overexpressed early endosomal marker protein GFP-RAB5, we could confirm 
published data (Hayer et al., 2010b; Ritz et al., 2011) that CAV1 localized to 
endosomes independently of the mutations (data not shown). These CAV1 
endosomes colocalized with ubiquitin signal in cells overexpressing CAV1 wild type 
but not the lysine-less CAV1 K5-176R (Figure 3.2 C). Importantly, also the CAV1 
variant that was mutated in the N-terminal region (K5-57R) did not colocalize with 
ubiquitin. The CAV1 K65-176R variant, on the other hand, colocalized with ubiquitin 
signal comparable to CAV1 wild type. These differences were quantified using an 
ImageJ routine that measured colocalization with ubiquitin for each CAV1 vesicle 
within a cell. This analysis showed that a median of about 20% of CAV1 vesicles in 
CAV1 wild type expressing cells colocalized with the ubiquitin signal (Figure 3.2 D). 
The colocalization was significantly reduced for the N-terminal (K5-57R) and full (K5-
176R) mutant of CAV1-HA. Mutation of the lysines that are not part of the N-terminal 
region of CAV1 (K65-176R) had no significant effect on colocalization. This suggests 
together with the data from Western blotting that the lysines in the N-terminal region 
but not the lysines in the other domains are critical for CAV1 ubiquitination. 
Interestingly, the N-terminal region harbors another regulatory residue. 
Phosphorylation on tyrosine-14 was described to regulate caveolae-mediated 
endocytosis and cell adhesion (del Pozo et al., 2005; Sverdlov et al., 2007). To 
investigate the effect of phosphorylation in the N-terminal region, we generated a 
phosphorylation-deficient variant of CAV1 with tyrosine-14 mutated to phenylalanine 
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(Y14F). The Y14F variant was expressed in U2OS cells and the cells were stained 
with HA- and ubiquitin (FK2)-specific antibodies (Figure 3.2 E). The CAV1 Y14F 
variant was less efficiently expressed compared to CAV1 wild type but showed no 
difference in localization to endosomal vesicles or colocalization with ubiquitin.  
3.1.3 Ubiquitination of CAV1 in the N-terminal region is promiscuous 
The ubiquitination site in the N-terminal region of CAV1 comprises half of all lysines 
in the CAV1 protein. In this context, we investigated the contribution of individual 
lysines in the N-terminal region towards CAV1 ubiquitination. First, we generated 
CAV1 variants with individual lysines of the N-terminal region mutated to arginine and 
expressed them in U2OS cells. The cell lysates were investigated by Western 
blotting using specific anti-caveolin-1 antibodies as described above. Interestingly, 
mutation of individual lysines did not affect the ubiquitination of CAV1 (Figure 3.3 A). 
The variation in intensity of the ubiquitination bands resulted from unequal 
expression of the CAV1 variants that was observed in shorter exposures of the 
caveolin-1 staining. This suggested that no individual lysine in the N-terminal region 
acted as the main acceptor for ubiquitin. To analyze if all lysines of the N-terminal 
region could be ubiquitinated equally well, we re-introduced individual lysines of the 
N-terminal region into the lysine-less variant of CAV1-HA and expressed these 
variants in U2OS cells (Figure 3.3 B). Importantly, re-introducing a single lysine at 
any of the six positions in the N-terminal region restored ubiquitination to the 
otherwise non-ubiquitinatable lysine-less CAV1 K5-176R. However, not all lysines 
were ubiquitinated with equal efficiency. While the lysines 39 and 47 were 
ubiquitinated the strongest, the lysines 30 and 57 served only as weak ubiquitin 
acceptors. Interestingly, re-introducing individual lysines into CAV1 K5-176R resulted 
in a single mono-ubiquitination band in contrast to the double band that was 
observed for CAV1 wild type mono-ubiquitination. In particular, ubiquitin conjugation 
at the lysines 5, 26, or 30 resulted in a slower migrating band, while conjugation at 
the lysines 39, 47, or 57 resulted in a slightly faster migrating band. Furthermore, if 
lysines from each sub-region were re-introduced into CAV1 K5-576R together 
(R30,39K) a double band was observed, but not if two lysines from the same sub-
region (R39,47K) were re-introduced. This suggested that the site of ubiquitin 
conjugation influences the migratory behavior of CAV1 in SDS gels. 
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Figure 3.3 Any lysine in the N-terminal region of CAV1 can serve as acceptor 
site for ubiquitination. 
A, mutation of single lysines in the N-terminal region does not affect CAV1 
ubiquitination. U2OS cells were transfected with pcDNA3.1 empty vector (-), CAV1-
HA wild type, or variants with a single lysine mutated to arginine, or the variants 
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described in Figure 3.2 B and lysed after 24 h. Cell lysates were analyzed in Western 
blotting using caveolin-1-specific antibodies. Staining for α -tubulin served as a 
loading control. The position of mono-ubiquitinated (CAV1-HA + Ub) CAV1-HA is 
indicated. B, ubiquitination of individual lysines in the N-terminal region of CAV1. 
U2OS cells were transfected with pcDNA3.1 empty vector (-), CAV1-HA wild type, 
K5-176R, or variants with individual lysines of the N-terminal region re-introduced 
into CAV1-HA K5-176R and processed for Western blotting as in A. Staining for α -
tubulin served as a loading control. The position of mono-ubiquitinated (CAV1-HA + 
Ub) CAV1-HA is indicated. C, quantification of colocalization between CAV1 variants 
harboring individual lysines of the N-terminal region and ubiquitin signal. U2OS cells 
were transfected with CAV1-HA wild type, K5-176R, or the K5-176R variants 
harboring individual lysines and formaldehyde fixed after 24 h. The cells were stained 
with HA- and ubiquitin (FK2)-specific antibodies and visualized by spinning disk 
microscopy using an x 100 objective. Colocalization of CAV1 vesicles with ubiquitin 
signal was quantified by automated image analysis. Whiskers indicate the 10th/90th 
percentile and () indicates outliers. n = 15 cells/condition. D, exemplary micrographs 
of the images used for the quantification in C. Scale bars = 10 µm. 
We confirmed these results by automated quantification of colocalization between 
CAV1 vesicles and ubiquitin signal in immunofluorescence microscopy (Figure 3.3 C 
and D). As expected from Western blotting, all CAV1 K5-176R variants harboring 
individual lysines of the N-terminal region showed colocalization with ubiquitin 
staining in contrast to lysine-less CAV1 K5-176R. However, the median percentage 
of CAV1 vesicles that colocalized with ubiquitin signal was reduced in comparison to 
CAV1 wild type. This difference was very pronounced for the R30K and R57K 
variants but less so for the R39K and R47K variants. This corresponds to the 
differences in ubiquitination that were observed in Western blotting. Representative 
micrographs of the images used in this analysis are shown for CAV1 wild type, K5-
176R, R30K, and R39K (Figure 3.3 D). 
Taken together, we established an experimental set up that allowed us to investigate 
the ubiquitination of CAV1 in Western blotting and immunofluorescence microscopy. 
Utilizing these assays, we could identify the lysines in the N-terminal region of CAV1 
as necessary and sufficient for CAV1 ubiquitination. This enabled us in the following 
to investigate the functional consequences of CAV1 ubiquitination without mutating 
all lysines in the CAV1 protein.  
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3.2 Ubiquitination regulates endosomal trafficking of CAV1 
The lysine-less CAV1 K5-176R variant has a markedly increased half-life compared 
to CAV1 wild type (Hayer et al., 2010b). Furthermore, treatment with lysosome 
inhibitors increases the half-life of overexpressed CAV1 wild type. In this context, we 
wanted to investigate the functional connection between CAV1 ubiquitination and 
endosomal sorting and lysosomal degradation of CAV1. Therefore, we transfected 
U2OS cells with CAV1 wild type or the non-ubiquitinatable CAV1 K5-57R variant and 
investigated the effect of mutating the ubiquitination site in the N-terminal region on 
endosomal sorting and lysosomal degradation of CAV1. 
3.2.1 Transport of CAV1 to the lysosome depends on ubiquitination of CAV1 
Lysosomal degradation of membrane proteins requires endosomal trafficking from 
early to late endosomes resulting in formation of multivesicular endosomes that fuse 
with lysosomes (Huotari and Helenius, 2011). Consequentially, we first investigated if 
the non-ubiquitinatable variants of CAV1 were efficiently transported to late 
endosomes and lysosomes. U2OS cells were transfected with CAV1-HA variants and 
stained with HA- and LAMP1 (lysosome-associated membrane glycoprotein)-specific 
antibodies. The LAMP1 protein localizes to membranes of the late endosomal and 
lysosomal compartment and stained many small vesicles throughout the cytoplasm in 
formaldehyde fixed cells (Figure 3.4 A). In cells overexpressing CAV1 wild type or the 
ubiquitinatable CAV1 K65-176R variant, a small number of CAV1 vesicles 
colocalized with LAMP1 vesicles. In contrast, if the non-ubiquitinatable CAV1 variants 
K5-57R or K5-176R were overexpressed the number of CAV1 vesicles colocalizing 
with LAMP1 signal was greatly reduced. This result was confirmed by automated 
quantification of colocalization with the same ImageJ routine we employed for 
analysis of colocalization between CAV1 vesicles and ubiquitin signal. The 
quantification showed that in cells expressing the CAV1 wild type a median of about 
7% of CAV1 vesicles colocalized with LAMP1 signal (Figure 3.4 B). A comparable 
median percentage of CAV1 K65-176R vesicles colocalized with LAMP1, indicating 
an equally efficient transport to late endosomes/lysosomes. Crucially, the median 
percentage of CAV1 vesicles colocalizing with LAMP1 signal was significantly 
reduced in cells expressing the non-ubiquitinatable CAV1 K5-57R variant that is 
mutated in the N-terminal region. This reduction in colocalization was comparable to 
the lysine-less CAV1 K5-176R variant and was consistent with the phenotype 
observed in the micrographs. These data demonstrated that ubiquitination of CAV1 in 
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the N-terminal region was required for efficient transport of CAV1 to late 
endosome/lysosomes.  
 
 
Figure 3.4 Ubiquitinatable variants of CAV1 colocalize with the late 
endosome/lysosome marker protein LAMP1. 
A, trafficking of CAV1 to late endosomes/lysosomes requires the ubiquitination site in 
the N-terminal region. U2OS cells were transfected with CAV1-HA wild type or 
indicated variants and formaldehyde fixed after 24 h. The cells were stained with HA- 
and LAMP1-specific antibodies. Images were acquired by spinning disk microscopy 
using an x 100 objective. Representative images are shown, arrows indicate 
colocalizing vesicles. Scale bars = 10 µm. B, quantification of A. Automated 
identification of CAV1-HA vesicles and colocalization with LAMP1 signal was carried 
out as detailed in “material and methods”. Whiskers indicate the 10th/90th percentile 
and () indicates outliers. ***, p < 0.001, n = 60 cells/condition from three 
independent experiments. 
3.2.2 Autophagy may partially play a role in degradation of overexpressed 
CAV1 wild type 
We could show that CAV1 is trafficked to late endosomes/lysosomes in an 
ubiquitination dependent manner. In addition to endosomal sorting, ubiquitinated 
proteins can be delivered to the lysosome through ubiquitin-specific autophagy. In 
autophagy, a double-membrane structure encircles for example protein aggregates 
targeted for degradation and forms an autophagosome. Subsequently, 
autophagosomes fuse with multivesicular bodies or lysosomes to degrade their cargo 
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(Weidberg et al., 2011). Therefore, we investigated if autophagy could play a role in 
degradation of transiently overexpressed CAV1 in addition to endosomal sorting. We 
co-transfected U2OS cells with CAV1-HA variants and the autophagosome marker 
LC3 (microtubule-associated proteins 1A/1B light chain 3A)-GFP (Figure 3.5 A). In 
control-transfected cells LC3-GFP was distributed uniformly throughout cytoplasm 
and nucleus comparable to GFP alone. In few cells LC3-GFP accumulated in small 
perinuclear spots. Interestingly, overexpression of CAV1 wild type caused 
accumulation of LC3-GFP in few larger vesicles near the nucleus that colocalized 
with CAV1 vesicles. In contrast, overexpression of the non-ubiquitinatable CAV1 K5-
57R variant did not result in accumulation of LC3-GFP in perinuclear vesicles and, as 
a consequence, no colocalization between CAV1 K5-57R and LC3-GFP could be 
observed. To confirm these data using a second marker for autophagosomes, we 
transfected U2OS cells with CAV1-HA variants and stained the cells with antibodies 
specific for the ubiquitin-adapter protein p62/SQSTM1. The ubiquitin-adapter p62 
recognizes ubiquitinated protein aggregates and directs them to autophagy via direct 
binding to LC3 (Kirkin et al., 2009b). In control-transfected cells, p62 was observed in 
many small vesicles that concentrated around the nucleus (Figure 3.5 B). 
Furthermore, preventing the degradation of autophagosomes with the lysosome 
inhibitor bafilomycin A1 caused a striking accumulation of p62 vesicles (data not 
shown). After overexpression of CAV1-HA wild type, the number and also the 
staining intensity of p62 vesicles increased in comparison to control transfected cells 
and a large fraction of CAV1 vesicles colocalized with these p62 spots. It should be 
noted that the number of CAV1 vesicles colocalizing with p62 was markedly higher 
than the number of CAV1 vesicles colocalizing with LC3-GFP. However importantly, 
in cells overexpressing the non-ubiquitinatable CAV1-HA K5-57R no increase in 
number of p62 spots was observed. Consistently, colocalization between CAV1 K5-
57R vesicles and p62 was rare. These experiments provided evidence that at least a 
fraction of overexpressed CAV1 might be funneled into the autophagy system in an 
ubiquitin-dependent manner.  
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Figure 3.5 CAV1 wild type partially colocalizes with markers for autophagy. 
A, CAV1-HA wild type but not the non-ubiquitinatable CAV1-HA K5-57R partially 
colocalizes with LC3-GFP vesicles. U2OS cells were co-transfected with pcDNA3.1 
empty vector, CAV1-HA wild type, or CAV1 K5-57R and GFP or LC3-GFP and 
formaldehyde fixed after 24 h. The cells were stained with HA-specific antibodies and 
visualized by spinning disk microscopy using an x 100 objective. Representative 
images are shown. Scale bars = 10 µm. B, CAV1-HA wild type colocalizes with the 
ubiquitin-adapter p62/SQSTM1. U2OS cells were transfected with pcDNA3.1 empty 
vector, CAV1-HA wild type, or CAV1 K5-57R and formaldehyde fixed after 24 h. The 
cells were stained with HA- and p62-specific antibodies. Images were acquired as in 
A. Representative images are shown. Scale bars = 10 µm. 
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3.2.3 Mutation of the N-terminal lysines has no effect on CAV1 biosynthesis 
and oligomerization 
The CAV1 protein is cotranslationally inserted into the endoplasmic reticulum (ER) 
where it oligomerizes and subsequently transported to the Golgi apparatus. 
Oligomers assemble into higher order structures and are transported to the plasma 
membrane in vesicular carriers (Hayer et al., 2010a). Mutations in the CAV1 protein 
might not only affect ubiquitination and endosomal sorting but could also influence 
the biosynthesis of CAV1. To exclude that overexpressed CAV1 wild type or mutant 
variants accumulated in the biosynthetic pathway, we stained CAV1 in transiently 
transfected U2OS cells together with specific markers of the ER and Golgi apparatus. 
First, we investigated the colocalization of overexpressed CAV1 with the ER 
membrane protein UBXD8. UBXD8 is a cofactor of the AAA-ATPase p97 and 
associates with p97 for the extraction of misfolded protein during ER associated 
degradation (ERAD) (Mueller et al., 2008). U2OS cells were transfected with CAV1-
HA variants and stained with HA- and UBXD8-specific antibodies (Figure 3.6 A). In 
control-transfected cells, UBXD8 was distributed in small spots throughout the cell 
with increasing density around the nucleus. This distribution was not visibly changed 
after expression of either CAV1 wild type or the non-ubiquitinatable K5-57R variant. 
Importantly, no CAV1-HA variant showed colocalization with the ER membrane 
protein UBXD8. To test if overexpressed CAV1 was able to exit the ER and was 
transported to the Golgi apparatus, we investigated colocalization of CAV1-HA with 
the ER-exit site marker SEC31A. ER-exit sites are special regions of the ER where 
vesicles bud off for ER to Golgi transport (Tang et al., 2000). In control-transfected 
cells the SEC31A staining appeared as small spots with increased density around 
the nucleus, comparable to the pattern of UBXD8 staining (Figure 3.6 B). This 
distribution was not affected by overexpression of either CAV1 wild type or the non-
ubiquitinatable K5-57R variant. In fact, no colocalization between CAV1 vesicles and 
the ER exit site marker SEC31A could be observed. From the ER, CAV1 is further 
transported to the Golgi apparatus where it binds cholesterol and oligomerizes. 
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Figure 3.6 Wild type and non-ubiquitinatable CAV1 do not colocalize with 
markers for ERAD or ER-exit sites and are exported from the Golgi apparatus. 
A, CAV1-HA does not colocalize with the ERAD cofactor UBXD8. U2OS cells were 
transfected with pcDNA3.1 empty vector, CAV1-HA wild type, or CAV1 K5-57R and 
methanol fixed after 24 h. The cells were stained with HA- and UBXD8-specific 
antibodies and visualized by spinning disk microscopy using an x 100 objective. 
Representative images are shown. Scale bars = 10 µm. B, CAV1 does not 
accumulate at ER-exit sites marked by SEC31A. U2OS cells were transfected, 
processed for immunofluorescence microscopy as in A, and stained with HA- and 
SEC31A-specific antibodies. Images were acquired as in A. Scale bars = 10 µm. C, a 
small fraction of CAV1-HA vesicles colocalizes with GM130-positive Golgi vesicles. 
U2OS cells were transfected as in A, formaldehyde fixed after 24 h and stained with 
HA- and GM130-specific antibodies. Images were acquired as in A. Scale bars = 10 
µm. 
To exclude accumulation of CAV1 in the Golgi apparatus, we stained CAV1-HA 
transfected U2OS cells with specific antibodies for HA and the Golgi matrix protein 
GM130. In control-transfected cells, GM130 localized to a dense patch of large 
vesicles on one side of the nucleus and overexpression of CAV1 wild type or CAV1 
K5-57R did not change the subcellular distribution of GM130 (Figure 3.6 C). 
Interestingly, we observed colocalization between a small fraction of CAV1 vesicles 
and GM130 staining that was comparable for CAV1 wild type and the non-
ubiquitinatable K5-57R variant. In contrast, an oligomerization deficient mutant of 
CAV1 (P132L) that accumulates in the Golgi apparatus (Lee et al., 2002) strongly 
colocalized with GM130 signal in HeLa cells (data not shown). These experiments 
showed that the mutation of lysines in CAV1 had no effect on biosynthesis and 
oligomerization of CAV1. 
3.2.4 Ubiquitination of CAV1 is required for sorting to early endosomes after 
endocytosis 
We could confirm that the CAV1 vesicles we observed after overexpression of CAV1-
HA variants did not result from accumulation of CAV1 in the biosynthetic pathway. 
Furthermore, we showed that trafficking of CAV1 to late endosomes/lysosomes 
required ubiquitination of CAV1 in the N-terminal region. Therefore, we analyzed if 
the non-ubiquitinatable variants accumulated in an endosomal compartment prior to 
the late endosome. We transfected U2OS cells with CAV1-HA and stained the cells 
with antibodies specific for marker proteins of the early endosomal compartment. In 
control-transfected cells, the early endosome antigen (EEA1) localized to many small 
vesicles that are dispersed throughout the cytoplasm with one denser cluster near 
the nucleus (Figure 3.7 A). Overexpression of CAV1 caused no visible changes in 
the subcellular localization of EEA1. However, in CAV1 wild type expressing cells, 
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the staining intensity of EEA1 vesicles was slightly increased and CAV1 vesicles 
frequently colocalized with EEA1 signal. Crucially, in cells transfected with the non-
ubiquitinatable CAV1-HA K5-57R the colocalization between CAV1 and EEA1 was 
greatly reduced. We confirmed this observation using automated quantification of 
colocalization in ImageJ as described above. In CAV1 wild type expressing cells. a 
median of about 30% of CAV1 vesicles colocalized with EEA1. In consistence with 
the micrographs, this number was significantly reduced in cells expressing CAV1 K5-
57R. To further support this result, we stained CAV1-HA transfected U2OS cells with 
antibodies specific for the small GTPase RAB5 as an additional marker for early 
endosomes. The intensity of the RAB5 staining was lower in comparison to EEA1 but 
showed the same subcellular localization (Figure 3.7 B). In a separate experiment, 
we could confirm that almost all RAB5 vesicles were also positive for EEA1 staining 
(data not shown). Overexpression of CAV1 wild type induced accumulation of RAB5 
on larger vesicles near the nucleus that colocalized with CAV1. Consistently, no 
colocalization was observed in cells overexpressing the non-ubiquitinatable CAV1 
K5-57R. Quantification of this colocalization in ImageJ confirmed that the number of 
CAV1 vesicles with colocalizing RAB5 staining was significantly reduced from a 
median of about 50% to less than 20% in cells expressing CAV1 K5-57R. The higher 
percentage of CAV1 vesicles that colocalized with RAB5 in contrast to EEA1 
probably resulted from the low RAB5 staining intensity and, therefore, increased 
detection of background signal. In cells overexpressing CAV1-HA wild type, the 
caveolar-coat protein PTRF/cavin-1-mCherry colocalizes with CAV1 on RAB5-GFP 
positive early endosomes (Hayer et al., 2010b). PTRF/cavin-1 is stably associated 
with the cytoplasmic face of caveolae and stays bound during endocytosis (Hill et al., 
2008). Therefore, we stained PTRF/cavin-1 as a marker for caveolar vesicles in 
U2OS cells overexpressing CAV1-HA variants (Figure 3.7 C). In control-transfected 
cells PTRF/cavin-1 uniformly stained the plasma membrane in small dots. 
Overexpression of CAV1 induced accumulation of PTRF/cavin-1 in large vesicles 
that almost completely colocalized with CAV1 vesicles. Crucially, this colocalization 
was independent of the N-terminal lysines in CAV1. Additionally, the PTRF/cavin-1 
vesicles that were induced by overexpression of the non-ubiquitinatable CAV1 K5-
57R variant were more brightly stained. 
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Figure 3.7 The non-ubiquitinatable CAV1 K5-57R does not colocalize with 
markers of the early endosome but accumulates together with PTRF/cavin-1. 
A, localization of CAV1-HA to EEA1-positive early endosomes depends on 
ubiquitination of CAV1. U2OS cells were transfected with pcDNA3.1 empty vector, 
CAV1-HA wild type, or CAV1 K5-57R and formaldehyde fixed after 24 h. The cells 
were stained with HA- and EEA1-specific antibodies and visualized by spinning disk 
microscopy using an x 100 objective. Representative images are shown. Scale bars 
= 10 µm. Colocalization of CAV1-HA vesicles with EEA1 signal was quantified by 
automated image analysis. Whiskers indicate the 10th/90th percentile and () indicates 
outliers. ***, p < 0.001. n = 20 cells/condition from two independent experiments. B, 
ubiquitinated CAV1-HA colocalizes with the early endosome marker RAB5. U2OS 
cells were transfected and processed for immunofluorescence microscopy as in A. 
The cells were stained with HA- and RAB5-specific antibodies and images were 
acquired as in A. Scale bars = 10 µm. The percentage of CAV1-HA vesicles 
colocalizing with RAB5 signal was quantified as in A. Whiskers indicate the 10th/90th 
percentile and () indicates outliers. ***, p < 0.001. n = 20 cells/condition from two 
independent experiments. C, the non-ubiquitinatable CAV1-HA K5-57R accumulates 
together with PTRF/cavin-1. U2OS cells were transfected and processed for 
immunofluorescence microscopy as in A. The cells were stained with HA- and 
PTRF/cavin-1-specific antibodies and images were acquired as in A. Scale bars = 10 
µm. The percentage of CAV1-HA vesicles colocalizing with PTRF/cavin-1 signal was 
quantified as in A. Whiskers indicate the 10th/90th percentile and () indicates outliers. 
*, p < 0.05. n = 30 cells/condition from three independent experiments. 
To confirm this observation, we quantified the colocalization between CAV1 and 
PTRF/cavin-1 in ImageJ. In CAV1 wild type expressing cells, a median of about 50% 
of CAV1 vesicles colocalized with PTRF/cavin-1 signal. This colocalization was 
significantly increased to a median of above 60% of CAV1 vesicles in cells 
overexpressing the non-ubiquitinatable CAV1 K5-57R. These data indicated that 
ubiquitination of CAV1 might be necessary for trafficking of PTRF/cavin-1 positive 
caveolar vesicles to early endosomes.  
Because the non-ubiquitinatable CAV1 K5-57R did not localize to the early 
endosome, we expected that the PTRF/cavin-1 vesicles that accumulate after CAV1 
K5-57R expression would be negative for markers of the early endosome. Therefore, 
we overexpressed CAV1-HA variants in U2OS cells and stained the cells with 
PTRF/cavin-1- and EEA1-specific antibodies. The overexpressed CAV1-HA was not 
visualized due to technical limitations. However, as shown in Figure 3.7 C, large 
PTRF/cavin-1 vesicles were only observed after CAV1 overexpression and were 
almost identical with CAV1 vesicles. In control-transfected cells, PTRF/cavin-1 and 
EEA1 stained the plasma membrane or small vesicles respectively (Figure 3.8 A). 
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Figure 3.8 Ubiquitinated CAV1 wild type colocalizes with PTRF/cavin-1 on 
early endosomes. 
A, PTRF/cavin-1 vesicles in CAV1-HA wild type expressing cells colocalize with the 
early endosome marker EEA1. U2OS cells were transfected with pcDNA3.1 empty 
vector, CAV1-HA wild type, or CAV1 K5-57R and formaldehyde fixed after 24 h. The 
cells were stained with PTRF/cavin-1- and EEA1-specific antibodies and visualized 
by spinning disk microscopy using an x 100 objective. Representative images are 
shown. Scale bars = 10 µm. Colocalization of PTRF/cavin-1 vesicles with EEA1 
signal was quantified by automated image analysis. Whiskers indicate the 10th/90th 
percentile and () indicates outliers. ***, p < 0.001. n = 20 cells/condition from two 
independent experiments. B, CAV1-HA wild type is ubiquitinated on PTRF/cavin-1 
vesicles. U2OS cells were transfected and processed for immunofluorescence 
microscopy as in A. The cells were stained with PTRF/cavin-1- and ubiquitin (FK2)-
specific antibodies and images were acquired as in A. Scale bars = 10 µm. The 
percentage of PTRF/cavin-1 vesicles colocalizing with ubiquitin signal was quantified 
as in A. Whiskers indicate the 10th/90th percentile and () indicates outliers. ***, p < 
0.001. n = 20 cells/condition from two independent experiments. 
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Crucially, overexpression of wild type CAV1 caused accumulation of PTRF/cavin-1 
on vesicles that at least partially colocalized with EEA1-positive vesicles. Moreover, 
the colocalization between PTRF/cavin-1 vesicles and EEA1 was reduced in cells 
that overexpressed the non-ubiquitinatable CAV1 K5-57R. We confirmed this result 
by automated quantification of colocalization in ImageJ. In CAV1 wild type 
expressing cells, a median of more than 30% of PTRF/cavin-1 vesicles colocalized 
with EEA1 signal. This colocalization was significantly reduced in cells expressing 
CAV1 K5-57R. Finally, we analyzed if the wild type CAV1 on PTRF/cavin-1 positive 
vesicles is ubiquitinated. Therefore, we transfected U2OS cells with CAV1-HA and 
stained the cells with PTRF/cavin1- and ubiquitin (FK2)-specific antibodies (Figure 
3.8 B). Again, CAV1-HA was not stained due to technical limitations. In control-
transfected cells, ubiquitin was distributed evenly through the cell with few spots of 
higher intensity in the nucleus. Overexpression of CAV1 wild type induced 
accumulation of ubiquitin on vesicles that frequently colocalized with PTRF/cavin-1 
vesicles. In contrast, in cells transfected with the non-ubiquitinatable K5-57R variant 
no ubiquitin-positive vesicles were observed and colocalization with PTRF/cavin-1 
vesicles was rare. Quantification of these images in ImageJ revealed that in CAV1 
wild type expressing cells a median of about 40% of PTRF/cavin-1 vesicles 
colocalized with ubiquitin signal. This percentage was significantly reduced in cells 
expressing CAV1 K5-57R. 
We could confirm that ubiquitination of CAV1 was important for trafficking of CAV1 to 
late endosomes/lysosomes. Importantly, this CAV1 transport defect correlates with 
decreased degradation of the non-ubiquitinatable CAV1 K5-176R (Hayer et al., 
2010b). Additionally, we found evidence that autophagy might at least partially be 
involved in degradation of ubiquitinated CAV1. In contrast, mutation of lysines in 
CAV1 did not affect biosynthesis of CAV1 and trafficking to the plasma membrane. 
Importantly, we showed that ubiquitination of CAV1 was required for trafficking of 
CAV1 to early endosomes after endocytosis on PTRF/cavin-1 positive vesicles. 
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3.3 Establishing a microscopy-based RNAi screen to identify E3 ligases that 
ubiquitinate CAV1 
In the previous experiments, we established a functional link between ubiquitination 
of CAV1 in the N-terminal region and endosomal trafficking of CAV1. However, to 
expand the possibilities for functional studies of CAV1 ubiquitination, we wanted to 
identify the E3 ubiquitin ligase that ubiquitinates CAV1. Therefore, we wanted to 
establish an immunofluorescence microscopy based assay of CAV1 ubiquitination. 
This assay could then be used to screen a large library of siRNAs targeting E3 
ligases for changes in CAV1 ubiquitination. 
3.3.1 Characterizing an inducible U2OS-CAV1-HA cell line with the help of a 
small set of candidate E3 ubiquitin ligases 
The initial requirement for a microscopy-based screening protocol was to generate a 
cell system with robust overexpression of CAV1. Therefore, we generated two U2OS 
cell lines to circumvent the need for transient transfection of CAV1. The first cell line 
constitutively expressed CAV1-HA after random integration of the CAV-HA cDNA 
sequence into the genome (U2OS-pIRES-CAV1-HA). Several clones of this cell line 
were tested and the clone #6 was chosen for its high expression of the transgene 
(data not shown). The second cell line expressed CAV1-HA under control of a 
doxycycline inducible promoter (U2OS-CAV1-HA). Several clones were tested and 
the clone #8 was chosen on basis of its high expression of CAV1-HA after induction 
with doxycycline (data not shown). The constitutively and inducibly expressing U2OS 
cell lines were compared in Western blotting with transient transfection of CAV1-HA 
in U2OS cells (Figure 3.9 A). Transient transfection resulted in high overexpression 
of CAV1-HA and strong ubiquitination. In comparison, the U2OS-pIRES-CAV1-HA 
cell line showed less strong expression and ubiquitination. The inducible U2OS-
CAV1-HA displayed further reduced, but still well detectable, overexpression and 
ubiquitination of CAV1 after induction with doxycycline. The induction efficiency was 
later improved by seeding the cells more dense (data not shown). 
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Figure 3.9 Comparison of constitutive or inducible overexpression of CAV1 
with transient overexpression in U2OS cells. 
A, ubiquitinated CAV1-HA accumulates after constitutive or inducible overexpression 
in U2OS cell lines. U2OS cells were transfected with pcDNA3.1 empty vector or 
CAV1-HA for 24 h. U2OS-CAV1-HA cells were left untreated or induced with 
doxycycline (DOX) for 24 h. The cells were harvested together with U2OS-pIRES-
CAV1-HA cells in lysis-buffer and analyzed in Western blotting using caveolin-1-
specific antibodies. Staining for α-tubulin served as a loading control. The position of 
mono-ubiquitinated (CAV1-HA + Ub) or multi-ubiquitinated (CAV1-HA + Ubn) CAV1-
HA is indicated. B, U2OS-CAV1-HA cells show localization of CAV1-HA to 
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endosomes and colocalization with ubiquitin signal. U2OS, U2OS-CAV1-HA, and 
U2OS-pIRES-CAV1-HA cells were treated as in A. After formaldehyde fixation, the 
cells were stained with HA- and ubiquitin (FK2)-specific antibodies and visualized by 
spinning disk microscopy using an x 40 objective. Representative images are shown. 
Scale bars = 20 µm. 
To confirm endosomal localization of CAV1-HA and colocalization with ubiquitin, we 
stained the cell lines with HA- and ubiquitin (FK2)-specific antibodies and compared 
them to transiently transfected U2OS cells (Figure 3.9 B). Transiently transfected 
U2OS cells were very heterogeneous for CAV1-HA expression. Many cells 
expressed low levels of CAV1-HA or accumulated overexpressed CAV1-HA in 
aggregates. Few cells showed localization of CAV1-HA to endosomes and 
colocalization with ubiquitin signal. The U2OS-pIRES-CAV1-HA cell line showed high 
expression of CAV1-HA and localization to endosomal vesicles in most cells. 
However, these vesicles often did not colocalize with ubiquitin signal. Overall, the 
distribution of ubiquitin was very variable and many cells displayed morphological 
alterations and were polynucleated. Finally, the inducible U2OS-CAV1-HA cell line 
showed overexpression of CAV1-HA in almost every cell after induction, though 
overexpression not always resulted in localization of CAV1 to endosomal vesicles. 
Crucially, the CAV1 vesicles frequently colocalized with ubiquitin signal. However, It 
has to be noted that the intensity of the ubiquitin signal was weaker in comparison to 
transient overexpression of CAV1 in U2OS cells. Based on the immunofluorescence 
microcopy, we chose the U2OS-CAV1-HA cell line clone #8 for further studies. The 
cells appeared healthy and frequently showed ubiquitin positive CAV1 vesicles. 
Next, we tested two assays to measure the levels of ubiquitinated CAV1 in response 
to depletion of E3 ubiquitin ligases in the inducible cell line. We either analyzed 
accumulation of ubiquitinated CAV1 in Western blotting or investigated colocalization 
between CAV1 endosomes and ubiquitin signal in immunofluorescence microcopy. 
To test these assays, we chose a set of candidate E3 ubiquitin ligases that are 
known to ubiquitinate membrane proteins. The candidate ligases contain four 
members (NEDD4, NEDD4L, WWP1, WWP2) of the NEDD4 family of HECT-type E3 
ligases that is associated with endocytosis of membrane proteins (Ingham et al., 
2004). Furthermore, we chose the RING finger E3 ligase cCbl that ubiquitinates the 
EGF receptor and mediates its lysosomal degradation (Haglund et al., 2003). 
Additionally, we selected the cullin-RING ligase cullin-3 (Cul3) because it was shown 
to be involved in the maturation of lysosomes (Huotari et al., 2012). We transfected 
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U2OS-CAV1-HA cells with siRNA oligonucleotides targeting the E3 ubiquitin ligases 
and induced CAV1-HA expression with doxycycline. 
 
 
Figure 3.10 Depletion of E3 ligases causes cellular accumulation of 
ubiquitinated CAV1 but has diverse effects on CAV1-HA localization. 
A, depletion of a set of E3 ubiquitin ligases leads to accumulation of ubiquitinated 
CAV1-HA. U2OS-CAV1-HA cells were transfected with control siRNA (si-ctrl) 
oligonucleotides or the indicated siRNAs for a total of 48 h. The siRNA treated 
U2OS-CAV1-HA cells were later induced with doxycycline (DOX) to express CAV1-
HA 24 h prior to lysis. Cell lysates were analyzed in Western blotting using HA-
specific antibodies. Staining for α-tubulin served as a loading control. The position of 
mono-ubiquitinated (CAV1-HA + Ub) and multi-ubiquitinated (CAV1-HA + Ubn) 
CAV1-HA is indicated. B, depletion of NEDD4L induces localization of CAV1-HA to 
the plasma membrane and possibly reduces colocalization with ubiquitin. U2OS-
CAV1-HA cells were transfected and induced as described in A. The cells were 
formaldehyde fixed and stained with HA- and ubiquitin (FK2)-specific antibodies and 
visualized by spinning disk microscopy using an x 100 objective. Representative 
images are shown. Scale bars = 10 µm. 
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First, we analyzed cell lysates in Western blotting using HA-specific antibodies 
(Figure 3.10 A).  Interestingly, we observed that depletion of any of the tested E3 
ligases increased the levels of ubiquitinated CAV1. In detail, knockdown of the two 
HECT-type ligases NEDD4 or NEDD4L caused weak accumulation of ubiquitinated 
CAV1. Knockdown of cCbl or Cul3 resulted in intermediate accumulation, while 
depletion of the two HECT-type ligases WWP1 or WWP2 resulted in strong 
accumulation of ubiquitinated CAV1. Second, we stained siRNA transfected and 
induced U2OS-CAV1-HA cells with antibodies specific for HA and ubiquitin (FK2) 
(Figure 3.10 B). In the control-depleted condition CAV1 localized to endosomal 
vesicles that colocalized with ubiquitin signal. In contrast, depletion of NEDD4 
caused accumulation of CAV1 in enlarged perinuclear and clearly ubiquitin positive 
vesicles. Interestingly, after knockdown of the E3 ligase NEDD4L CAV1 frequently 
showed increased localization to the plasma membrane in comparison to the control 
depletion. Moreover, the colocalization between CAV1 vesicles and ubiquitin staining 
appeared to be reduced. Because NEDD4L directly interacts with the caveolin-family 
member CAV3 (Guo et al., 2012), we chose to further investigate this phenotype. In 
contrast, depletion of either WWP1 or WWP2 increased the overall number of cells 
with CAV1 endosomes as well as the number of ubiquitin positive CAV1 endosomes 
per cell.  
3.3.2 Automated image quantification can detects changes in CAV1 
ubiquitination over a wide range 
We decided to improve the detection of CAV1 ubiquitination in immunofluorescence 
microscopy by using automated image analysis together with chemical inhibition of 
CAV1 degradation. Therefore, we treated siRNA transfected and induced U2OS-
CAV1-HA cells with NH4Cl to block lysosomal degradation of CAV1 (Hayer et al., 
2010b) and accumulate ubiquitinated CAV1 in the cells. As a negative control we 
used the proteasome inhibitor MG132 that was shown by Hayer and colleagues to 
have no effect on CAV1 half-life. Cell lysates of siRNA transfected and inhibitor 
treated U2OS-CAV1-HA cells were analyzed in Western blotting using HA- and 
NEDD4L-specific antibodies (Figure 3.11 A). Importantly, we could confirm efficient 
depletion of NEDD4L by the NEDD4L siRNA oligonucleotide. In control depleted 
cells, ubiquitinated CAV1 accumulated after lysosome inhibition with NH4Cl but 
decreased after proteasome inhibition. 
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Figure 3.11 In NEDD4L depleted cells ubiquitinated CAV1 does not accumulate 
after lysosome inhibition. 
A, in NEDD4L depleted cells lysosome inhibition causes no accumulation of 
ubiquitinated CAV1-HA. U2OS-CAV1-HA cells were transfected with control siRNA 
(si-ctrl) oligonucleotides or siRNA targeting NEDD4L for a total or 48 h and induced 
with doxycycline (DOX) to express CAV1-HA for 24 h. The cells were treated with 
NH4Cl or solvent alone (PBS) for 18 h prior to lysis. Cell lysates were analyzed in 
Western blotting using HA-and NEDD4L-specific antibodies. Staining for α -tubulin 
served as a loading control. The position of mono-ubiquitinated (CAV1-HA + Ub) and 
multi-ubiquitinated (CAV1-HA + Ubn) CAV1-HA is indicated. B, NEDD4L depletion 
reduces the colocalization of CAV1 vesicles with ubiquitin signal in mock or NH4Cl 
treated cells. U2OS-CAV1-HA cells were transfected and induced as described in A. 
  Results 
 96 
The cells were formaldehyde fixed and stained with HA- and ubiquitin (FK2)-specific 
antibodies and visualized by spinning disk microscopy using an x 100 objective. 
Representative images are shown. Scale bars = 10 µm. C, quantification of B. 
Colocalization of CAV1-HA vesicles with ubiquitin signal was quantified by automated 
image analysis as detailed in “material and methods”. Whiskers indicate the 10th/90th 
percentile and () indicates outliers. Calculated p-values are indicated. n = 20 
cells/condition from two independent experiments. 
Interestingly, in NEDD4L depleted cells, lysosome inhibition caused no accumulation 
of ubiquitinated CAV1, while the decrease in ubiquitinated CAV1 after proteasome 
inhibition was not affected. This suggested that NEDD4L had an influence on the 
levels of ubiquitinated CAV1 destined for lysosomal degradation. In the next step, we 
wanted to reproduce this effect in immunofluorescence microscopy and stained 
siRNA transfected and inhibitor treated U2OS-CAV1-HA cells with HA- and ubiquitin 
(FK2)-specific antibodies (Figure 3.11 B). In the control-depleted cells, NH4Cl caused 
a marked accumulation of CAV1 positive endosomes accompanied by an increase in 
colocalization with ubiquitin signal. In NEDD4L depleted cells, CAV1 endosomes 
accumulated after NH4Cl treatment but there was less increase in colocalization with 
ubiquitin signal, supporting the phenotype that we observed in Western blotting. This 
experiment was quantified using automated colocalization analysis in ImageJ (Figure 
3.11 C). NH4Cl treatment of the control-depleted cells significant increased the 
median number of CAV1 vesicles colocalizing with ubiquitin from 50% to 70%. 
Consistently, treatment of NEDD4L depleted cells with NH4Cl significantly increased 
the median percentage of CAV1 vesicles colocalizing with ubiquitin from 20% to 
more than 50%. However, the median percentage of CAV1 vesicles colocalizing with 
ubiquitin signal was always significantly lower in NEDD4L depleted cells in 
comparison to control-depleted cells. Overall, we could detect significant differences 
in the median percentage of CAV1 endosomes that colocalize with ubiquitin signal 
ranging from 20% up to 70%. 
We established an inducible U2OS-CAV1-HA cell line for robust overexpression of 
CAV1. With this cell line, we tested several E3 ubiquitin ligases in Western blotting 
and immunofluorescence microscopy for effects on the levels of ubiquitinated CAV1. 
Depletion of these ligases resulted in accumulation of ubiquitinated CAV1. 
Furthermore, we observed that NEDD4L depletion decreased the levels of 
ubiquitinated CAV1 after lysosome inhibition but not in control-treated cells. 
Importantly, we could show that automated analysis was able to detect differences in 
colocalization between CAV1 vesicles and ubiquitin signal over a wide range. 
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3.4 The p97-UBXD1 complex interacts with CAV1 and regulates lysosomal 
turnover of CAV1 
In our lab we previously showed that wild type CAV1 but not the lysine-less CAV1 
K5-176R interacts with the AAA-ATPase p97 and the cofactor UBXD1. Furthermore, 
expression of the dominant negative p97 E578Q variant caused accumulation of 
CAV1 on enlarged endosomes (Ritz et al., 2011). In this study we observed that 
ubiquitination of CAV1 in the N-terminal region was important for endosomal sorting 
of CAV1. Therefore, we asked if the lysines in the N-terminal region of CAV1 also 
were required for the interaction between CAV1 and p97 and how p97 regulated 
endosomal sorting of ubiquitinated CAV1. 
3.4.1 The ubiquitination site in the N-terminal region of CAV1 is required for 
interaction with p97-UBXD1 on endosomes 
Initially, we analyzed if mutation of the six lysines in the N-terminal region of CAV1 
was sufficient to abolish interaction with p97 and the p97 cofactor UBXD1. Therefore, 
we immunoprecipitated CAV1-myc from cell lysates of transiently transfected 
HEK293 cells using myc-specific antibodies and investigated co-precipitation of p97 
and UBXD1 in Western blotting (Figure 3.12 A). Co-precipitation of p97 and UBXD1 
was observed with the CAV1 wild type as well as with the CAV1 K65-176R variant. 
Both variants harbor a wild type N-terminal region and were shown to be 
ubiquitinated. Crucially, mutating the N-terminal lysines (K5-57R) or all lysines in 
CAV1 (K5-176R) abolished the co-precipitation of p97 and UBXD1. Since we 
observed that ubiquitinated CAV1 localized to endosomes, we analyzed if the 
interaction between CAV1 and the p97-UBXD1 complex takes place on endosomes. 
Because specific localization studies of endogenous or transiently overexpressed 
p97 were previously unsuccessful, we generated an U2OS cell line that expresses 
low levels of p97-myc-strep (U2OS-p97-myc-strep) under control of a doxycycline 
inducible promoter (Figure 3.12 B). The U2OS-p97-myc-strep cells were transfected 
with CAV1-HA variants, induced to express p97-myc-strep, and stained with HA- and 
myc-tag-specific antibodies. Importantly, in cells overexpressing CAV1 wild type or 
the ubiquitinatable K65-176R variant, p97-myc-strep accumulated on CAV1-positive 
vesicles (Figure 3.12 C). In contrast, if the non-ubiquitinatable CAV1 variants K5-57R 
and K5-176R were overexpressed the localization of p97-myc-strep to CAV1 
endosomes was greatly reduced although not completely abolished. 
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Figure 3.12 The lysines in the N-terminal region of CAV1 are required for 
interaction with P97-UBXD1 and recruitment to endosomes. 
A, ubiquitinatable CAV1 interacts with p97-UBXD1. HEK293 cells were transfected 
with pcDNA3.1 empty vector (-), CAV1-myc wild type or the indicated variants and 
lysed after 24 h. Cell lysates were immunoprecipitated using myc-specific antibodies. 
Immunoprecipitation with HA-specific antibodies was used as a negative control (-). 
Immunoprecipitates (IP) were analyzed together with input samples in Western 
blotting using myc-, UBXD1-, and p97-specific antibodies. The asterisk indicates the 
position of the antibody heavy chain. B, expression of p97-myc-strep in U2OS cells 
under a doxycycline inducible promoter. U2OS-p97 cells were left untreated or 
induced with doxycycline (DOX) to express p97-myc-strep and lysed after 24 h. Cell 
lysates were analyzed in Western blotting using p97-specific antibodies. Staining for 
α-tubulin served as a loading control. The position of endogenous p97 and p97-myc-
strep is indicated. C, ubiquitinatable CAV1 variants recruit p97 to endosomes. U2OS-
p97-myc-strep cells were induced with doxycycline (DOX) to express p97-myc-strep 
and transiently transfected with CAV1-HA wild type and the indicated variants. The 
cells were formaldehyde fixed and stained with HA- and myc-specific antibodies. 
Images were acquired on a spinning disk microscope using an x 100 objective. 
Representative images are shown. Scale bars = 10 µm. D, quantification of C. 
Colocalization between CAV1-HA and p97-myc positive vesicles was quantified by 
automated image analysis. Whiskers indicate the 10th/90th percentile and () indicates 
outliers. *, p < 0.05, **, p < 0.01. n = 30 cells/condition from three independent 
experiments. E, ubiquitinatable CAV1 variants localize UBXD1-mCherry to 
endosomes. U2OS cells were transiently transfected with UBXD1-mCherry and 
CAV1-HA wild type or the indicated variants and processed for immunofluorescence 
microscopy using HA-specific antibodies as in C. Scale bars = 10 µm. F, 
quantification of E as in D. Whiskers indicate the 10th/90th percentile and () indicates 
outliers. ***, p < 0.001. n = 30 cells/condition from three independent experiments. 
We quantified these images using automated colocalization analysis in ImageJ as 
described above. In cells expressing the ubiquitinatable CAV1 wild type or K65-176R 
a median of above 20% of CAV1 vesicles colocalized with p97-myc-strep (Figure 
3.12 D). Importantly, this colocalization was significantly reduced in cells expressing 
the non-ubiquitinatable CAV1 variants. However, a median of above 10% of CAV1 
endosomes still showed colocalization with p97-myc-strep comparable to the 
phenotype observed by eye. Along this line, we investigated if the p97 cofactor 
UBXD1 showed a comparable localization to endosomes after overexpression of 
ubiquitinatable CAV1. Importantly, previous experiments showed colocalization of 
UBXD1-mCherry with wild type CAV1-GFP in life cell microscopy (Ritz et al., 2011). 
We expressed the CAV1-HA variants and UBXD1-mCherry in U2OS cells and 
confirmed colocalization of UBXD1-mCherry with wild type CAV1 and CAV1 K65-
176R in fixed cells (Figure 3.12 E). In contrast, in cells expressing the non-
ubiquitinatable variants of CAV1-HA, UBXD1-mCherry did not localize to CAV1 
endosomes. Quantification of this colocalization in ImageJ confirmed that a median 
of about 10% of CAV1 wild type and CAV1 K65-176R vesicles colocalized with 
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UBXD1-mCherry (Figure 3.12 F). In contrast, the percentage of CAV1 vesicles 
colocalizing with UBXD1-mCherry was significantly reduced in cells expressing the 
non-ubiquitinatable CAV1 variants. This colocalization study indicated together with 
the CAV1 immunoprecipitations that the six N-terminal lysines in CAV1 are important 
for interaction with p97-UBXD1. Moreover, this interaction probably takes place on 
endosomes. 
3.4.2 CAV1 is degraded in the lysosome and this requires p97 activity 
We have established that ubiquitination of CAV1 is required for endosomal transport 
of CAV1 to late endosomes/lysosomes and could show that p97 interacts with 
ubiquitinated CAV1. Therefore, we investigated a functional connection between p97 
and endosomal sorting of ubiquitinated CAV1. We utilized the inducible U2OS-CAV1-
HA cell line that we generated for the siRNA screen of E3 ubiquitin ligases (Figure 
3.9) to confirm that ubiquitinated CAV1 is degraded in the lysosome. U2OS-CAV1-
HA cells were induced and treated with inhibitors of lysosomal or proteasomal 
degradation. The cell lysates were investigated in Western blotting using caveolin-1- 
and ubiquitin (FK2)-specific antibodies (Figure 3.13 A). Inhibition of lysosomal 
degradation with either bafilomycin A1 or ammonium chloride (NH4Cl) accumulated 
ubiquitinated and unmodified CAV1. This was not the case if the cells were treated 
with the proteasome inhibitor MG132 even though proteasome inhibition caused a 
general accumulation of ubiquitinated substrates as seen in the ubiquitin staining. 
Interestingly, the levels of ubiquitinated CAV1, especially of multi-ubiquitinated CAV1 
(CAV1-HA + Ubn), were reduced after proteasome inhibition. This is consistent with a 
depletion of free ubiquitin and reduced ubiquitin conjugation in MG132 treated cells 
(Melikova et al., 2006). After confirming that ubiquitinated CAV1 was degraded in the 
lysosome, we investigated the effect of pharmacological inhibition of p97 on the 
levels of ubiquitinated CAV1. Due to the high toxicity of the p97 inhibitor DBeQ (Chou 
et al., 2011) we could not extend the treatment beyond 4 h in comparison to the 18 h 
treatment we used for lysosome inhibitors. Nonetheless, we observed some 
accumulation of ubiquitinated CAV1 in comparison to the DMSO control (Figure 3.13 
B). 
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Figure 3.13 Ubiquitinated CAV1 accumulates after pharmacological inhibition 
of the lysosome or p97. 
A, inhibitors of the lysosome but not of the proteasome cause accumulation of 
ubiquitinated CAV1. U2OS-CAV1-HA cells were induced with doxycycline (DOX) for 
24 h to express CAV1-HA. The cells were mock treated (m.t.), treated with DMSO or 
the lysosome inhibitors bafilomycin A1 or NH4Cl for 18 h or treated with the 
proteasome inhibitor MG132 for 4 h prior to lysis. Cell lysates were analyzed in 
Western blotting using HA- and ubiquitin (FK2)-specific antibodies. Staining for α -
tubulin served as a loading control. The position of mono-ubiquitinated (CAV1-HA + 
Ub) and multi-ubiquitinated (CAV1-HA + Ubn) CAV1-HA is indicated. B, short 
pharmacological inhibition of p97 causes weak accumulation of ubiquitinated CAV1. 
U2OS-CAV1-HA cells were induced as in A. The cells were mock treated (m.t.), or 
treated with DMSO, or DBeQ for 4 h prior to lysis. Cell lysates were analyzed in 
Western blotting as in A using caveolin-1-specific antibodies. C, CAV1 accumulates 
on late endosomes after inhibition of the lysosome or p97. U2OS cells were induced 
and treated with lysosome, proteasome, or p97 inhibitors as in A and B. The cells 
were formaldehyde fixed and stained with HA- and LAMP1-specific antibodies. 
Images were acquired on a spinning disk microscope using an x 100 objective. 
Representative images are shown. Scale bars = 10 µm. 
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To investigate the subcellular localization of CAV1 after treatment with lysosome, 
proteasome, or p97 inhibitors, we stained U2OS-CAV1-HA cells with antibodies 
specific for HA and the late endosome/lysosome marker protein LAMP1. In the 
untreated or DMSO control-treated cells, CAV1 localized to many small endosomal 
vesicles that were frequently positive for LAMP1 (Figure 3.13 C). Interestingly, the 
colocalization between CAV1 and LAMP was increased in the inducible cell line 
compared to transiently transfected U2OS (Figure 3.4 A). After lysosome inhibition 
with bafilomycin A1, CAV1 accumulated on many large endosomes that strongly 
colocalized with LAMP1 staining. Additionally, the LAMP1 vesicles appeared 
clumped and enlarged compared to the control. Treatment with the proteasome 
inhibitor MG132 caused no accumulation of CAV1 and did not affect the 
colocalization between CAV1 vesicles and LAMP1. However, treatment with the p97 
inhibitor DBeQ induced accumulation of CAV1 on LAMP1-positive enlarged 
endosomes. In comparison to bafilomycin A1 treated cells the vesicles were smaller 
and the colocalization with LAMP1 was less stringent. Along this line, we could show 
that after lysosome or p97 inhibition CAV1 accumulated together with ubiquitin (data 
not shown). 
We chose an RNAi approach to analyze the function of p97 in lysosomal degradation 
of CAV1 from an additional angle. Therefore, we depleted p97 and the cofactor 
UBXD1 that interacted with ubiquitinated CAV1. The inducible U2OS-CAV1-HA cells 
were transfected with specific siRNA oligonucleotides targeting p97 and UBXD1 and 
CAV1-HA expression was induced with doxycycline. Cell lysates were probed in 
Western blotting with specific antibodies and efficient depletion of p97 and UBXD1 
was shown (Figure 3.14 A).  Importantly, transfection of siRNA oligonucleotides 
targeting p97 or UBXD1 but not of non-targeting control siRNA or mock transfection 
caused a strong accumulation of ubiquitinated CAV1. Recently, we identified several 
p97 cofactors including the deubiquitinating enzymes (DUBs) YOD1 and VCPIP1 and 
the substrate-recruiting cofactor PLAA to be involved in endosomal trafficking and 
lysosomal degradation of the EGF receptor (M. Bug, unpublished data). Therefore, 
we investigated if these p97 cofactors were also involved in lysosomal turnover of 
ubiquitinated CAV1. We transfected U2OS-CAV1-HA cells with siRNA 
oligonucleotides targeting p97, UBXD1, p47, YOD1, VCPIP1, and PLAA and induced 
expression of CAV1-HA as above. Effective knockdown efficiency was confirmed for 
the siRNA targeting PLAA (Figure 3.14 B), as well as the other siRNAs (data not 
shown). As described above, strong accumulation of ubiquitinated CAV1-HA was 
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observed after depletion of p97 and UBXD1. Interestingly, depletion of the substrate-
recruiting cofactor PLAA and the DUB VCPIP1 but not YOD1 showed a comparable 
effect. However, knockdown of another substrate-recruiting cofactor, p47, did not 
affect the levels of ubiquitinated CAV1. This shows that functional p97 is required for 
lysosomal degradation of ubiquitinated CAV1 and may require additional cofactors. 
 
 
Figure 3.14 Depletion of p97, UBXD1, VCPIP1, or PLAA causes accumulation 
of ubiquitinated CAV1. 
A, depletion of p97 or UBXD1 leads to accumulation of ubiquitinated CAV1. U2OS-
CAV1-HA cells were left untreated (no siRNA) or transfected with control siRNA 
oligonucleotides (si-ctrl), siRNAs targeting p97, or UBXD1 for a total of 48 h. The 
cells were induced with doxycycline (DOX) to express CAV1-HA 24 h prior to lysis. 
Cell lysates were analyzed in Western blotting using caveolin-1-specific antibodies. 
Staining for α-tubulin served as a loading control. The position of mono-ubiquitinated 
(CAV1-HA + Ub) or multi-ubiquitinated (CAV1-HA + Ubn) CAV1-HA is indicated. B, 
depletion of the substrate-recruiting cofactor PLAA or the deubiquitinating enzyme 
VCPIP1 causes accumulation of ubiquitinated CAV1. U2OS-CAV1-HA cells were 
transfected with control siRNA oligonucleotides (si-ctrl) or the indicated siRNAs for a 
total of 48 h and induced as in A. Two different siRNA oligonucleotides were tested 
for YOD1 (s1 and s2) and PLAA (s2 and s3). Cell lysates were analyzed in Western 
blotting using HA-specific antibodies. Staining for α -tubulin served as a loading 
control. The position of mono-ubiquitinated (CAV1-HA + Ub) or multi-ubiquitinated 
(CAV1-HA + Ubn) CAV1-HA is indicated. 
3.4.3 A systematic screen identifies no ubiquitin-binding cofactor that is 
required for the interaction between CAV1 and p97 
The finding that the substrate-recruiting cofactor PLAA is involved in CAV1 turnover 
prompted us to investigate the molecular details of the interaction between CAV1 and 
the p97-UBXD1 complex. While p97 by itself has weak affinity for ubiquitin it usually 
interacts with ubiquitinated substrates through substrate-recruiting cofactors (Jentsch 
and Rumpf, 2007; Meyer et al., 2002). Importantly, no p97 cofactor was known to 
mediate the interaction between ubiquitinated CAV1 and p97. PLAA can bind to p97 
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via a PUL domain and to ubiquitin through a WD40 and a PFU domain (Mullally et 
al., 2006). We immunoprecipitated CAV1-myc from HEK293 cells in the background 
of siRNA mediated PLAA depletion (Figure 3.15 A). As a control we depleted the p97 
cofactor UBXD1 that contains no ubiquitin-binding motif and was shown in our lab to 
be not required for the interaction between CAV1 and p97 (Ritz et al., 2011). The 
non-ubiquitinatable K5-57R variant of CAV1 was transfected as an additional control 
that does not bind p97. Efficient depletion of UBXD1 and PLAA was confirmed in the 
input samples. As expected, p97 and UBXD1 were found to interact with CAV1 wild 
type but not with CAV1 K5-57R in control-depleted cells. Furthermore, depletion of 
UBXD1 did not interfere with binding of p97 to CAV1 wild type. Importantly, also 
depletion of PLAA had no effect on the co-precipitation of p97 and UBXD1 with CAV1 
wild type. This is supported by the observation that PLAA itself did not co-precipitate 
with CAV1 wild type or K5-57R. However, the levels of PLAA detected in the input 
samples were close to the detection threshold of the Western blot. Therefore, weak 
or transient interaction of PLAA and CAV1 might not have been detected in this 
experiment. Moreover, in mass spectrometry analyses, D. Ritz could identify PLAA 
only in precipitates of the substrate trapping p97 E578Q variant (Ritz et al., 2011). 
Therefore, we co-expressed p97-GFP wild type or E578Q and CAV1-myc variants in 
HEK293 cells and immunoprecipitated CAV1-myc from the cell lysates using specific 
antibodies. Overexpression of p97-GFP wild type and E578Q was confirmed in the 
input samples, although at lower levels compared to endogenous p97 (Figure 3.15 
B). We observed no difference in expression of the CAV1 variants between p97-GFP 
wild type and E578Q expressing cells. However, the levels of ubiquitinated CAV1 
that were precipitated from the lysates of p97-GFP E578Q expressing cells were 
slightly reduced in comparison to p97-GFP wild type expressing cells. As expected, 
the p97-UBXD1 complex co-isolated with CAV1 wild type in p97-GFP wild type 
expressing cells. Additionally, weak co-precipitation of p97 and UBXD1 was 
observed with the non-ubiquitinatable CAV1 K5-176R variant. However, HEK293 
cells express endogenous wild type CAV1 that can be ubiquitinated and possibly 
forms hetero-oligomers together with the exogenous non-ubiquitinatable CAV1. This 
may be sufficient to precipitate the p97-UBXD1 complex if p97-GFP wild type is 
overexpressed. In p97-GFP E578Q expressing cells p97 and UBXD1 co-precipitated 
with CAV1 wild type although at lower levels in comparison to cells expressing p97-
GFP wild type. Importantly, PLAA was not found to co-precipitate with CAV1 under 
any tested condition.  
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Figure 3.15 Depletion of PLAA does not affect interaction between CAV1 and 
the p97-UBXD1 complex. 
A, UBXD1 and PLAA are not required for the interaction between CAV1 and p97. 
HEK293 cells were transfected with control siRNA oligonucleotides (si-ctrl) or siRNAs 
targeting UBXD1 or PLAA for a total of 48 h. The siRNA treated cells were transiently 
transfected with pcDNA3.1 empty vector (-), CAV1-myc wild type or CAV1-myc K5-
57R 24 h prior to lysis. Cell lysates were immunoprecipitated using myc-specific 
antibodies. Immunoprecipitates (IP) were analyzed together with input samples in 
Western blotting using myc-, PLAA-, UBXD1-, and p97-specific antibodies. The 
asterisk and the cross indicate the position of the antibody heavy and light chain 
respectively. B, Overexpression of the substrate trapping p97 E578Q variant does 
not stabilize co-precipitation of PLAA with CAV1. HEK293 cell were co-transfected 
with CAV1-myc wild type or K5-176R and p97-GFP wild type or E578Q for 24 h. Cell 
lysates were immunoprecipitated as in A and analyzed in Western blotting using 
caveolin-1-, PLAA-, UBXD1-, and p97-specific antibodies. The cross marks the 
position of the antibody light chain. The position of mono-ubiquitinated (CAV1-HA + 
Ub) CAV1-HA is indicated. 
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Because we found no evidence that PLAA mediated the interaction between 
ubiquitinated CAV1 and p97, we performed a small-scale RNAi screen of all known 
substrate-recruiting cofactors. Graphical representations of the substrate-recruiting 
cofactors with the respective p97- and ubiquitin-binding domains are shown in Figure 
3.16 A. The siRNA oligonucleotides targeting p97, UBXD1, UFD1, NPL4, p47, PLAA, 
and DVC1 were already established in the lab and shown in Western blotting to 
deplete their target proteins (Figure 3.16 B, Figure 3.17) (Dobrynin et al., 2011). The 
NPL4 siRNA oligonucleotide co-depleted UFD1 as described by G. Dobrynin. We 
confirmed efficient depletion of UBXD7 and UBXD8 with the specific siRNA 
oligonucleotides in this and the following experiment. Importantly, the SAKS1 siRNA 
used in this screen was later shown to have no knockdown efficiency (Figure 3.17). 
HEK293 cells were transfected with siRNA oligonucleotides and additionally 
transfected with CAV1-myc prior to lysis. The cell lysates were immunoprecipitated 
with anti-myc antibodies and co-precipitation of p97 and UBXD1 was investigated in 
Western blotting using specific antibodies. As described above, depletion of UBXD1 
and PLAA did not affect the interaction between CAV1 and p97. Importantly, 
depletion of none of the other substrate-recruiting cofactors affected co-precipitation 
of p97 and UBXD1 with CAV1 (Figure 3.16 B). However, we could not control the 
knockdown efficiency of all siRNAs used in this screen. Interestingly, we observed 
that the p97 cofactor UBXD8 co-precipitated with CAV1. This was the only p97 
cofactor so far, apart from UBXD1 that we observed to interact with CAV1. Therefore, 
we tested the possibility that UBXD1 and UBXD8 mediated the interaction between 
CAV1 and p97 together. However, co-depletion of UBXD1 and UBXD8 did not 
abolish with the interaction between CAV1 and p97 (data not shown). 
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Figure 3.16 RNAi screen for a substrate-recruiting cofactor that mediates the 
interaction between ubiquitinated CAV1 and p97-UBXD1. 
A, siRNA mediated depletion of substrate-recruiting cofactors did not affect the 
interaction between CAV1 and p97-UBXD1. HEK293 cells were transfected with 
control siRNA (si-ctrl) or the indicated siRNA oligonucleotides for a total of 48 h. The 
siRNA treated cells were transiently transfected with pcDNA3.1 empty vector (-) or 
CAV1-myc wild type for 24 h prior to lysis. The cell lysates were immunoprecipitated 
using myc-specific antibodies. Immunoprecipitates (IP) were analyzed together with 
input samples in Western blotting using the indicated specific antibodies. The cross 
marks the position of the antibody light chain. 
3.4.4 Cellular depletion of substrate-recruiting cofactors affects turnover of 
ubiquitinated CAV1 
Owing to the fact that depletion of PLAA caused accumulation of ubiquitinated CAV1 
even though it did not mediate interaction between CAV1 and p97-UBXD1, we tested 
the cofactor library that was used in the siRNA screen for effects on the levels of 
ubiquitinated CAV1. U2OS-CAV1-HA cells were transfected with siRNA 
oligonucleotides for and induced to express CAV1-HA prior to lysis. Cell lysates were 
analyzed in Western blotting using specific antibodies. In addition to the previously 
confirmed siRNA oligonucleotides we confirmed depletion of UBXD7 with the specific 
siRNA oligonucleotide. However, the original siRNA oligonucleotide targeting SAKS1 
(s1) was shown to have no knockdown efficiency and was replaced by a second 
siRNA (s2) that efficiently depleted SAKS1 (Figure 3.17). We confirmed that 
depletion of p97, UBXD1, and PLAA accumulated ubiquitinated CAV1 as shown 
above. Depletion of UFD1 or NPL4 had no effect on ubiquitinated CAV1, while 
depletion of p47 and FAF1 decreased the levels of ubiquitinated CAV1. Interestingly, 
knockdown of SAKS1 with the second oligo (s2) caused a marked accumulation of 
ubiquitinated CAV1, as did depletion of DVC1. This was accompanied by 
accumulation of the unmodified CAV1. Intermediate levels of ubiquitinated CAV1 
accumulated after Ataxin3 depletion comparable to depletion of PLAA. The 
knockdown of ZFAND2b, AMFR, UBXD7, UBXD8, or UBXD9 caused minor to strong 
accumulation of ubiquitinated CAV1. However, these effects showed high variation 
between experiments. Especially the effect of UBXD7 depletion was sometimes on 
par with or greater than the effect of UBXD9 depletion. 
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Figure 3.17 Depletion of some substrate-recruiting cofactors accumulates or 
decreases ubiquitinated CAV1. 
A, depletion of SAKS1 or DVC1 accumulates, while depletion of p47 or FAF1 
decreases ubiquitinated CAV1. U2OS-CAV1-HA cells were transfected with control 
siRNA (si-ctrl) oligonucleotides or the indicated siRNAs for a total of 48 h. The siRNA 
treated U2OS-CAV1-HA cells were then induced with doxycycline (DOX) to express 
CAV1-HA for 24 prior to lysis. Cell lysates were analyzed in Western blotting using 
the indicated specific antibodies. The position of mono-ubiquitinated (CAV1-HA + Ub) 
CAV1-HA is indicated. 
Summarizing, we could show that the lysines in the N-terminal region of CAV1 were 
required for interaction of CAV1 with the p97-UBXD1 complex on endosomes. 
Furthermore, inhibition of the lysosome but not of the proteasome resulted in 
accumulation of ubiquitinated CAV1 on late endosomes. Additionally, we confirmed 
that p97 ATPase activity was required for endosomal sorting of CAV1 and that 
pharmacological inhibition of p97 accumulated CAV1 on late endosomes. Moreover, 
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depletion of p97, UBXD1, the deubiquitinating enzyme YOD1, or the substrate-
recruiting cofactor PLAA caused accumulation of ubiquitinated CAV1. In contrast, we 
found no evidence that PLAA mediated the interaction between ubiquitinated CAV1 
and p97-UBXD1. Moreover, an RNAi-based screen of all known substrate-recruiting 
cofactors yielded no cofactor that was required for this interaction. Cellular depletion 
of these p97 cofactors, however, had diverse effects on the levels of ubiquitinated 
CAV1. 
3.5 Establishing p97 as a general regulator of endocytosis 
We showed that p97 was involved in sorting of ubiquitinated CAV1 to the lysosome 
and asked if p97 may function as a general regulator of endosomal sorting. The 
ligand-induced endocytosis and lysosomal degradation of the EGF receptor (EGFR) 
is a widely used model system for endosomal sorting (Madshus and Stang, 2009). 
Following endocytosis the EGFR is sorted into the lumen of late endosomes and 
eventually degraded in the lysosome (Bache et al., 2004). We investigated the effect 
of chemical inhibition and siRNA mediated depletion of p97 on the ligand-induced 
degradation of the EGFR. 
3.5.1 Pharmacological inhibition of p97 delays degradation of the EGFR 
We used small molecule inhibitors of p97 as a fast way of modulating p97 ATPase 
activity. Confluent HEK293 cells were starved for 4 h to accumulate the EGF receptor 
on the plasma membrane in the presence of either the p97 inhibitor DBeQ (Chou et 
al., 2011) or vehicle alone. The cells were stimulated with EGF and harvested after 0, 
30, 60, and 90 minutes. EGFR levels were analyzed in Western blotting using EGFR 
specific antibodies (Figure 3.18 A). The intensities of the EGFR bands were 
quantified and calculated relative to the first time point. In the DMSO-treated controls, 
80% of the EGFR was degraded after 90 minutes of stimulation. In contrast, in the 
cells treated with the p97 inhibitor DBeQ, EGFR degradation was significantly 
inhibited as early as 30 minutes and only little degradation was observed after 90 
minutes. This result showed that p97 ATPase activity is important for lysosomal 
degradation of the EGFR. 
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Figure 3.18 Pharmacological inhibition of p97 delays degradation of the EGFR. 
A, the p97 inhibitor DBeQ prevents EGFR degradation in HEK293 cells. HEK293 
cells were grown to confluence, serum-starved in serum-free DMEM for 4h, and at 
the same time treated with DMSO or DBeQ. EGFR degradation was induced by 
addition of 50 ng/ml EGF and cells were harvested in lysis buffer 0, 30, 60, and 90 
minutes after stimulation. Cell lysates were analyzed in Western blotting using 
EGFR- and p97-specific antibodies. Staining for α-tubulin served as a loading control. 
Electrochemiluminescence signals were quantified from scanned X-ray films using 
the Bio1D software (Vilber Lourmat) and normalized to the first time point. Error bars 
represent standard deviation, n = 5. *, p < 0.05. **, p < 0.01. B, chemical inhibition of 
p97 delays degradation of the EGFR in HeLa cells. HeLa cells were grown to 
confluence, serum-starved in serum-free DMEM for 4h, and at the same time treated 
with DMSO, DBeQ, I8, I5, or I1. EGFR degradation was induced by addition of 100 
ng/ml EGF and cells were harvested in lysis buffer 0, 20, 40, and 60 minutes after 
stimulation. Cell lysates were analyzed in Western blotting using EGFR-specific 
antibodies. Staining for HSC70 served as a loading control. 
Electrochemiluminescence signals were digitally acquired using a CCD camera, 
quantified in ImageJ (1.45k, NIH), and normalized to the first time point. Error bars 
represent standard deviation, n = 3. C, EGFR degradation curves from B plotted for 
each inhibitor individually together with the respective DMSO control. Error bars 
represent standard deviation, n = 3. *, p < 0.05. 
We confirmed this finding in HeLa cells that express more EGFR and are more 
widely used to study EGFR regulation. Moreover, we expanded the portfolio of p97 
inhibitors to include three additional inhibitors that were made available to the lab for 
characterization. These unpublished inhibitors (I8, I5 and I1) were identified in high 
throughput screens to inhibit p97 ATPase activity. Unfortunately, due to an 
information embargo, we cannot provide structural and biochemical details on these 
compounds. We starved confluent HeLa cells for 4 h to accumulate the EGFR on the 
plasma membrane in the presence of p97 inhibitor or vehicle alone. The cells were 
then stimulated with EGF and harvested after 0, 20, 40, and 60 minutes. EGFR 
levels were analyzed in Western blotting as described above. The quantification 
showed that in HeLa cells about 70% of the EGFR was degraded after 60 minutes 
(Figure 3.18 B). The p97 inhibitor DBeQ delayed EGFR degradation and only 30% of 
the protein were degraded after 60 minutes. In cells treated with the p97 inhibitor I8, 
about 30% of EGFR was degraded after 60 minutes comparable to DBeQ treatment. 
Interestingly, the amount of EGFR at the first time point was slightly lower in I8 
treated cells in comparison to DMSO or DBeQ treated cells. The p97 inhibitor I5 
showed an inhibitory effect on EGFR degradation that was comparable to DBeQ and 
I8. In contrast, the p97 inhibitor I1 delayed EGFR degradation only up to 40 minutes. 
Beyond that time point, the EGFR levels quickly dropped and about 60% of the 
EGFR was degraded after 60 minutes. In Figure 3.18 C the effect of each inhibitor is 
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plotted individually together with the respective DMSO control. For DBeQ, I8, and I5 
significant differences in EGFR levels were observed at the 40- and 60-minute time 
points. Furthermore the inhibitors I8 and I5 already caused significant delay of EGFR 
degradation after 20 minutes of stimulation. The inhibitor I1 caused a significant 
difference in EGFR levels only at the 40-minute time point but not after 60 minutes of 
EGFR treatment. 
3.5.2 Depletion of p97 and PLAA inhibits EGFR degradation 
To identify the p97 cofactors that work together with p97 in endosomal sorting and 
lysosomal degradation of the EGFR, we performed a siRNA-mediated screen in the 
lab (M. Bug, unpublished data). In this screen, p97 and several cofactors were 
identified as putative regulators of EGFR sorting. Depletion of the substrate-recruiting 
cofactor PLAA or the deubiquitinating enzymes YOD1 and VCPIP1 in HeLa cells 
caused accumulation of the EGFR on enlarged endosomes. To confirm this result in 
Western blotting, we depleted the cofactors in HeLa cells and investigated the EGFR 
degradation after EGF stimulation. As a control, we depleted the ESCRT factor 
TSG101 that is required for endosomal sorting of membrane proteins and to delays 
EGFR degradation (Raiborg et al., 2008). Knockdown efficiency was tested and 
confirmed for the TSG101, p97, PLAA, and VCPIP1 siRNAs (data not shown). The 
YOD1 protein could not be stained in these experiments due to technical problems. 
However, depletion of YOD1 was shown In HEK293 cells (data not shown). In the 
control-depleted cells, the EGFR was quickly degraded (Figure 3.19). In contrast, in 
cells depleted for TSG101, the cellular levels of EGFR were already decreased at the 
first time point but still a substantial fraction of the initial amount remained after 60 
minutes of EGF treatment. Importantly, depletion of p97 did not affect the cellular 
levels of EGFR but markedly stabilized the EGFR after stimulation. Depletion of 
PLAA prevented degradation of the EGFR comparable to p97 knockdown. 
Interestingly, we observed no shift of the EGFR to higher molecular weights after 
EGF stimulation in this condition. In YOD1 depleted cells the initial levels of EGFR 
appeared slightly increased and the degradation rate was lower in comparison to the 
control. In VCPIP1 depleted cells, the cellular EGFR levels were already decreased 
prior to EGF stimulation comparable to the TSG101 depleted condition. However, in 
contrast to TSG101 knockdown, the EGFR was not stabilized and at the 60-minute 
time point almost all EGFR was degraded.  
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Figure 3.19 Depletion of p97 or p97 cofactors affects the cellular EGFR levels 
and the EGFR degradation rate. 
A, cellular depletion of p97 and PLAA causes a marked delay in EGFR degradation. 
HeLa cells were transfected with control siRNA (si-ctrl) oligonucleotides or siRNAs 
targeting TSG101, p97, PLAA, YOD1 or VCPIP1 for a total of 72 h. The cells were 
serum-starved in serum-free DMEM for 4 h and then EGFR degradation was induced 
by addition of 100 ng/ml EGF. The cells were harvested in lysis buffer 0, 20, 40, and 
60 minutes after stimulation. Cell lysates were analyzed in Western blotting using 
EGFR-specific antibodies. Staining for HSC70 served as a loading control. The 
asterisk indicates an unspecific band that is recognized by the EGFR antibody. 
We could show in two cell lines and using three inhibitors that the ATPase activity of 
p97 was required for EGF induced degradation of the EGFR. These data were 
confirmed by siRNA-mediated depletion of p97. Furthermore, depletion of the 
substrate-recruiting cofactor PLAA delayed EGFR degradation comparable to p97 
knockdown. Knockdown of the deubiquitinating enzyme YOD1 caused a small delay 
of EGFR degradation, while depletion of TSG101 and VCPIP1 decreased the cellular 
EGFR levels already prior to stimulation. 
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4 Discussion 
In this study, we identified the six lysines 5 to 57 in the N-terminal region of CAV1 as 
critical for ubiquitination of CAV1. We used this information to investigate the 
functional role of CAV1 ubiquitination in endosomal sorting and lysosomal 
degradation of CAV1. Furthermore, we showed that the ubiquitination site in the N-
terminal region is required for interaction between CAV1 and the AAA-ATPase p97 
and performed detailed analyses of this interaction. We found that p97 is involved in 
endosomal sorting and lysosomal degradation of CAV1 and, importantly, also in 
endosomal sorting of the EGF receptor. These findings will be discussed with regard 
to the structural details of CAV1 ubiquitination, the functional relevance of CAV1 
ubiquitination for endosomal sorting, the interaction between CAV1 and p97, and the 
functional role of p97 in endosomal sorting. 
4.1 Ubiquitination of CAV1 in the N-terminal region 
Caveolae are stable cholesterol-rich microdomains in the plasma membrane that do 
not move laterally or exchange subunits (Mundy et al., 2002; Pelkmans and Zerial, 
2005; Tagawa et al., 2005; Thomsen et al., 2002). Still, overexpression of CAV1 is 
sufficient to mobilize CAV1 and induce endocytosis and degradation in the lysosome. 
For this process, CAV1 is modified mostly with mono-ubiquitin in addition to short 
ubiquitin chains (Hayer et al., 2010b). As a consequence, mutating all lysines in 
CAV1 to arginine (K5-176R) inhibits ubiquitination and lysosomal degradation of 
CAV1. However, the lysine-less CAV1 K5-176R variant does not provide information 
about which functional domain in CAV1 is ubiquitinated and how ubiquitination 
affects the CAV1 protein. Therefore, our initial goal was to define the ubiquitination 
site in CAV1 more closely. 
4.1.1 CAV1 is exclusively ubiquitinated in the N-terminal region 
We confirmed our data that overexpressed CAV1-myc is modified with HA-ubiquitin 
(Ritz et al., 2011) and found indication that mutation of the lysines of the N-terminal 
region interfered with ubiquitination. To improve detection of changes in CAV1 
ubiquitination, we generated a human CAV1-HA expression-construct. We chose to 
use human CAV1 cDNA in contrast to earlier studies (Hayer et al., 2010a; Hayer et 
al., 2010b) to avoid unspecific effects from expressing dog cDNA in human cell 
culture. Using this tool, we showed in Western blotting that mutation of the six lysines 
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in the N-terminal region (K5-57R) was sufficient to abolish CAV1 ubiquitination. In 
contrast, mutation of the six lysines in the other structural domains of CAV1 (K65-
176R) did not affect CAV1 ubiquitination. Consistently, we observed in 
immunofluorescence microscopy that mutation of the lysines in the N-terminal region 
significantly reduced the colocalization between CAV1 endosomes and ubiquitin 
signal. Crucially, the mutation of lysines in CAV1 did not affect the trafficking of CAV1 
in the biosynthetic pathway. CAV1 did not accumulate in the ER, at ER-exit sites, or 
in the Golgi apparatus as shown with specific marker proteins for these cellular 
compartments. This is important in light of a recent study by Hanson and colleagues 
that showed that adding a GFP-tag was sufficient to induce defects in CAV1 
trafficking (Hanson et al., 2013). Our findings are supported by published data that 
confirm comparable localization of CAV1 wild type and the lysine-less CAV1 K5-
176R to the plasma membrane (Hayer et al., 2010b). 
During the course of this study, two large-scale analyses of the ubiquitinated 
proteome were published (Kim et al., 2011; Wagner et al., 2011). In these screens, 
ubiquitinated proteins were isolated on the basis of a characteristic diglycine remnant 
on ubiquitin-conjugated lysines (Peng et al., 2003) and identified in mass 
spectrometry. Crucially, both studies together identify characteristic diglycine 
modification of all six lysines in the N-terminal region in CAV1 in line with our 
mutagenesis data. In addition, Kim and colleagues find evidence for ubiquitination of 
lysine-176 in the C-terminal domain of CAV1. In our hands, mutation of all lysines 
that are not part of the N-terminal region (K65-176R) had no effect on CAV1 
ubiquitination, while mutation of the lysines in the N-terminal region was sufficient to 
abolish CAV1 ubiquitination. This argues against involvement of lysine-176 in the 
mono-ubiquitination of overexpressed CAV1. Importantly, the mass spectrometry 
approach does not distinguish if a lysine-residue is modified with mono-ubiquitin or 
poly-ubiquitin chains. It is possible that lysine-176 is modified with poly-ubiquitin 
chains in cellular processes other than endosomal sorting. For example, an 
oligomerization deficient variant (P104L) of the caveolin-family member CAV3 is 
ubiquitinated with K48-linked ubiquitin chains and degraded by the proteasome 
because it accumulates in the Golgi apparatus (Galbiati et al., 2000). 
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Figure 4.1 The site of CAV1 ubiquitination is located in the N-terminal region. 
Topology model of CAV1 in the plasma membrane. CAV1 is inserted into the plasma 
membrane through a hairpin-like intra-membrane domain with both N- and C-termini 
facing the cytoplasm. The oligomerization/scaffolding domain is partially inserted into 
the hydrophobic core of the membrane where it may associate with cholesterol. The 
C-terminal domain is palmitoylated on three cysteines and anchored in the plasma 
membrane. In contrast, the N-terminal region is more flexible and protrudes into the 
cytoplasm. We show that the six lysines in the N-terminal region are sufficient and 
required for CAV1 ubiquitination. Interestingly, ubiquitination of the first three lysines 
(5, 26, 30), or the following three lysines (39, 47, 57) produces a small difference in 
the running behavior of mono-ubiquitinated CAV1 in SDS gels. The second sub-
region partially overlaps with a putative membrane interface helix (Parton et al., 
2006). (modified from Parton and del Pozo, 2013) 
Interestingly, ubiquitination of CAV1 appears to be promiscuous in a manner similar 
to sumoylation of CAV3 (Fuhs and Insel, 2011). Mutation of individual lysines in the 
N-terminal region had no effect on CAV1 ubiquitination. Consistently, re-introducing 
any lysine of the N-terminal region into the lysine-less CAV1 K5-176R variant 
resulted in a partial restoration of ubiquitination. However, not all lysines could serve 
as ubiquitin acceptor sites equally well. Ubiquitination of lysines 39 and 47 was the 
most prominent, while the lysines 30 and 57 were only marginally ubiquitinated. 
Interestingly, the faintly ubiquitinated lysine-57 is located within the minimal CAV1 
required for caveolae formation (Kirkham et al., 2008; Parton et al., 2006) and might 
not be readily accessible for ubiquitination. Likewise, the minor ubiquitin-acceptor 
lysine-30 is positioned at the start of a predicted amphipathic helix between residues 
30 and 50 (Parton et al., 2006) (Figure 4.1). The two most efficiently ubiquitinated 
lysines (K39 and K47) are present in both CAV1 isoforms α and β (Kogo and 
Fujimoto, 2000). This might allow efficient ubiquitination of the β-isoform by the same 
ubiquitin ligase as the α-isoform. Furthermore, the conjugation of ubiquitin to the first 
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three lysines (K5, K26, K30) or the following three lysines (K39, K47, K57) resulted in 
a small difference in the migration speed of mono-ubiquitinated CAV1 in SDS gels. 
This indicates that the observed double band of mono-ubiquitinated CAV1 wild type 
probably is the result of ubiquitin conjugation in both sub-regions with equal 
frequency. 
4.1.2 The N-terminal region of CAV1 is accessible for posttranslational 
modifications 
The finding that CAV1 is ubiquitinated in the N-terminal region provides insight into 
the molecular consequences of CAV1 ubiquitination. The CAV1 protein contains 
several membrane-binding domains in addition to the intra-membrane domain 
(Figure 4.1). The C-terminal domain is palmitoylated on three conserved cysteines, 
while the scaffolding domain is partially buried in the inner leaflet of the plasma 
membrane (Epand et al., 2005; Parton et al., 2006). Additionally, the oligomerization 
and scaffolding domains are involved in intermolecular interactions and 
oligomerization of CAV1 (Fernandez et al., 2002; Sargiacomo et al., 1995). In 
contrast, the N-terminal region is less structured and protrudes into the cytoplasm 
apart from predicted helix between residues 30 and 50 that may interact with the 
plasma membrane interface (Parton et al., 2006). We speculate that this allows 
ubiquitination of oligomerized CAV1 without disruption of caveolae. Consistently, we 
observed that ubiquitinated CAV1 colocalized with PTRF/cavin-1, a coat protein that 
only associates with caveolar CAV1 but not biosynthetic pools of CAV1 (Hill et al., 
2008; Kirkham et al., 2008; Liu and Pilch, 2008). The lysines of the N-terminal region 
are conserved in CAV1 from zebrafish, chicken, and mouse (data not shown); also 
the closely related CAV3 harbors lysines corresponding to position 47 and 57 in 
CAV1 plus one additional lysine close to the N-terminus. This is consistent with the 
notion that ubiquitination in the N-terminal region is a conserved mechanism of 
regulating caveolin proteins and can take place prior to disassembly of the caveolar 
scaffold. However, fusion of the N-terminal region alone to GFP was not sufficient to 
serve as an ubiquitination signal (data not shown). One explanation is that 
ubiquitination of the N-terminal region of CAV1 may require localization to lipid raft 
domains in the plasma membrane and does not occur if the N-terminal domain is 
fused to freely diffusible GFP.  
Another posttranslational modification in the N-terminal region is the phosphorylation 
of tyrosine-14 that has been described as a regulator of caveolar endocytosis (Aoki 
et al., 2007; del Pozo et al., 2005; Gaus et al., 2006; Sverdlov et al., 2007). In 
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agreement with the work from del Pozo and colleagues, we observed that a 
phosphorylation-deficient CAV1 variant (Y14F) localized to the plasma membrane 
similar to wild type CAV1. Yet crucially, we found no evidence for reduced 
endocytosis or ubiquitination of CAV1 Y14F. 
4.1.3 Establishing a microscopy-based assay of CAV1 ubiquitination in E3 
ubiquitin ligase depleted cells 
The non-ubiquitinatable CAV1 K5-57R variant makes it possible to analyze the 
functional consequences of CAV1 ubiquitination. However, for a comprehensive 
analysis it would be interesting to directly influence the ubiquitination state of wild 
type CAV1 by depleting or overexpressing the E3 ubiquitin ligase that modifies 
CAV1. Because to date no E3 ligase was known to ubiquitinate CAV1, we decided to 
establish a microscopy-based assay of CAV1 ubiquitination in parallel to performing 
functional analyses of the non-ubiquitinatable CAV1 K5-57R variant. This assay 
could then be used to screen a large library of siRNA oligonucleotides targeting E3 
ubiquitin ligases for effects on CAV1 ubiquitination. For this purpose, we generated 
an U2OS cell line that expresses CAV1-HA under control of a doxycycline inducible 
promoter to investigate ubiquitination of CAV1 in Western blotting and 
immunofluorescence microscopy. In this cell line, we tested a small number of E3 
ubiquitin ligases that are known to ubiquitinate membrane proteins. In particular, the 
HECT-type ligase NEDD4L interacts with transiently overexpressed CAV3 in 
HEK293 cells (Guo et al., 2012). Depletion of NEDD4L caused accumulation of 
ubiquitinated CAV1 in untreated cells but prevented accumulation of ubiquitinated 
CAV1 in cells treated with a lysosome inhibitor. However, this probably represents an 
unspecific effect of NEDD4L depletion since NEDD4L is also involved in the 
ubiquitination of several important regulators of endosomal sorting (Yang and Kumar, 
2010). Nevertheless, we were able to establish that the automated analysis of 
colocalization between CAV1 vesicles and ubiquitin is a suitable assay to quantify 
CAV1 ubiquitination in E3 ubiquitin ligase depleted cells. Due to time limitations, this 
analysis was only performed with a small number of pre-selected E3 ligases. 
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4.2 What are the functional consequences of CAV1 ubiquitination? 
Previous studies showed that mutation of all lysines in CAV1 increases the half-life of 
CAV1 by preventing lysosomal degradation (Hayer et al., 2010b; Ritz et al., 2011). 
Along this line, lysosomal inhibitors but not proteasome inhibitors prevent 
degradation of overexpressed CAV1 (Hayer et al., 2010b) and inhibit stimulated 
degradation of CAV1 (Martinez-Outschoorn et al., 2010; Peterson et al., 2003; 
Vassilieva et al., 2009). Importantly, sorting of CAV1 into multivesicular endosomes 
requires the AAA-ATPase p97, and overexpression of the dominant negative p97 
E578Q variant prevents the formation of intralumenal vesicles (Ritz et al., 2011). 
Moreover, CAV1 wild type but not the lysine-less CAV1 K5-176R interacts with the 
p97 and the cofactor UBXD1 supporting a role of p97 in the endosomal sorting of 
ubiquitinated CAV1. However, the functional connection between CAV1 
ubiquitination and endosomal trafficking of CAV1 was not known. 
4.2.1 Sorting of ubiquitinated CAV1 on late endosomes requires p97 
We could confirm that inhibition of the lysosome, but not of the proteasome 
accumulated ubiquitinated CAV1 on late endosomes. Moreover, also cellular 
depletion or pharmacological inhibition of the p97-UBXD1 complex caused 
accumulation of ubiquitinated CAV1. Along this line, we observed that the non-
ubiquitinatable CAV1 variants showed significantly reduced colocalization with the 
late endosome marker LAMP1 in comparison to wild type CAV1. These data indicate 
that p97-UBXD1 acts downstream of CAV1 ubiquitination and regulates sorting of 
ubiquitinated CAV1 on late endosomes prior to degradation in the lysosome. 
Crucially, we could show that the ubiquitination site in the N-terminal region of CAV1 
was required for interaction between CAV1 and the p97-UBXD1 complex and 
mediated recruitment of p97-UBXD1 to endosomes. The functional connection 
between CAV1 ubiquitination and endosomal sorting by the p97-UBXD1 complex will 
be discussed in more detail below. 
4.2.2 CAV1 ubiquitination regulates trafficking of CAV1 to the early endosome 
after endocytosis 
Importantly we could show that, in addition to mediating interaction with p97-UBXD1 
and sorting at the late endosome, ubiquitination of CAV1 was already required for 
trafficking of CAV1 to the early endosome. Following stimulus dependent 
endocytosis, CAV1 localizes to stable membrane domains on early endosomes 
(Hayer et al., 2010b; Pelkmans et al., 2004; Pelkmans and Zerial, 2005). 
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Consequently, we observed that wild type CAV1 colocalized with the early endosome 
markers EEA1 and RAB5. However, this was not the case for the non-ubiquitinatable 
K5-57R variant. Moreover, non-ubiquitinatable CAV1 accumulated on ubiquitin- and 
EEA1-negative endocytic vesicles that were marked by the caveolar coat protein 
PTRF/cavin-1. PTRF/cavin-1 associates with large 70S caveolar scaffolds and 
regulates the stability of caveolae and interaction with the cytoskeleton (Hansen et 
al., 2013; Liu and Pilch, 2008; Vinten et al., 2005). Importantly, PTRF/cavin-1 stays 
associated with CAV1 oligomers after endocytosis and during trafficking to early 
endosomes (Hayer et al., 2010b; Hill et al., 2008). The PTRF/cavin-1 positive 
vesicles that accumulate after CAV1 overexpression probably are related to RAB5-
negative endocytic vesicles prior to fusion with the early endosome (Sharma et al., 
2003). However, these vesicles are usually small and short-lived but might be 
enlarged and stabilized by the high levels of CAV1 after transient overexpression. 
Data by Hayer and colleagues and our own experiments showed that, in contrast to 
endogenous RAB5, CAV1 colocalized with overexpressed GFP-RAB5 independently 
of ubiquitination (Hayer et al., 2010b). The discrepancy between these observations 
may be explained by the fact that overexpression of GFP-RAB5 increases the size of 
the early endosomal compartment (Bucci et al., 1992; Roberts et al., 1999). This 
might reduce the need for CAV1 ubiquitination by increasing the rate of fusion 
between endocytic vesicles and the early endosome (Zeigerer et al., 2012). It is not 
known how CAV1 ubiquitination regulates trafficking to the early endosome but a 
recent study showed that CAV1 could directly interact with RAB5 and increase the 
GTPase activity of RAB5 (Hagiwara et al., 2009). Interestingly, RAB5 has to be 
present on both the incoming vesicle and the early endosome for fusion to occur 
(Barbieri et al., 1998). Thus, ubiquitination of CAV1 may be required to effectively 
recruit or activate RAB5 on endocytic vesicles. Figure 4.2 shows a graphical 
representation of our model for trafficking of CAV1 after endocytosis. Life cell 
microscopy could help to clarify this endosomal sorting event by following the fate of 
individual CAV1-positive vesicles from endocytosis to fusion with the early 
endosome. In a similar experiment, Zoncu and colleagues tracked single endosomes 
after endocytosis and investigated the sequential recruitment of membrane proteins 
upstream of the early endosome (Zoncu et al., 2009). 
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Figure 4.2 Model for the sorting of ubiquitinated CAV1 after endocytosis. 
Ubiquitination of CAV1 may mediate trafficking of caveolar vesicles to the early 
endosome. CAV1 may be ubiquitinated in caveolae at the plasma membrane or on 
endocytic vesicles. The endocytic vesicles are marked by the coat protein PTRF-
cavin-1 that associates with caveolar scaffolds. From early endosomes, CAV1 is 
further sequestered into intralumenal vesicles and transported to the lysosome for 
degradation. In contrast, non-ubiquitinatable CAV1 is endocytosed on PTRF/cavin-1 
positive vesicles comparable to CAV1 wild type but does not colocalize with the early 
endosome markers EEA1 and RAB5. Therefore, we propose that ubiquitination of 
CAV1 may be required for fusion of endocytic vesicles with the early endosome. The 
molecular connection between CAV1 ubiquitination and trafficking to early 
endosomes is not known but might involve direct interaction of ubiquitinated CAV1 
and the endosomal GTPase RAB5.  
4.2.3 Autophagy might be involved in the degradation of ubiquitinated CAV1 
In addition to endosomal markers, CAV1 wild type colocalized with the 
autophagosome marker LC3-GFP. This interaction was limited to few vesicles per 
cell but strikingly absent in cells expressing the non-ubiquitinatable CAV1 K5-57R 
variant. Moreover, a substantial fraction of CAV1 wild type vesicles colocalized with a 
second autophagy marker, the ubiquitin adapter protein p62. Again, this was specific 
for CAV1 wild type and not observed with non-ubiquitinatable CAV1. It is unclear why 
more CAV1 vesicles colocalize with p62 in comparison to LC3-GFP. It could be 
possible that quenching of the GFP fluorescence in acidified endosomes reduces the 
number of LC3-GFP vesicles we can visualize (Pankiv et al., 2007). However, this 
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appears unlikely in light of the small percentage (7%) of CAV1 vesicles that 
colocalize with acidified LAMP1-positive late endosomes. 
In selective autophagy, p62 aggregates ubiquitinated cytoplasmic proteins and 
directs them to the autophagosome via direct interaction with the autophagic 
membrane protein LC3 (Kirkin et al., 2009b). However, In addition to degradation of 
cytoplasmic proteins, autophagy can be involved in degradation of proteins that 
accumulate in the ER (Yorimitsu and Klionsky, 2007). Importantly, we could exclude 
that the colocalization of CAV1 with LC3-GFP or p62 was due to accumulation of 
misfolded or aggregated CAV1 in the biosynthetic pathway. We showed that 
overexpressed CAV1 did not colocalize with UBXD8, a p97 cofactor that resides in 
the ER membrane and is involved in retro-translocation of misfolded proteins. 
Moreover, we did not observe accumulation of CAV1 on ER-exit sites or in the Golgi 
apparatus. Therefore, we suggest that the source of colocalization between CAV1 
and LC3-GFP or p62 is not ubiquitinated CAV1 in the biosynthetic pathway but rather 
on endosomes.  
We do not know if the colocalization between CAV1 and p62 or LC3-GFP is the 
result of a direct interaction and how autophagy is involved in endosomal sorting of 
CAV1. One possibility is that interaction between ubiquitinated CAV1 and p62 on 
endosomes induces sequestration of CAV1 vesicles in autophagosomes. 
Interestingly, it has been shown that overexpression of a mono-ubiquitin fused 
protein that localizes to peroxisomes was sufficient to recruit p62 and induce 
degradation of these vesicles in autophagy (Kim et al., 2008). In this context, p97 has 
been shown to regulate autophagy of ubiquitinated proteins (Chou et al., 2011; Ju et 
al., 2009; Tresse et al., 2010) and could be equally required for CAV1 degradation 
via endosomal sorting and autophagy. Interestingly, in addition to its function as an 
ubiquitin adapter in autophagy, p62 is reported to interact with a wide variety of 
membrane proteins and mediate ubiquitination or deubiquitination in endosomal 
sorting (Duran et al., 2011; Geetha et al., 2005; Geetha et al., 2008; Layfield and 
Shaw, 2007). Therefore, p62 may facilitate endosomal sorting of CAV1 by mediating 
CAV1 deubiquitination. A model for the functional connection between p62 and 
trafficking of ubiquitinated CAV1 is presented in Figure 4.3. 
  Discussion 
 124 
 
 
Figure 4.3 Possible functions for p62 on CAV1 endosomes. 
After overexpression of ubiquitinatable CAV1, the ubiquitin adapter protein p62 
colocalizes with CAV1 on endosomes. Furthermore, a smaller percentage of CAV1 
vesicles colocalizes with the autophagic membrane protein LC3-GFP. Interaction 
between ubiquitinated CAV1 and p62 might be a signal for degradation of CAV1-
positive endosomes in autophagy. As an alternative, p62 could recognize 
ubiquitinated CAV1 on endosomes and coordinate deubiquitination. This may involve 
the activity of unknown deubiquitinating enzymes in association with the p97-UBXD1 
complex (discussed below). 
 
4.3 How does p97 interact with ubiquitinated CAV1? 
We have established that ubiquitination of CAV1 in the N-terminal region regulates 
sorting of CAV1 on early and late endosomes. Previous studies by our group showed 
that overexpression of the dominant negative p97 variant E578Q accumulates CAV1 
on the limiting membrane of enlarged late endosomes (Ritz et al., 2011). 
Furthermore, CAV1 wild type but not the non-ubiquitinatable CAV1 K5-176R variant 
interacts with the AAA-ATPase p97 in a complex with the cofactor UBXD1. In the 
following, we will discuss the functional connection between the p97-UBXD1 complex 
and sorting of ubiquitinated CAV1 on late endosomes. 
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4.3.1 The p97-UBXD1 mediates turnover of ubiquitinated CAV1 
Importantly, we could show that the ubiquitination site in the N-terminal region of 
CAV1 was required for interaction with p97 and UBXD1. Along this line, we observed 
that CAV1 wild type but not the non-ubiquitinatable CAV1 variants recruited p97 and 
UBXD1 to endosomes. However, a fraction of p97 localized to endosomes also in the 
absence of CAV1 ubiquitination. This indicates that additional factors might be able 
to target p97 to endosomes. Interestingly, a recent study described direct interaction 
between p97 and the early endosomal marker protein EEA1 that could recruit p97 to 
early endosomes (Ramanathan and Ye, 2012). Taken together, our data suggest that 
the p97-UBXD1 complex interacts with ubiquitinated CAV1 on endosomes and 
directly regulates endosomal trafficking of CAV1. Crucially, we could show that 
siRNA mediated depletion of p97 or UBXD1 caused accumulation of ubiquitinated 
CAV1 comparable to lysosome inhibition. Furthermore, short pharmacological 
inhibition of p97 with the inhibitor DBeQ (Chou et al., 2011) caused a weak but 
consistent accumulation of ubiquitinated CAV1 on late endosomes. This indicates 
that p97 and UBXD1 act downstream of CAV1 ubiquitination and regulate turnover of 
ubiquitinated CAV1. During the course of this study, Chen and colleagues published 
their finding that CAV1 interacts with p97 in a complex with UFD1 and Derlin-1 and 
facilitates the extraction of ubiquitinated COX2 proteins from the ER (Chen et al., 
2013). In contrast, we never observed localization of overexpressed CAV1 to the ER. 
Additionally, in previous studies we showed that CAV1 exclusively precipitated 
UBXD1 but not the p97 cofactor UFD1 (Ritz et al., 2011). 
4.3.2 The interaction between p97 and ubiquitinated CAV1 might not require 
an ubiquitin-binding cofactor 
The interaction between p97 and ubiquitinated substrates is generally mediated 
through substrate-recruiting cofactors (Jentsch and Rumpf, 2007; Meyer et al., 2002). 
Therefore, we investigated if an ubiquitin-binding cofactor is required for the 
interaction between p97 and ubiquitinated CAV1. Initially, we tested the substrate-
recruiting cofactor PLAA because we observed that depletion of PLAA caused 
accumulation of ubiquitinated CAV1 comparable to depletion of p97. Furthermore, 
the yeast homologue Ufd3 is known to be involved in sorting of ubiquitinated cargo 
proteins on multivesicular endosomes (Ren et al., 2008). PLAA interacts with the C-
terminus of p97 through a PUL domain and can bind ubiquitin through and a PFU 
domain together with a WD40 β -propeller (Mullally et al., 2006). Nevertheless, 
cellular depletion of PLAA did not affect the interaction between p97 and 
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ubiquitinated CAV1. Along this line, PLAA did not co-isolate with p97 in CAV1 
immunoprecipitates. However, it is possible that we cannot co-precipitate PLAA 
because the interaction between the PLAA cofactor and p97 is only transient. 
Importantly, we found in previous mass spectrometry analyses (Ritz et al., 2011) that 
PLAA only interacted with the dominant negative E578Q variant of p97 that cannot 
release protein substrates after binding (Ramadan et al., 2007; Ye et al., 2003). 
However, expressing the substrate-trapping p97 E578Q variant together with CAV1 
did not stabilize co-isolation of the PLAA cofactor in CAV1 immunoprecipitates. 
Interestingly, the interaction between CAV1 and p97 E578Q was rather decreased in 
comparison to p97 wild type. One possible explanation could be that the p97 E578Q 
variant is trapped in many substrate-protein complexes and thus sequestered away 
from ubiquitinated CAV1.  
To systematically address the question if a substrate-recruiting cofactor mediates the 
interaction between p97 and ubiquitinated CAV1, we screened a siRNA library of all 
known p97 cofactors that harbor ubiquitin-binding motifs. Interestingly, depletion of 
none of these cofactors affected the interaction between ubiquitinated CAV1 and 
p97-UBXD1. However, not all siRNAs used in the screen were confirmed to deplete 
their target protein efficiently. Especially, the siRNA targeting SAKS1 used in this 
screen was later found ineffective to deplete SAKS1. Additionally, several cofactors 
might facilitate the interaction between CAV1 and p97 in a redundant fashion. In the 
scope of this study, however, it was not possible to verify the depletion efficiency of 
all siRNAs and to exclude cofactor redundancy in the CAV1-p97-UBXD1 complex. At 
least, the results from this screen suggest that p97 might be able to interact with 
ubiquitinated CAV1 without the help of an ubiquitin-adapter protein. Along this line, a 
recent study in yeast described a group of proteasome substrates that accumulate 
after deletion of Cdc48 but not after deletion of substrate-recruiting cofactors (Kolawa 
et al., 2013). Furthermore, p97 has a weak affinity for mono-ubiquitinated substrates 
(Rape et al., 2001; Ye et al., 2003) and even can recognize non-ubiquitinated protein 
substrates (Ye et al., 2003). The ubiquitin-binding site resides on the N domain of 
p97 that is structurally similar to the UFD1 cofactor (Park et al., 2005; Pye et al., 
2007). Additionally, the N-domain interacts with ubiquitin-like domains, for example 
the UBX domain that is present in several p97 cofactors (Schuberth and Buchberger, 
2008). The weak binding affinity of p97 to mono-ubiquitin might be amplified by 
simultaneous interaction with several ubiquitinated CAV1 molecules. In this context, 
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we found in a previous study that p97 preferentially binds SDS-resistant CAV1 
oligomers (Ritz et al., 2011). 
4.4 How does p97 regulate endosomal sorting of CAV1 and the EGFR? 
We established p97, together with the cofactor UBXD1, as a regulator of endosomal 
sorting of ubiquitinated CAV1. In this context, we asked if p97 is a more general 
regulator of endosomal sorting and investigated the lysosomal degradation of the 
EGF receptor. Additionally, we investigated the involvement of further p97 cofactors 
in p97-mediated endosomal sorting. 
4.4.1 Lysosomal turnover of ubiquitinated CAV1 might involve the p97 
cofactors PLAA and VCPIP1 
Mass spectrometry and immunoprecipitation studies in our lab (D. Ritz and M. Bug, 
unpublished data) identified an interaction between the p97-UBXD1 complex and the 
substrate-recruiting cofactor PLAA. Moreover, the deubiquitinating enzymes YOD1 
and VCPIP1 were also indentified in this complex. The yeast homologue of PLAA, 
Ufd3, was shown to genetically interact with deubiquitinating enzymes and regulate 
the mono-ubiquitination of histone H2B is response to DNA damage (Lis and 
Romesberg, 2006). Furthermore, Ufd3 is involved in sorting of ubiquitinated proteins 
on multivesicular endosomes (Ren et al., 2008). Importantly, we could show that 
depletion of PLAA or the deubiquitinating enzyme VCPIP1 resulted in accumulation 
of ubiquitinated CAV1 comparable to depletion of p97 or UBXD1. The DUB activity of 
VCPIP1 in p97-p47-mediated reassembly of the Golgi apparatus is regulated through 
the activator protein WAC (Totsukawa et al., 2011). Consequentially, depletion of 
WAC caused accumulation of ubiquitinated CAV1 comparable to VCPIP1 depletion 
(data not shown). The function of PLAA might be to bring VCPIP1 into close contact 
with ubiquitinated CAV1. However, as discussed above, we could not identify an 
interaction between ubiquitinated CAV1 and PLAA. In this context, we tested the 
effect of cellular depletion of all known substrate-recruiting cofactors on the levels of 
ubiquitinated CAV1 to identify other components of the p97-UBXD1 complex. 
Knockdown of several cofactors such as SAKS1 and DVC1 caused accumulation of 
ubiquitinated CAV1, while depletion of p47 or FAF1 decreased the levels of 
ubiquitinated CAV1. However, the results gathered from this experiment are only 
preliminary. 
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4.4.2 p97 regulates lysosomal degradation of activated EGF receptor 
To investigate if p97 is a general regulator in endosomal trafficking of membrane 
proteins, we analyzed degradation of the EGF receptor. Ligand-induced endocytosis 
and degradation of the EGF receptor is a widely studied model for ubiquitin-
dependent degradation of plasma membrane proteins in the lysosome (Goh and 
Sorkin, 2013; Madshus and Stang, 2009). Importantly, we could show that treatment 
of HEK293 cells with the p97 inhibitor DBeQ (Chou et al., 2011) inhibited the ligand-
induced degradation of the EGF receptor. This was confirmed in HeLa cells using 
DBeQ and two new p97 inhibitors that were supplied to our lab for characterization. A 
third inhibitor with lower inhibitory activity in vitro (R. Pöhler, unpublished data), 
consistently, had a weak effect on EGFR degradation. We further confirmed that p97 
was required for EGFR degradation by cellular depletion of p97 with specific siRNA 
oligonucleotides. This establishes p97 as a general regulator of endosomal 
trafficking. To elucidate the cofactors that work together with p97 in endosomal 
sorting of ligand stimulated EGFR, we screened a siRNA library of p97 cofactors 
using immunofluorescence microscopy (M. Bug unpublished data). In this screen we 
found that depletion of PLAA or the deubiquitinating enzymes YOD1 and VCPIP1 
caused accumulation of the EGF receptor on enlarged endosomes. Consistently, we 
observed in Western blotting that depletion of PLAA, and to a lesser extend YOD1, 
delayed EGFR degradation. In contrast, depletion of VCPIP1 had no effect on the 
rate of EGFR degradation. However, knockdown of VCPIP1 decreased the cellular 
levels of EGFR similar to depletion of the ESCRT-I protein TSG101. This could 
indicate that the knockdown of VCPIP1 affects endosomal recycling of the EGFR, as 
was proposed for depletion of TSG101 (Morris et al., 2012; Rush and Ceresa, 2013). 
4.4.3 What is the functional connection between p97 and endosomal sorting? 
Cellular depletion of PLAA had a comparable effect on the endosomal trafficking of 
both ubiquitinated CAV1 and EGFR. In contrast, depletion of the DUB VCPIP1 
specifically caused accumulation of ubiquitinated CAV1, while depletion of YOD1 
inhibited EGFR degradation. Therefore, we speculate that p97, together with PLAA, 
could form a scaffold that associates with substrate-specific deubiquitinases to 
regulate membrane trafficking (Figure 4.4). As mentioned above, this model is similar 
to the regulation of histone H2b ubiquitination in yeast by the PLAA homologue Ufd3 
in association with deubiquitinases (Lis and Romesberg, 2006). It is well established 
that deubiquitination is a crucial step in the MVE sorting of membrane proteins on 
late endosomes (Goh and Sorkin, 2013). In this context, we discussed above that the 
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ubiquitin-adapter protein p62 might be recruited to ubiquitinated CAV1 on 
endosomes to mediate deubiquitination and MVE sorting. It could be possible that 
such a deubiquitination step involves p97 together with deubiquitinating enzymes. 
 
 
Figure 4.4 Hypothetical model for the functions of p97 in endosomal sorting 
of ubiquitinated CAV1 and the EGFR 
We could show that p97 is an important regulator in endosomal sorting and 
lysosomal degradation of ubiquitinated CAV1 and the EGFR. There are several 
possible models that could explain the molecular function of p97 in endosomal 
sorting. Deubiquitination of cargo proteins is essential for their sorting into 
intralumenal vesicles (ILVs) and degradation in the lysosome. This deubiquitination 
may could be mediated by p97-associated deubiquitinases and involve targeting 
factors like PLAA. Furthermore, this could be connected to the localization of the 
ubiquitin-adapter p62 to CAV1-positive endosomes. As an alternative, the segregase 
activity of p97 might be required to disassemble the large caveolar scaffolds prior to 
intralumenal vesicle formation. Finally, p97 might regulate the endosomal sorting 
machinery on multivesicular endosomes (MVEs) that facilitates ILV formation. In this 
model, p97 could mediate deubiquitination of ESCRT component and prevent their 
proteasomal degradation, or enable recycling of the ESCRT machinery after vesicle 
abscission. 
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In an alternative model, the p97-PLAA-DUB complex could be required to 
deubiquitinate and thus stabilize factors that are involved in multivesicular endosome 
biogenesis, for example VPS34 PI3P-kinase subunits (Abrahamsen et al., 2012; 
Raiborg et al., 2013) or ESCRT components (Clague and Urbe, 2006; Wright et al., 
2011). Finally, p97 utilizes the energy of ATP hydrolysis to segregate ubiquitinated 
protein complexes, for example in ERAD (Meyer et al., 2012; Stolz et al., 2011; Ye, 
2006) or in mitosis (Ramadan et al., 2007). Given that caveolae induce membrane 
curvature towards the cytosol (Parton et al., 2006), disassembly of the caveolar 
scaffold is probably required for MVE sorting of CAV1 because intralumenal vesicles 
curve away from the cytosol (Raiborg and Stenmark, 2009). Interestingly, we showed 
in a previous study that p97 predominantly interacted with SDS-resistant CAV1 
oligomers (Ritz et al., 2011). In an alternative model, the segregase activity of p97 
may be required to recycle subunits of the ESCRT endosomal-sorting machinery 
after vesicle abscission, similar to the activity of the AAA-ATPase VPS4 (Wollert et 
al., 2009). Interestingly, p97 was proposed to regulate vesicle fusion by regenerating 
free Syntaxin-5 from SNARE complexes following vesicle fusion (Rabouille et al., 
1998). The models for the molecular function of p97 in endosomal sorting of 
ubiquitinated CAV1 and the EGFR are presented in Figure 4.4. However, further 
work is required to define the molecular function of p97 in endosomal sorting of 
ubiquitinated cargo proteins in more detail. 
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